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1 INTRODUCTION 
 
1.1 Nucleic acids as drugs 
 
In all living organisms, deoxyribonucleic acid (DNA) is the carrier of the genetic information 
and ribonucleic acid (RNA) is responsible for the regulated translation of this information into 
structural and functional molecules.  
Given the distinguished role of nucleic acids in living systems, one can conclude that any 
cellular process may be influenced to some particular purpose by the introduction of nucleic 
acids into cells from outside. Already in 1966, Tatum formulated the basic concepts of nucleic 
acid therapy: gene complementation, modification/regulation of gene activities, and gene 
repair or replacement (Tatum, 1966). 
Today, great efforts are put into the development of nucleic acid drugs which potentially can 
be used to treat diseases like e.g. Duchenne muscular dystrophy, cystic fibrosis, haemophilia, 
cancer or angiopathies. Drugs based on nucleic acids include expressing sequences (like 
complementary DNA, genes inclusive noncoding regulatory regions, messenger RNA), gene 
silencing molecules (like triple helix-forming oligonucleotides, antisense, small interfering 
RNA, long double-stranded RNA, ribozymes, deoxyribozymes, aptamers) and nucleic acids 
for gene repair/replacement (triple helix-forming oligonucleotides, RNA-DNA 
oligonucleotides or chimeraplasts, small DNA fragments).  
Very commonly used is complementary (c)DNA which is cloned into bacterial plasmids or 
viral vectors and that is e.g. expressed under control of strong viral promoters (like e.g. the 
cyto-megalo-virus promoter). Successfully delivered cDNA is deposited in the nucleus either 
extrachromosomally or it is integrated into the host genome which is e.g. a special feature of 
retroviruses. 
 
1.2 Delivery of nucleic acids 
 
Current nucleic acid drugs are supposed to act either in the cytoplasm or in the nucleus of 
cells and therefore efficient transport to these sites is the prerequisite for any therapeutic 
benefit. Nature itself has provided the ideal solution for this delivery problem in the form of 
viruses. These obligatorily parasitic entities need to cross cellular membranes and ultimately 
need to shuttle their genetic information into cell nuclei in order to propagate. Consequently, 
genetically engineered viruses were among the earliest and in many respects are still the most 
INTRODUCTION  10 
efficient shuttles (e.g. adenoviruses or retroviruses) used for nucleic acid delivery (Barzon et 
al., 2005).  
In addition to viral vectors also nonviral vectors, composed of synthetic modules, were 
developed. The nonviral vector engineers try to mimick viruses in terms of nucleic acid 
compaction, cell specificity, cellular uptake, endosomal escape, nuclear transport, exploitation 
of cellular functions and stability (Plank et al., 2005). Today, the most commonly used 
nonviral vectors are cationic lipid-nucleic acid complexes (lipoplexes) which were inspired by 
viral membrane envelopes and polycation-nucleic acid complexes (polyplexes) which were 
inspired by viral capsid proteins. Lipofection (transfection with lipoplexes) was developed in 
1987 by Felgner et al. who used N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium 
chloride (DOTMA) to prepare small unilamellar liposomes which were able to form cationic 
lipid-DNA complexes for successful in vitro transfection (Felgner et al., 1987). In 1989, Behr 
et al. prepared lipopolyamine-coated DNA complexes highly efficient in gene transfer 
through simple addition of excess lipospermine solution (e.g. 
dioctadecylamidoglycylspermine, abbreviated as DOGS) to DNA (Behr et al., 1989). 
Examples for popular polyplexes are poly-L-lysine (Wu and Wu, 1987), polyamidoamine 
dendrimers (Haensler and Szoka, 1993) and polyethylenimine (PEI) (Boussif et al., 1995). 
Crucial are the positive charges of the lipids and polyelectrolytes as they enable binding and 
compaction of the negatively charged nucleic acids. This compaction creates vector particles 
of small (often less than 100 nm) and uniform size and within the complexes the nucleic acids 
are also protected from degradation by nucleases (Vijayanathan et al., 2002). Further, the 
positive net charge of lipoplexes and polyplexes enables electrostatic binding of nucleic acid 
vectors to negatively charged proteoglycans (bearing heparan sulfate) on the cellular surfaces 
and thus mediates cellular uptake (Belting, 2003). It is generally accepted that endocytosis is 
the major cellular uptake mechanism for lipoplexes. However, depending on the biophysical 
properties of lipoplexes, direct fusion with the cytoplasmic membrane can occur as well (Lin 
et al., 2003; Pedroso de Lima et al., 2001). The endosomal escape of nucleic acids formulated 
as lipoplexes is thought to be mediated by lipid exchange reactions between the endosomal 
membrane and the lipoplex; i.e. anionic lipids from the endosomal membrane compete with 
the nucleic acid for binding to the cationic lipid moieties and thereby release the nucleic acid 
from the complex. Through this process, the endosomal membrane is destabilized (Xu and 
Szoka, 1996; Zelphati and Szoka, 1996a; Zelphati and Szoka, 1996b). Polyplexes are 
internalized by endocytosis as well (Rejman et al., 2005). The endosomal escape of PEI was 
explained by the “proton sponge hypothesis” (Boussif et al., 1995) which was experimentally 
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confirmed by Sonawane et al. (Sonawane et al., 2003). At physiological pH, PEI has a great 
buffering capacity by virtue of its secondary and tertiary amines and it will buffer the 
acidification process within endosomes. This means that the endosomal proton pump (H+ 
ATPase) needs to pump way more protons into the endosome until the natural endosomal pH 
of about 5.5 to 6.5 is reached. Because of H+/ Cl¯ charge coupling, endosomal Cl¯ entry is 
increased as well and consequently osmotic swelling and endosomal leakage/lysis is 
promoted. An additional mechanic destabilization may be provided through swelling of the 
internalized polymer itself due to electrostatic repulsion of its protonated amino groups. 
Similar mechanisms probably account for the activity of polyamidoamine dendrimer whereas 
polylysine is already fully protonated at physiological pH and has therefore no endosomal 
buffering capacity (Sonawane et al., 2003). Additionaly, membrane-active agents can enhance 
the endosomolytic potential of polyplexes. For example (inactivated) adenovirus particles 
(Cotten et al., 1992; Curiel et al., 1991; Wagner et al., 1992b) or pH-specific fusogenic 
peptides such as the N-terminus of influenza virus haemagglutinin HA-2 (Plank et al., 1994; 
Wagner et al., 1992a) and the N-terminus of rhinovirus HR V2 VP-1 protein (Zauner et al., 
1995) are able to disrupt the endosomal membrane at acidic pH. Further modules that can be 
added to nonviral vectors are e.g. nuclear localization signals (Ritter et al., 2003; Rudolph et 
al., 2004) to enhance nuclear uptake, or molecules like e.g. polyethylene glycol (PEG) that 
reduce the surface charge of polyplexes which results in decreased plasma protein binding, 
decreased vector and erythrocyte aggregation, stabilized complex size and prolonged 
circulation in the blood (Finsinger et al., 2000; Gunther et al., 2005). 
The delivery of naked or packaged nucleic acids for therapeutic purposes can either follow the 
ex vivo or the in vivo strategy. In the ex vivo approach, the target cells are removed from the 
patient, get genetically manipulated by nucleic acids in vitro, and are transferred back into the 
organism. In the in vivo approach, the nucleic acid drugs are delivered either systemically or 
directly to the target organ (in situ).  
 
1.3 Localized drug and nucleic acid delivery 
 
1.3.1 The importance of localized delivery 
 
The general objective in drug delivery is to obtain a drug concentration at the target site that is 
high enough to show therapeutic effect. Optimum drug delivery would even enable to exploit 
locally the full dose-response range to the level of saturation of the biologic process the drug 
INTRODUCTION  12 
is designed to act on. But in vivo it is often difficult to achieve sufficiently high drug 
concentrations at the target site because clearance of drugs by macrophages of the 
reticuloendothelial system (reticulum and endothelial cells in liver, spleen, lung and bone 
marrow) and by mobile neutrophiles, clearance by the kidney, interactions with blood 
proteins, metabolism (enzymatic degradation), immune responses and complex 
biodistribution patterns limit the bioavailability of a drug at a target site and therefore high 
doses have to be applied.  
From in vitro experiments with plasmid DNA as nucleic acid drug, it has been estimated for 
polyethylenimine(PEI)-DNA vectors, that of about 700.000 plasmid copies applied per cell in 
a standard transfection, roughly 50.000 copies per cell will be present in the cell after 7 hours 
of incubation (Kichler et al., 2001). In another publication, it was estimated that one out of 
100 microinjected cytoplasmic pDNA copies in PEI-DNA formulation reaches the nucleus 
(Pollard et al., 1998). These two estimates together would predict that at least 1.400 plasmid 
copies in PEI formulation per cell would be required in order to have one copy reach the 
nucleus. As it can not be assumed that each cell-associated copy is located in the cytoplasm, a 
more realistic estimate would predict that rather 10.000 or more copies in PEI formulation per 
cell would be required for this purpose. In vivo, as a consequence of the limited bioavailability 
of drugs at the target site, the required nucleic acid copy number per cell will be much higher 
than in cell culture. In summary, the threshold of action for nucleic acid delivery in terms of 
required copy number per target cell can be quite high. 
Unfortunately, high doses of many drugs are toxic for organs which are not the desired target 
site (e.g. kidney or liver toxicity). Sometimes toxicity even sets in before any therapeutic 
effect is detectable. The art is to apply a dose that results in a concentration with therapeutic 
effect at the target tissue while systemic toxicity and side effects are bearable for the patient. 
This therapeutic window is often narrow (Plank et al., 2003a). Therefore, localization 
(targeting) of drug delivery is an important objective and serves mainly three related 
purposes: Firstly, to exceed the local threshold of drug action at the target site while 
remaining below this threshold at non-target sites, secondly, to avoid side effects in this 
manner, and thirdly, to enlarge the therapeutic window (i.e. to locally exploit the full dose-
response range of a drug).  
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1.3.2 Hierarchies of localization (targeting) 
 
Useful classifications of drug targeting, exemplified by tumor targeting, have been published 
by Lübbe et al. (Lubbe et al., 2001). Among these, a discrimination between first, second, 
third order targeting (Lubbe et al., 2001) is useful and in addition a fourth order of targeting is 
appropriate for nucleic acid delivery. According to Lübbe et al., first order targeting refers to 
the localization of a drug at the capillary bed of the target site (organ or tissue). Second order 
targeting refers to the selective passage of the drug to target versus normal cells, and third 
order targeting involves uptake into cells by processes such as endocytosis. Fourth order 
targeting for nucleic acids is e.g. site-specific genomic integration versus random integration 
or extrachromosomal (episomal) localization. 
 
1.3.3 Passive and active targeting 
 
Passive targeting refers to the preferred accumulation of a drug formulation or a nucleic acid 
vector in a particular tissue based on the biophysical properties, notably size and charge, of 
the formulation (Nishikawa et al., 2005). Additionally, special characteristics of certain 
tissues can lead to site specific concentration of a drug. For example the enhanced 
permeability of tumor vasculature and the inadequate lymphatic drainage of solid tumors 
(enhanced permeability and retention [EPR] effect) results in an accumulation of long 
circulating particles (e.g. particles shielded with polyethylene glycol) in tumor tissues (Greish 
et al., 2003). Therefore passive targeting can be seen as a method exploiting the physical and 
biological characteristics of the drug and the recipient organism, respectively. 
For example, after tail vein injection of cationic nucleic acid formulations in mice, the 
cationic vectors aggregate due to interactions with serum proteins and blood cells and the 
large aggregates are trapped in the capillary bed of the lung, the first-pass organ from the tail 
vein route. Barron et al. injected cationic lipoplexes intravenously into mice and they 
explained the preferred gene transfer to lung by a particular high density of proteoglycans on 
lung endothelial cells to which cationic vectors can bind for efficient cellular uptake (Barron 
et al., 1999). Additionally, Zou et al. (Zou et al., 2000) showed that small positively charged 
linear PEI-DNA complexes, intravenously injected in a large nonionic glucose bolus, 
efficiently transfected alveolar cells (including pneumocytes). They assumed that the large 
nonionic glucose bolus prevents aggregation as well as mixing of the cationic complexes and 
excess free PEI with blood. This may enable extravasation in the area of lung alveoli and the 
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cationic vectors can be taken up by the heparan sulphate receptors on alveolar cells. Apart 
from the lung tropism of cationic vectors, intravenously injected cationic complexes 
accumulate in the liver where they are efficiently taken up by phagocytes (Takakura et al., 
2002). In contrast to cationic vectors, intravenously administered naked plasmid DNA 
(negatively charged) shows no passive targeting to the lung but to the liver. Polyanionic 
macromolecules like naked DNA are efficiently taken up by the scavenger receptors of liver 
nonparenchymal cells, such as Kupffer and endothelial cells. But despite efficient uptake, no 
significant gene expression was detected in the liver probably because naked plasmid DNA is 
rapidly degraded by nucleases in the serum and in the cells (Kawabata et al., 1995).  
Enhanced gene transfer into the nucleus of dividing cells can also be seen as a kind of passive 
targeting. For example, Moloney murine leukemia virus based retroviral vectors can only 
transduce dividing cells, such as tumor cells. This has been applied for specific delivery of a 
suicide gene to glioblastoma (Rainov and Ren, 2003). Further, transfection with most types of 
nonviral vectors is strongly enhanced in dividing cells, leading to increased expression levels 
in tumors (Wagner et al., 2004).  
 
Traditionally, active targeting is using some form of molecular recognition which allows a 
formulation to specifically interact with target cells (e.g. receptor-ligand and antigen-antibody 
interactions). A more comprehensive definition suggests that any active procedure exerted on 
a formulation which will lead to localization of a drug (e.g. nuclear localization sequences) is 
active targeting. Further, there are active techniques for local control of delivery (e.g. release 
of a drug from its shell by ultrasound) and nucleic acid expression (e.g. transcriptional 
targeting). All biological and all physical methods of localization and of local control belong 
to the category of active targeting, the only exception is the biodistribution due to biophysical 
properties of the drug. Methods of active targeting are available for all four hierarchies of 
localization. 
 
1.4 Biological methods of targeting applied in research up to now 
 
1.4.1 Receptor-ligand interactions 
 
Wu & Wu first introduced nonviral receptor-mediated gene delivery (Wu and Wu, 1987; Wu 
and Wu, 1988a; Wu and Wu, 1988b). By coupling asialoorosomucoid, a natural ligand of the 
asialoglycoprotein receptor on hepatocytes, to the DNA compacting moiety polylysine, they 
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generated vectors with increased target cell specificity that are taken up into cells by receptor-
mediated endocytosis. Following a similar concept, Wagner et al. established 
“transferrinfection”, based on bioconjugates of (iron-loaded) transferrin and polycations that 
enter cells by transferrin receptor mediated endocytosis (Cotten et al., 1990; Wagner et al., 
1990; Zenke et al., 1990). The transferrin receptor is widely expressed on actively dividing 
cells, such as tumor cells. Further ligands employed are e.g. galactose which binds to the 
asialoglycoprotein receptor on hepatocytes (Plank et al., 1992), mannose which binds to the 
mannose-receptor abundantly expressed on antigen-presenting dendritic cells and 
macrophages (Diebold et al., 2002; Kawakami et al., 2000), folate which binds to the folate-
receptor on tumor cells (Reddy et al., 2005), and epidermal growth factor (EGF) which binds 
to the EGF-receptor on tumor cells (Ogris and Wagner, 2002). In the meantime a multitude of 
suitable receptor ligands attached to nucleic acid binding moieties have been described. These 
include synthetic carbohydrates, synthetic peptides and recombinant proteins (Gust and 
Zenke, 2002; Pardridge, 2001; Varga et al., 2000). Another approach for targeting cell type-
specific surface molecules is the use of monoclonal antibodies, antibody fragments that bind 
the antigen (Fab), and single chain antibody fragments (scFv) consisting of the variable 
domains of the light and heavy chain (Gust and Zenke, 2002). For example, monoclonal anti-
CD3 antibodies coupled to PEI efficiently transfected T lymphocytes and stimulated human 
peripheral blood mononuclear cells (Buschle et al., 1995; O'Neill et al., 2001). Similarly, 
immuneglobulin G (IgG) was efficient for Fc receptor (which binds the constant region of the 
antibody molecule) mediated gene delivery into alveolar macrophages (Rojanasakul et al., 
1994). Fab antibody fragments of the antihuman epidermal growth factor receptor (EGFR) 
antibody conjugated to polylysine efficiently bound DNA and successfully targeted EGFR-
hyperproducing tumor cells (Chen et al., 1998). An ErbB2-specific single chain antibody 
fragment (scFv) coupled to protamine, cationic lipid and vector DNA selectively transfected 
ErbB2-positive human breast cancer cells (Li et al., 2001). 
In conclusion, providing vectors with targeting ligands can greatly improve transfection 
efficiencies and specificities if at the same time non-specific interactions can be reduced. This 
has been demonstrated in vitro and in vivo, particularly in tumor targeting upon intravenous 
adminstration. Vectors were shielded from non-specific interactions by PEGylation while 
epidermal growth factor (EGF), transferrin or galactose provided targeting specificity (Frisch 
et al., 2004; Ogris et al., 2003). Another example is a particular class of lipid-based 
nanoparticles with bound nucleic acids, provided with an integrin αvβ3-targeting ligand which 
INTRODUCTION  16 
mediated efficient and therapeutically relevant gene delivery to tumor endothelium (Hood et 
al., 2002).  
 
1.4.2 Localization sequences 
 
In the field of nucleic acid therapy, especially nuclear localization sequences (NLS) are of 
great interest because in non-mitotic cells uptake of delivered nucleic acids into the nucleus is 
a very rare event (Escriou et al., 2003). NLS are short peptide sequences comprising 
predominantly basic amino acids of endogenous or exogenous proteins such as transcription 
factors, ribosomal proteins, oncogene products, or the large T antigen of the simian virus 
(Poon and Jans, 2005) which mediate their transport from the cytoplasm through nuclear pore 
complexes (NPC) into the cell nucleus by interaction with specific nuclear shuttle proteins 
called nuclear transport receptors or karyopherins (importin β, transportin, or the adapter 
importin α). Whereas small molecules such as metabolites pass the NPC through passive 
diffusion (the channel diameter is limited to 9 nm), larger proteins require a selective (and 
active) transport mode (the channel diameter opens up to 45 nm) which is based on nuclear 
localization signals (Peters, 2005). The nuclear transport receptors bind their transport cargo 
in the cytoplasm through nuclear localization sequences (NLS) and subsequently mediate 
their translocation via direct interaction with the NPC to the nuclear side, release the cargo 
and finally return to the cytoplasm to begin with a new shuttling cycle. Directionality of the 
transport process is accomplished through a RanGTP concentration gradient across the 
nuclear envelope, i.e. low cytoplasmic and high nuclear RanGTP concentration. RanGTP 
binds to the dimeric transport complex consisting of the nuclear transport receptor and the 
cargo in the nucleus thereby dissociating the cargo from the nuclear transport receptor 
resulting in the release of the cargo in the nucleus. “Classical” NLS motifs (e.g. from the large 
T antigen of the simian virus) do not bind directly to the nuclear transport receptor (importin 
β or transportin) but they require the adapter molecule importin α (Pemberton and Paschal, 
2005). 
Strategies to provide nucleic acids with nuclear localization signals (NLS) are either direct 
conjugation (covalent binding) of a NLS to the nucleic acid (Zanta et al., 1999) or 
noncovalent incorporation of NLS peptides into gene vector complexes and NLS-
modification of the gene transfer carrier, respectively (Chan et al., 2000; Ritter et al., 2003; 
Rudolph et al., 2003).  
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Apart from nuclear localization signals on peptides, Dean et al. have reported that certain 
plasmid DNA sequences translocate into the nucleus after cytoplasmic delivery. Such 
nuclear translocation has been observed when a 72 bp fragment of the simian virus 40 (SV40) 
enhancer element is present on the plasmid DNA. The authors postulated the “piggyback” 
mechanism which is based on the binding of transcription factors (harbouring NLS) to the 
enhancer element and transport into the nucleus by exploiting the endogenous 
nucleocytoplasmic transport machinery (Dean et al., 2005).  
Finally, it has to be mentioned that Pollard et al. found out that polymers like PEI or 
polylysine promote gene delivery from the cytoplasm into the nucleus (Pollard et al., 1998). 
 
1.4.3 Site-specific genomic integration 
 
The wild-type adeno-associated virus (AAV) can insert its genome at a specific site 
(AAVS1) in human chromosome 19 through the activity of a specific replicase/integrase 
protein (Rep) binding both the AAVS1 and the viral inverted terminal repeats (ITRs). But due 
to the very limited packaging size of AAV particles, AAV vectors are deleted of all viral 
genes and have therefore lost the Rep-mediated, site-specific integration property of the wild-
type virus (Ponnazhagan et al., 2001). Recchia et al. generated a hybrid AAV-adenovirus 
vector carrying a double-reporter gene integration cassette flanked by AAV ITRs and a tightly 
regulated, drug-inducible Rep expression cassette (Recchia et al., 2004). Rep-dependent 
integration of ITR-flanked cassettes of intact size and function was obtained in human 
primary cells, cell lines and in an AAVS1 transgenic mouse model. 
Site-specific genomic integration has also been achieved with the φC31 integrase system. 
This is a recombinase found in a Streptomyces phage that mediates stable chromosomal 
integration of genes into host genomes without any additional co-factors. The genomic 
integration is unidirectional and sequence specific. The φC31 integrase mediates the 
integration of attB attachment sites of the transgenic DNA into attP attachment sites in the 
host genome, which occur as pseudo-attP attachment sites in mammalian genomes (Groth and 
Calos, 2004).  
Distantly related to the φC31 integrase is the Lactococcus lactis cremoris phage TP901-1 
integrase which carried out efficient site-specific intramolecular integration on a transfected 
plasmid substrate in the human cell environment without any additional co-factors (Stoll et 
al., 2002). Recombinases such as Cre, FLP and beta-recombinase perform site-specific 
integration and excision (Branda and Dymecki, 2004; Canosa et al., 2003). But as the net 
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integration frequency is low, these recombinases are not an appropriate tool for site-specific 
gene therapy approaches. 
The bacterial transposon Tn7 is unique among transposons, in that it inserts into a single site 
in the Escherichia coli chromosome. This site is termed attTn7 and insertion is mediated by 
the sequence-specific DNA binding of the target selector protein TnsD. Kuduvalli et al. 
(Kuduvalli et al., 2005) showed that Tn7 can transpose in vitro downstream to the glutamine-
fructose-6-phosphate-transaminase-1 and 2 gene (gfpt-1 and gfpt-2) in the human genome. 
The presence of a Tn7 element at a target site prevents multiple insertions and one would 
expect a single copy of Tn7 to be inserted in a site- and orientation-specific manner. 
 
1.5 Biological methods of local control applied in research up to now 
 
1.5.1 Tissue-specific and inducible promoters (“transcriptional targeting”) 
 
Tissue-specific promoters switch on their genes only in certain tissues. Therefore in gene 
therapy, tissue-specific promoters are combined with reporter and therapeutic genes to 
achieve local tissue-specific expression. Some examples are the tyrosinase promoter to target 
melanocytes and melanomas, the prostate-specific antigen (PSA) promoter which is expressed 
predominantly in the prostate, the albumin-promoter which is active in the liver and 
hepatocellular carcinomas, the surfactant protein B-promoter for targeting type II alveolar and 
bronchial cells, the ovarian-specific promoter which is expressed in ovarian tissue and the 
human vascular smooth muscle cell (VSMC) alpha-actin promoter which is active in vascular 
smooth muscle, cardiac muscle and skeletal muscle (Robson and Hirst, 2003). 
Inducible promoters can be activated or attenuated by exogenous stimuli like e.g glucose or 
drugs. By means of such stimuli the duration and level of gene expression can be regulated. 
For example, the human insulin promoter and the glucose 6-phosphatase promoter may be 
useful for local regulated hepatic insulin gene expression in type 1 diabetes (Burkhardt et al., 
2003). The most famous drug-responsive promoters are tetracycline controlled (Toniatti et al., 
2004). In the tet-off system (Gossen and Bujard, 1992), an engineered minimal promoter is 
activated in the absence of tetracycline whereas in the tet-on system (Gossen et al., 1995), 
tetracycline derivatives (like doxycycline or anhydrotetracycline) activate transcription. 
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1.5.2 Activation of prodrugs 
 
A very elegant method of local control is the conversion of a prodrug into its active form in 
the target tissue. Two examples for such a strategy are the antibody directed enzyme-prodrug 
therapy (ADEPT) and the gene directed enzyme prodrug therapy (GDEPT). 
The antibody directed enzyme-prodrug therapy or ADEPT includes a two-step process 
for drug delivery. In the first step, monoclonal antibodies conjugated chemically to enzymes 
or monoclonal antibody-enzyme fusion proteins were delivered to cell surfaces presenting the 
corresponding antigens. In the second step, prodrugs were administered and converted into 
active agents at the sites where monoclonal antibody-enzyme conjugates are located. An 
example for an enzyme used in ADEPT is the cytosine deaminase, a protein that converts the 
non-cytotoxic 5-fluorocytosine into the anticancer drug 5-fluorouracil (Sharma et al., 2005).  
The gene directed enzyme prodrug therapy (GDEPT) is a therapy for malignant diseases. 
An exogenous gene coding for an enzyme is delivered to the target tumor cells. The expressed 
enzyme can then convert a non-toxic prodrug into a cytotoxic drug. One of the most 
frequently used systems is the Herpes simplex virus thymidine kinase (HSV-tk) combined 
with ganciclovir (McKeown et al., 2004).  
 
1.5.3 Triggering localized drug delivery 
 
Enzyme-activated targeting of liposomes uses tissue-specific enzymes to locally transform 
stable liposomes (e.g. composed of N-acetylated alanyl alanine linked to 
dioleoylphosphatidylethanolamine [N-Ac-AA-DOPE]) into fusogenic lipid structures 
(hexagonal phase). The tissue-specific enzymes can be located in the vicinity of the target 
cells, can be presented by target cells or can be located in endolysosomal compartments of 
target cells. For example the enzyme elastase is abundant in inflammatory tissues (like in 
cystic fibrosis lungs or rheumatoid arthritis joints), either in a free form or bound to a receptor 
of human neutrophils (Meers, 2001).  
pH-sensitive liposomes, polymers and peptides provide a further strategy for triggered 
localized drug delivery. In response to lower pH in pathological tissues (e.g. tumor, 
metastases, inflammation and infection tissues) or in endolysosomal compartments, pH-
sensitive liposomes (containing e.g. DOPE) can be locally transformed from a stable lamellar 
phase into fusogenic lipid structures (hexagonal phase) and their encapsulated drugs are 
released directly into the cytoplasm of the target cells (Simoes et al., 2004). Analogously, the 
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incorporation of pH-specific polymers (like e.g. PEI) or pH-specific fusogenic peptides (such 
as the N-terminus of influenza virus haemagglutinin HA-2) into nucleic acid complexes 
enables disruption of the endosomal membrane at acidic pH and thus release of the nucleic 
acid vector into the cytoplasm (Wagner, 2004). 
Finally, biological stimuli-sensitive hydrogels have the potential for locally acting controlled 
drug and nucleic acid release systems. Hydrogels can protect an entrapped drug from hostile 
environments (e.g. the presence of enzymes and low pH in the stomach) and they can control 
drug release by reversible volume phase transitions or gel-sol phase transitions in response to 
environmental stimuli. Biological stimuli are e.g. pH, glucose concentration, specific ion 
concentrations, specific antigens and thrombin (Miyata et al., 2002; Qiu and Park, 2001).  
 
1.6 Physical methods of targeting applied in research up to now 
 
1.6.1 Gravitational force 
 
Methods using gravitational force are only applicable in cell culture, but cell culture serves as 
an instructive model from which conclusions for in vivo applications can be drawn. From cell 
culture experiments, Luo and Saltzman concluded that nucleic acid transfection efficiency is 
limited by the number of vector – cell contacts or in other words by low vector concentration 
at the cell surface (Gemeinhart et al., 2005). The chance for a vector to get in contact with a 
cell is mainly by Brownian motion (diffusion). The probability of contact increases with drug 
concentration, incubation time and temperature (which can not be chosen arbitrarily). The 
number of contacts between vector and cells is proportional to the number of cellular uptake 
events unless saturation of cells with vectors is reached. In the following lines three methods 
exploiting gravitational force to obtain enhanced accumulation of vectors on cells in cell 
culture (first order targeting) are introduced. 
Settlement of nucleic acid vectors under gravity as a method to increase transfection 
efficiencies in cell culture was used by Luo and Saltzman (Luo et al., 2004; Luo and 
Saltzman, 2000). They associated vectors with dense silica particles that sedimented vectors 
on the cell surfaces and consequently the vector concentration on the cell layer and the 
transfection efficiency was significantly increased. 
The precipitate formation method exploits the phenomenon that large and heavy vector 
precipitates settle in cell culture. Therefore with vector precipitates the number of vector - cell 
contacts is significantly higher than with small vectors which have only a chance to get in 
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contact with the cells by Brownian motion (Graham and van der Eb, 1973; Tovell and Colter, 
1967). Already in 1973 Graham and Van der Ebb established the calcium phosphate 
precipitation method (Graham and van der Eb, 1973). Also for PEI-DNA vectors, it has been 
found that large DNA complexes transfect more efficiently than smaller ones (Ogris et al., 
1998).  
Centrifugation (acceleration) of nucleic acid vectors down to the cell layer(s) in cell culture 
results in enhanced vector accumulation on the cell surfaces (Boussif et al., 1996; Bunnell et 
al., 1995; Huth et al., 2004; O'Doherty et al., 2000). 
An example for increased transduction of non-adherent pheripheral blood lymphocytes with 
retroviral vectors by centrifugation was given by Bunnell et al. (Bunnell et al., 1995). 
Centrifugation of the retroviral vector and PBLs-containing supernatant was one important 
step in their optimized transduction protocol. 
 
1.6.2 Local injection 
 
Direct injection of nucleic acids into target tissues was performed by several groups in the 
1980ies (Benvenisty and Reshef, 1986; Dubensky et al., 1984; Will et al., 1982). For example 
Benvenisty and Reshef injected DNA precipitated with calcium phosphate intraperitoneally 
into newborn rats and observed gene expression in liver and spleen. In 1990, Wolff and 
coworkers found that direct intramuscular injection of naked DNA and RNA expression 
vectors leads to high and persistent transfected gene expression (Wolff et al., 1990), 
(Herweijer and Wolff, 2003). 
 
1.6.3 Intravascular delivery combined with occlusion of the blood outflow from the 
target organ 
 
Intravascular nucleic acid delivery into the liver combined with occlusion of the blood 
outflow from the liver was used by Budker et al. in 1996. They found that naked DNA 
injected in hypertonic solution intraportally in mice with transient occlusion of hepatic veins 
leads to quite efficient gene delivery to hepatocytes (Budker et al., 1996). Later, the same 
group injected naked plasmid DNA and siRNA into transiently isolated distal veins of 
mammalian limbs and obtained efficient nucleic acid delivery to limb skeletal muscle 
(Hagstrom et al., 2004). 
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1.6.4 Hydrodynamic force 
 
Hydrodynamic methods of nucleic acid delivery in cell culture are only using the acceleration 
of vectors towards target cells whereas hydrodynamic methods of nucleic acid delivery in vivo 
are a combination of orthotopic (localized) vector administration and an acceleration of 
vectors towards target cells concomittant with permeabilization of the target tissue. 
 
Nucleic acid vector flow towards target cells is a method for cell culture experiments. 
Chuck et al. (Chuck et al., 1996) showed that the short half-lives of retroviral vectors limit the 
distance that they can effectively travel in cell culture by Brownian motion and that therefore 
only a relatively small number of vectors can get in contact with the cell layer(s). But net 
convective flow of vector-containing medium through a layer of target cells increased the 
vector - cell contacts and consequently enhanced the transduction efficiencies significantly. 
Hydroporation is an in vivo method which was established in two independent studies in 
1999. Rapid injection of large volumes of DNA solutions (volumes equalling or exceeding the 
animal’s blood volume) in tail veins of mice resulted in enormous expression levels in the 
livers of the animals with up to 40 % of the hepatocytes becoming transfected (Liu et al., 
1999; Zhang et al., 1999). The mechanism of this method (in mice) involves a transient 
irregularity of heart function, but importantly an enlargement of liver fenestrations and a 
transient permeabilization of hepatocyte membranes (Zhang et al., 2004). Most recently, it 
was shown that the method may be relevant in therapy, as it can be applied in transiently 
isolated limbs to achieve highly efficient nucleic acid delivery throughout muscle cells of the 
isolated limb (Hagstrom et al., 2004).  
 
1.6.5 Aerosolization 
 
Aerosols are solid (Greek: sol) particles and/or liquid drops, that float in the air (Greek: aero). 
Aerosol particles can be from ca. 1 nm to ca. 100 µm in diameter. The aerosol therapy enables 
direct deposition of drugs (= localization) in the upper and lower airways. The optimum 
particle size in drug aerosols is between 1 and 5 µm. Droplets with higher diameters are not 
delivered to the lower airways and droplets with lower diameter are exhaled to a large extent 
by the patient.  
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In nucleic acid delivery, especially PEI-based formulations have proven stable during jet 
nebulization and in animal models gene expression is restricted to the lung (Densmore, 2003; 
Rudolph et al., 2004). 
 
1.6.6 Ballistic methods 
 
In the gene gun method, gold particles coated with DNA are shot into target tissues or cells 
by using a gene gun. This approach allows DNA to penetrate directly through cell membranes 
into the cytoplasm or even nuclei and to bypass the endosome/lysosome where it would get 
enzymatically degraded. For example skin, liver and muscle have been successfully 
transfected (Wells, 2004).  
The biojector method is using an instrument, the biojector, which employs compressed 
carbon dioxide as a power source to eject liquid medication through a tiny orifice that is held 
against the patient’s skin. In this way, an ultra-fine stream of high pressure fluid is created 
that penetrates the skin without using a needle and intramuscular or subcutaneous injections 
are possible. Trimble et al. used the biojector technique to deliver DNA vaccines 
intradermally (Trimble et al., 2003). Also Mumper and Cui described the usage of biojectors 
to deliver plasmid DNA-coated cationic nanoparticles intradermally for genetic immunization 
(Mumper and Cui, 2003). 
 
1.6.7 Systems for controlled drug release 
 
Controlled release systems for low-molecular-weight drugs and proteins are well established 
in industry and recently researchers try to adapt these systems to the delivery of nucleic acids 
(Pannier and Shea, 2004). Systems for controlled release of plasmid DNA (gene activated 
matrices) were shown to increase transgene expression and enhance the duration of 
expression relative to naked plasmid DNA delivery upon injection of aqueous solutions. As 
an advantage of these systems, naked plasmid DNA or gene vectors are delivered locally 
which avoids distribution to more distant tissues and reduces both toxicity to nontarget cells 
and immune response to the gene vector. Generally, there are two classes of controlled release 
depots: solid drug carrier systems (which get implanted) like e.g. collagen or poly(lactide-
co-glycolide) (PLG) matrices and injectable carrier systems (which solidify to form a depot 
after injection) like e.g. PEG-(poly-lactic-co-glycolic acid)-PEG (PEG-PLGA-PEG) 
hydrogels, PLG in glycofurol, fibrin glue or collagen solutions. Another type of injectable 
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implants for controlled drug release are nanoparticles consisting of PLG, PLGA, gelatin or 
chitosan and microparticles composed of PLGA or poly-ortho-esters (Plank et al., 2005). In 
our laboratory, collagen sponges were used as solid nucleic acid carrriers and in vitro and in 
vivo experiments revealed that especially the coating with copolymer-protected PEI-DNA 
vectors leads to sustained gene delivery (Scherer et al., 2002b). 
 
1.6.8 Electric fields 
 
Electroporation is a widely used physical method to introduce polar and charged agents such 
as dyes, drugs, DNA, RNA, proteins, peptides and amino acids into cells. Traditionally, 
electroporation is performed with large electrodes in a batch mode to transform bacteria or to 
transfect eukaryotic cells in suspension. In vivo electroporation, also called electrotransfer, is 
a promising strategy for the local treatment of muscle disorders or of tumors. Special 
electrodes produce extremely localized electric fields and thus locally enhanced nucleic acid 
transfer is possible (Andre and Mir, 2004; Bloquel et al., 2004).  
The Nucleofector technology, developed by Amaxa biosystems (www.amaxa.de), uses a 
combination of electric pulses and special solutions to introduce nucleic acids directly into the 
nucleus of cells in culture. Consequently, transfection of cells is no longer dependent on cell 
division, i.e. even non-dividing cells such as resting blood cells or neurons can be transfected 
with high efficiencies (Hamm et al., 2002). 
 
1.6.9 Magnetic drug targeting 
 
The principle of magnetic drug targeting is that drugs bound to magnetic particles are guided 
by an external magnetic field to target tissues like e.g. tumors. Successful targeting of 
magnetic particle-drug complexes has been shown in animal models and the magnetic carriers 
are well tolerated by animals and humans. 
A detailed description of the development of magnetic drug targeting and its current state is 
given in 1.8. 
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1.7 Physical methods of local control applied in research up to now 
 
1.7.1 Stress-inducible promoters (“transcriptional targeting”) 
 
In gene therapy, the local generation of physical stress enables local tissue-specific expression 
of delivered therapeutic genes which are driven by stress-inducible promoters. For example 
hyperthermia (locally generated through ultrasound, lasers, microwaves or magnetite 
cationic liposomes in an alternating magnetic field) induces transcription of genes under 
control of heat-sensitive promoters like the HSP70 or gadd 153 promoter. The HSP70 
promoter is further inducible by low frequency (< 300 Hz) electromagnetic fields (EMFs). 
Hypoxia (e.g. in tumors) activates genes under control of hypoxia response element (HRE) 
which are contained e.g. in the erythropoietin (Epo) and the vascular endothelial growth factor 
(VEGF) gene. And finally, ionizing radiation (IR) activates IR response elements which 
were found in the early growth response 1 (Egr1) gene promoter (Blank and Goodman, 2004; 
Robson and Hirst, 2003). 
 
1.7.2 Triggering localized drug delivery 
 
Drugs can be formulated in a manner that makes physical activation necessary to induce drug 
release. In these systems, release of the drug takes place at the site to which the physical 
trigger is focussed. Examples for such controlled release formulations are microbubbles, 
temperature-sensitive liposomes and physical stimuli-sensitive hydrogels. 
Microbubbles are gas-filled microspheres (smaller than 5 – 7 µm) or gas emulsions. The 
shell can consist of renografin, indocyanin green, carbohydrates such as dextrose, proteins, 
denatured proteins, surfactants, lipids or synthetic polymers such as polylactides. 
Perfluorocarbons have turned out to be ideal gases for microbubble preparation due to low 
aqueous solubility and sufficient volatility. More recent compositions are so-called 
nanoemulsions consisting of a bubble shell filled with a liquid perfluorocarbon. Both low 
molecular weight drugs and high molecular weight drugs such as nucleic acids can be 
associated with microbubbles. At the target site ultrasound is used to trigger local drug release 
from the microbubbles (Bekeredjian et al., 2003; Tsutsui et al., 2004).  
Temperature-sensitive liposomes can release their drugs specifically at a target area where 
heat is applied. For example dipalmitoylphosphatidylcholine (DPPC) membranes undergoe a 
gel-to-liquid phase transition at 41 degrees Celsius and liposomes made of DPPC release their 
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contents at this clinically attainable temperature. Inclusion of various colipids, such as 
distearoylphosphatidylcholine (DSPC) and cholesterol, can further improve the temperature 
sensitivity of DPPC liposomes. Additionally, thermosensitive polymers like e.g. poly(N-
isopropylacrylamide) (PNIPAM) are employed to optimize temperature-sensitive liposomes 
(Kono and Takagishi, 2004). 
Finally, physical stimuli-sensitive hydrogels can control drug release by reversible swelling-
shrinking phase transitions or gel-sol (solution) phase transitions in response to physical 
stimuli like e.g. temperature, electric current, light and pressure (Qiu and Park, 2001). 
 
1.8 The development of magnetic drug targeting and its current state 
 
Magnetic drug targeting was already mentioned in 1.6 (physical methods of targeting applied 
in research up to now) but because of its great importance for this thesis its developement and 
current state is described here in an extra paragraph. 
In 1963, Mayers et al. showed in animal experiments that radioactive and nonradioactive 
carbonyl iron particles (1 to 3 µm in size) could be held in a specific location in blood and 
lymphatic vessels by an external permanent magnet. Further they demonstrated magnetically 
controlled extravasation of radioactive iron particles from arteries. From these results Mayer 
and coworkers concluded that magnetically directed iron particles could be used as contrast 
agents for roentgenogramms, for localized radiation therapy or for targeted delivery of 
chemotherapeutic agents (Meyers et al., 1963). In 1965, Alksne and Fingerhut showed in 
experiments with dogs that it is possible to induce thrombosis of an artery or of an artificial 
aneurism by intra-arterial administration of carbonyl iron-albumin spheres (average diameter 
3 µm) and attraction of these particles to an external permanent magnet (Alksne and 
Fingerhut, 1965). In 1975, Turner et al. injected carbonyl iron-silicone microspheres into the 
arteries of dogs and successfully directed the particles to the kidney by a superconducting 
electromagnet. This technique should be used for arterial vascular occlusion of 
hypernephromas and other organs (Turner et al., 1975). Widder et al. (Widder et al., 1978) 
were probably the first who successfully realized the concept of magnetically controlled drug 
targeting. They prepared biodegradable albumin microspheres with entrapped Fe3O4 and 
adriamycin HCl with a mean particle size of 1 µm. When these magnetic albumin 
microspheres were infused into the caudal artery of rat tails, approximately 50% of the 
carriers was retained in the targeted tail segment exposed to a permanent magnetic field of 
8000 Oe (oersteds) and the adriamycin concentration at the target segment was comparable to 
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that achieved by administration of a 100-fold higher dose of the free drug. In a further 
publication, Widder and coworkers described the application of this drug delivery system to 
Yoshida sarcoma grown in the rat tail (Widder et al., 1981). Most of the treated animals had 
complete tumor remission in contrast to progressive tumor growth in the control group. 
Independently of Widder et al., Kato et al. developed a magnetic control system of 
microcapsules. They constructed two prototypes of ferromagnetic ethylcellulose 
microcapsules containing the anticancer drug mitomycin C (FM-MMC-mc): the outer type 
(approximately 300 µm in diameter) with zinc ferrite on the capsular surface and the inner 
type (approximately 250 µm in diameter) with zinc ferrite in the core. Both types were 
magnetically responsive and provided sustained release properties. Animal studies showed 
that the microcapsules could be magnetically controlled in the artery and urinary bladder and 
VX2 tumors in the rabbit hind limb and urinary bladder were succesfully treated (Kato et al., 
1984). In 1989, Gupta et al. demonstrated by transmission electron microscopy that 
adriamycin-associated magnetic albumin microspheres (similar preparations as those used by 
Widder et al.) traverse the vascular endothelium of even healthy tissue and confirmed second-
order drug targeting (Gupta et al., 1989). In 1994, Häfeli et al. prepared biodegradable 
poly(lactic acid) microspheres that incorporate magnetite and the beta-emitter Yttrium-90 
(Hafeli et al., 1994). Subsequently, they showed in a murine tumor model that 24 h after 
intraperitoneal injection, roughly 73% of the radioactivity was found in a subcutaneous tumor 
exposed to a magnet (Hafeli et al., 1995). A new and much smaller type of magnetic carrier, 
starch-phosphate coated iron oxide nanoparticles with an average diameter of 100 nm, was 
used by Lübbe et al. (Lubbe et al., 1996a). The endstanding negatively charged phosphate 
groups on the surface of these particles allowed reversible electrostatic binding of the 
positively charged chemotherapeutic agent epirubicin. In animal experiments, epirubicin 
loaded nanospheres were injected intravenously in tumor-bearing nude mice and rats and 
directed into the tumor using a permanent magnetic field. The magnetic carrier/epirubicin 
complex was well tolerated by the animals and tumor remission was achieved. As a second 
step, Lübbe et al. used this approach for the first clinical experiments in human patients with 
magnetic drug targeting worldwide (Lubbe et al., 1996b). This phase I clinical trial included 
14 patients with advanced solid tumors and for magnetic drug targeting a permanent magnet 
was arranged at the tumor surface outside of the organism. The studies showed that magnetic 
drug targeting with epirubicin (4’-epidoxorubicin) was well tolerated and that the ferrofluid 
could be successfully directed to the tumors in about one-half of the patients. Lubbe et 
coworkers concluded that magnetic drug targeting seems to be safe but improvements are 
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necessary to make it more effective. Subsequently Alexiou et al. tried to improve the efficacy 
of magnetic drug targeting in tumor-bearing rabbits (Alexiou et al., 2000). They used starch-
phosphate coated iron oxide particles (100 nm in size) as well and the positively charged 
chemotherapeutic agent mitoxantrone which was reversibly (electrostatically) bound to the 
negatively charged phosphate groups. The ferrofluid-mitoxantrone complexes were injected 
intra-arterially (femoral artery) or intravenously (ear vein) and for magnetic drug targeting an 
external extremely strong electromagnet (1.7 Tesla) was focused on the experimental VX-2 
squamous cell carcinoma in the median portion of the hind limb of rabbits. The intra-arterial 
application of the complexes plus magnetic field resulted in significant complete and 
permanent remission of the tumors compared with the control group (no treatment) and the 
intravenous group. Additionally, no signs of toxicity were detected. A special type of 
magnetic particles (MTCs, Magnetic Targeted Carriers) was developed and used by FeRx 
Incorporated, San Diego, USA. MTCs are microparticles (0.5 to 5 µm in size) composed of 
metallic (elemental) iron and activated carbon and are prepared by a high-energy milling 
process (Goodwin et al., 1999; Rudge et al., 2000). These particles have a higher magnetic 
susceptibility than particles made of iron oxides (including magnetite [Fe3O4] and hematite 
[Fe2O3]) and are therefore captured more efficiently by an external magnetic field. Many 
chemotherapeutic agents and also peptides and proteins can be simply adsorbed to the 
activated carbon component of MTCs and controlled release (desorption) of the drugs is 
possible (Johnson et al., 2002; Rudge et al., 2001). In a swine model, MTC and MTC-drug 
suspension was administered intra-arterially by placing a catheter proximal to the selected 
target site and a magnet was positioned on the body surface above the desired site (Goodwin 
et al., 1999; Goodwin et al., 2001). Even irreversible binding of radionuclides to MTCs could 
be achieved by simple chemistry modifications (Hafeli et al., 2003). However, the lead 
product of FeRx was doxorubicin adsorbed to MTC (MTC-DOX) and it was used in a clinical 
study where 32 patients with hepatocellular carcinoma have been enrolled. But in April 2004, 
a phase II/III clinical trial involving this technology has been discontinued as the clinical 
endpoints could not be met with statistical significance. 
In summary, at least in animal models it has been clearly demonstrated that (i) magnetic drug 
targeting is feasible even if the drug administration site is remote from the target site under 
magnetic field influence, (ii) that magnetic particles can extravasate under the influence of the 
magnetic field and that the magnetic carriers are well tolerated. 
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1.9 Topic of this thesis 
 
As described in 1.1, up to date several approaches for nucleic acid-based therapy are available 
and once nucleic acid vectors are accumulated at the target cells (like e.g. in cell culture) they 
show in many cases efficient nucleic acid transfer to the desired cellular compartments 
(nucleus or cytosol). But despite numerous approaches (see above), efficient concentration of 
nucleic acid vectors at the target site in vivo is still one of the major challenges for clinical 
successful nucleic acid therapy. 
A very promising physical method to localize anti-cancer drugs in vivo is provided by 
magnetic drug targeting (see 1.6.9 and 1.8). In this method, the drug is bound to magnetic 
particles and an external magnetic field can guide the applied magnetic particle-drug complex 
to the desired site. At least in animal models it has been clearly demonstrated that magnetic 
drug targeting is feasible even if the drug administration site is remote from the target site 
under magnetic field influence, that magnetic particles can extravasate under the influence of 
the magnetic field and that the magnetic carriers are well tolerated. 
Basis of this thesis was the idea to use the principle of magnetic drug targeting for the 
delivery of nucleic acids. Similar as cytostatics, nucleic acids require third order targeting 
which involves cellular uptake and localization in the cytoplasm or in the nucleus. Moreover, 
some nucleic acid approaches require even fourth order targeting when e.g. site-specific 
genomic integration is desired. Referring to the chemical structure, nucleic acids are quite 
different from classical cytostatics. While anti-cancer drugs are usually low molecular weight 
molecules, nucleic acids are high molecular weight macromolecules harbouring a high 
number of negative charges.  
The objective of this thesis was to bind nucleic acid vectors to magnetic particles in a way that 
allows nucleic acid vectors to be magnetically controlled and additionally at the target site the 
nucleic acid vectors should still retain all their functionalities like e.g. endosomal escape or 
accessibility to the transcriptional machinery.  
For this thesis superparamagnetic iron oxide nanoparticles with various cationic or anionic 
coatings were provided by Chemicell GmbH, Berlin, and the first step was to find and to 
further develop appropriate particles for vector binding and efficient magnetically controlled 
nucleic acid transfer in cell culture without toxic side effects. Subsequently, the mechanism of 
magnetic nucleic acid targeting, termed “magnetofection”, was examined by cell culture 
experiments and through electron microscopy. In further cell culture experiments the 
magnetofection method was optimized, the nucleic acid transfer efficiency compared to 
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standard transfection methods without magnet, magnetic-field guided localization of nucleic 
acid transfer was shown, different cell types were transfected and the applicability of 
magnetofection in a pig, a rabbit and a rat model was proven. In all experiments bacterial 
plasmids harbouring the cDNA of reporter genes (either luciferase or β-galactosidase) were 
chosen as representatives for the large number of different nucleic acid-based drugs and 
exemplary nonviral vectors were used.  
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2 MATERIALS AND METHODS 
 
2.1 Abbreviations, reagents and materials 
 
If not otherwise stated, reagents were purchased from Sigma-Aldrich (Deisenhofen, 
Germany). 
 
Abbreviation Article purchased from 
ACC DSMZ number  
aqua dest. distilled water  
ATP adenosine-5‘-triphosphate Roche, Mannheim 
AVET adenovirus-enhanced-transfection  
α-32P-dATP deoxyadenosin-5’-triphosphate which 
contains radioactive 32P in the α 
position (phosphorus atom bonded to 
the ribose) 
Hartmann Analytic, 
Braunschweig 
 β-mercaptoethanol  
bPEI biotinylated polyethylenimine, 
preparation see in “General methods” 
 
Bq becquerel  
Br bromine  
BSA bovine serum albumin Bio-Rad, Munich 
°C degrees Celsius  
CA membrane cellulose acetate membrane Peske, Aindling-Pichl, 
Germany 
cDNA complementary DNA  
 cell culture dishes, 96-well and 24-well 
and 6-well plates, tissue culture flasks  
(all articles gamma-sterilized and cell 
culture-treated) 
produced by TPP, 
Switzerland 
purchased from Peske, 
Aindling-Pichl, Germany 
 chloroform Fluka, Neu-Ulm 
CHO-K1 cells Chinese hamster ovary cell line DSMZ, Braunschweig 
Chol cholesterol  
Ci curie  
cm centimeter  
CO2 carbon dioxide  
COPROG copolymer-protected gene vector  
cP centipoise = 1/100 poise  
c.p.m. counts per minute  
d diameter  
DMEM-medium Dulbecco’s Modified Eagles medium Gibco, Eggenstein 
DMF N, N dimethylformamide  
DMSO dimethyl sulfoxide  
DNA deoxyribonucleic acid  
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DOTAP 1,2-dioleoyl-3-trimethylammonium-
propane (transfection reagent) 
Avanti Polar Lipds, USA 
DSMZ Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
(Braunschweig, Germany) 
 
DTT dithiothreitol  
e.g. for example  
Ellman Reagent dithiobis-2-nitrobenzoic acid Aldrich, USA 
EM electron microscope  
EtOH ethanol  
FCS fetal calf serum Gibco, Eggenstein 
 formaldehyde  
g gramm  
g gravitational constant (at centrifugation)  
GP GenePORTER (transfection reagent) Gene Therapy Systems 
(GTS), La Jolla, CA, USA 
 glucose  
 glutaraldehyde  
 glycil-glycine  
h hours  
h height  
HaCaT cells cell line derived from human 
keratinocytes 
kindly provided by Dr. 
Martin Mempel, 
Dermatology, TU Munich, 
Germany 
HBS HEPES buffered saline (20 mM 
HEPES, pH 7.3; 150 mM NaCl) 
 
HCl hydrochloric acid  
HeLa cells human cervix carcinoma cell line DSMZ, Braunschweig 
HEPES N-2-hydroxyethyl-piperazine-N‘-2-
ethanesulphonic acid 
Aldrich, USA 
HepG2 cells human hepatic carcinoma cell line DSMZ, Braunschweig 
H2O water (aqua)  
i.m. intramuscular  
inact. adv inactivated adenovirus: the adenovirus 
was psoralen-treated (to inactivate the 
viral DNA) and biotinylated; it was 
used as endosomolytic agent 
kindly provided by Prof. Dr. 
Ernst Wagner, Vienna 
University Biocenter, Austria 
INF7 synthesized membrane-disrupting 
peptide derived from the amino-
terminal sequence of influenza virus 
hemagglutinin HA-2 
in house synthesis 
i.v. intravenous  
kb kilobases  
KCl potassium chloride  
kDa kilodalton = 1000 dalton  
K3Fe(CN)6 potassium ferricyanide crystalline  
K4Fe(CN)6x3H2O potassium ferricyanide trihydrate  
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kg kilogramm  
kV kilovolt  
l liter  
LDV laser Doppler velocimetry  
LF Lipofectamine (transfection reagent) Life Technologies, Karlsruhe 
 luciferase Roche Mannheim 
 luciferin Roche Mannheim 
µA microampere  
µg microgramm  
µl microliter  
µm micrometer  
µM micromolar (µmol/l)  
M molar (mol/l)  
mg milligramm  
MgCl2 magnesium chloride  
MgSO4 magnesium sulfate  
min minutes  
ml milliliter  
mm millimeter  
mM millimolar (millimol/l)  
mmol millimol  
mT millitesla  
mV millivolt  
Mw molecular weight in g/mol or dalton  
NaCl sodium chloride  
Nd-Fe-B magnet neodymium-iron-boron magnet 
(NeoDelta) 
IBS Magnet, Berlin 
ng nanogramm  
NHS-LC-Biotin succinimidyl-6-(biotinamido) hexanoate Pierce, Rockford, IL, USA 
NIH National Institute of Health  
NIH 3T3 cells mouse fibroblast cell line (from the 
NIH) 
DSMZ, Braunschweig 
nm nanometer  
nmol nanomol  
N/P ratio nitrogen (from the PEI)/phosphate 
(from the DNA) ratio 
 
32P radioactive phosphorus  
PBS phosphate buffered saline  
pCMV-β-gal plasmid coding for the β-galactosidase kindly provided by Dr. 
Walter Schmidt, Intercell, 
Vienna, Austria 
PCR polymerase chain reaction  
pDNA plasmid-DNA (purified by cesium 
chloride gradient) 
 
PEG polyethylene glycol  
PEI polyethylenimine, if not otherwise 
stated 25 kD; preparation see in 
“General methods” 
 
pg picogramm  
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pH negative decadic logarithm of the 
hydrogen ion (H+) concentration 
 
pL polylysine  
p55pCMV-IVS-
luc+ 
plasmid coding for the firefly luciferase kindly provided by Andrew 
Baker, Bayer, USA 
prep preparation  
PROCOP protective copolymer  
P6YE5C copolymer of polyethylene glycol (6000 
Da) and the negatively charged peptide 
(YE5)2KεC 
in house synthesis 
RIF-1 cells mouse radiation-induced fibrosarcoma 
cell line 
kindly provided by Ellen 
Kolbe, Experimental 
Oncology, TU Munich, 
Germany 
rpm rounds per minute  
SDS sodiumdodecylsulphate  
sec seconds  
SPDP succinimidylpyridyldithiopropionate = 
3-(2-pyridyldithio) propionic acid N-
hydroxysuccinimide ester 
 
St-pL streptavidinylated polylysine kindly provided by Prof. Dr. 
Ernst Wagner, Vienna 
University Biocenter, Austria 
 streptavidin Molecular Probes, Leiden, 
The Netherlands 
TEM transmission electron microscopy 
(Philips EM 410 or Philips CM 10) 
Philips, Eindhoven, The 
Netherlands 
TFA trifluoroacetic acid  
Tris trishydroxymethylaminomethan   
trMAG superparamagnetic iron oxide (mainly 
magnetite, Fe3O4) nanoparticles with 
various coatings 
Chemicell, Berlin 
trMAG-ARA trMAGs coated with arabinic acid, 
sodium salt, Mw 250 kDa 
Chemicell, Berlin 
trMAG-DAEA trMAGs coated with a polymer 
prepared from dimethylamine, 
epichlorohydrine and ethylene diamine. 
Chemicell, Berlin 
trMAG-DEAE trMAGs with a dextran monolayer 
coating, introduction of end-standing 
DEAE groups with 2-diethylamino-
ethyl chloride-hydrochloride 
Chemicell, Berlin 
trMAG-pACRYL trMAGs coated with polyacrylic acid, 
sodium salt, Mw 20 kDa 
Chemicell, Berlin 
trMAG-pACRYL-
MAL 
trMAGs coated with polyacrylic acid-
co-maleic acid, sodium salt, Mw 50 
kDa 
Chemicell, Berlin 
trMAG-pASP or 
trMAG-pAsp 
trMAGs coated with polyaspartic acid, 
sodium salt, Mw 3000 kDa 
Chemicell, Berlin 
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trMAG-PEI trMAGs coated with a monolayer of 
PEI (Mw 800 kDa, Fluka, Neu-Ulm, 
Germany) 
Chemicell, Berlin 
trMAG-PEI-C1/1 trMAGs coated with a commercially 
available PEI, should result in relatively 
small particles 
Chemicell, Berlin 
trMAG-PEI-
epichlorohydrin 
trMAGs with a monolayer coating of 
PEI 20 kDa (Aldrich, USA) modified 
with epichlorohydrin 
Chemicell, Berlin 
trMAG-PEI-
ethoxylated 
trMAGs with a monolayer coating of 
PEI 50 kDa (Aldrich, USA) which has 
been ethoxylated (80 %) 
Chemicell, Berlin 
trMAG-PEI-
lowMW 
trMAGs with a monolayer coating of 
PEI, Mw 1.7 kDa (Aldrich, USA) 
Chemicell, Berlin 
trMAG-PEI-SDS trMAGs with a monolayer coating of 
PEI 800 kDa (Aldrich, USA) modified 
by a covalent coupling of sodium 
dodecyl sulfate (SDS) by carbodiimide 
activation (N-Ethyl-N’-
(dimethylaminopropyl)-carbodiimide) 
Chemicell, Berlin 
trMAG-PEI-SH thiolated trMAG-PEI  
trMAG-PEI-Sta streptavidinylated trMAG-PEI, 
preparation see in “General methods” 
 
trMAG-PO4 trMAGs coated with starch-phosphate, 
Mw 20 kDa 
Chemicell, Berlin 
trMAG-STARCH-
PEI 
trMAGs with a multilayer coating of 
starch, Mw 60 kDa (Fluka, Neu-Ulm, 
Germany) followed by covalent 
coupling of PEI via amino groups to the 
periodate-oxidized starch layer 
Chemicell, Berlin 
trMAG-13/1 trMAGs coated with a monolayer of 
PEI 2 kDa  
Chemicell, Berlin 
trMAG-14/1 trMAGs coated with a monolayer of 
PEI 60 kDa  
Chemicell, Berlin 
trMAG-15/1 trMAGs coated with a monolayer of 
PEI 750 kDa (Fluka, Neu-Ulm, 
Germany) 
Chemicell, Berlin 
trMAG-16/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany) 
Chemicell, Berlin 
trMAG-17/1 trMAGs coated with linear PEI 
(Aldrich, USA) 
Chemicell, Berlin 
trMAG-18/1 trMAGs coated with a multilayer of PEI 
2000 kDa (Aldrich, USA) 
Chemicell, Berlin 
trMAG-19/1 trMAGs coated with a multilayer of PEI 
2000 kDa (Aldrich, USA), but with a 
different coating procedure than 
trMAG-18/1 
Chemicell, Berlin 
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trMAG-20/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany), 
but with a different coating procedure 
than trMAG-16/1 
Chemicell, Berlin 
trMAG-21/1 trMAGs ultraloaded with layers of PEI 
800 kDa (Fluka, Neu-Ulm, Germany) 
Chemicell, Berlin 
trMAG-22/1 trMAGs coated with a commercially 
available polyamine from Merck, 
Darmstadt, Germany 
Chemicell, Berlin 
trMAG-23/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany), 
but with a different coating procedure 
than trMAG-16/1 
Chemicell, Berlin 
trMAG-24/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany), 
but with a different coating procedure 
than trMAG-16/1 
Chemicell, Berlin 
trMAG-25/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany), 
but with 50% less PEI than trMAG-16/1
Chemicell, Berlin 
trMAG-26/1 trMAGs coated with poly(bis(2-
chlorethyl)ether-alt-1,3 bis(3-dimethyl-
amino)propyl)urea, quaternized 
Chemicell, Berlin 
UV ultraviolet (light)  
V Volt  
w/w ratio weight/weight ratio (e.g. µg trMAG / µg 
DNA) 
 
X-Gal 5-bromo-4-chloro-3-indolyl-beta-
galactopyranosid 
Roche, Mannheim 
 Triton X-100  
Table 1 Abbreviations, reagents, materials and source of supply 
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2.2 General methods 
 
2.2.1 Radioactive (32P) labeling of plasmid DNA by nick translation 
 
Plasmid DNA (of approximately 5 kb size) was labeled with 32P using the Nick Translation 
Kit from Amersham-Pharmacia with the protocol of the supplier modified such that the 
incubation time was 15 min at 15 °C instead of 2 h. α-32P-dATP (Hartmann Analytic, 
Braunschweig, Germany) with a specific activity of 3000 Ci/mmol was used for the labeling 
reaction. The labeled plasmid was purified using MicroSpin columns (Pharmacia) and the 
Promega Wizard PCR Preps DNA Purification System (Promega, Mannheim, Germany) for 
removal of unincorporated nucleotides and enzymes from the reaction mixture. Agarose gel 
electrophoresis (1 % gel, 35 min running time at 100 V, ethidiumbromide staining) was used 
to examine the resulting plasmid. A mixture of labeled and unlabeled plasmid was loaded on 
the gel. After electrophoresis and gel drying the plasmids were monitored in the UV-light, a 
photo was taken and an autoradiography performed. By comparing the UV-light photo and 
the autoradiograph the same size of labeled DNA and unlabeled starting DNA could be 
confirmed. 
 
2.2.2 Cell culture, transfection and reporter gene assays 
 
2.2.2.1 Cells 
 
NIH 3T3 mouse fibroblasts (DSMZ #ACC 59), chinese hamster ovary (CHO-K1) cells 
(DSMZ #ACC 110), human hepatic carcinoma (HepG2) cells (DSMZ #ACC 180), human 
cervix carcinoma (HeLa) cells (DSMZ #ACC 57) and mouse radiation-induced fibrosarcoma 
(RIF-1) cells (kindly provided by Ellen Kolbe, Experimental Oncology, TU Munich, 
Germany ) were grown at 37 °C in an atmosphere of 5 % CO2 in Dulbecco’s Modified Eagles 
medium (DMEM, purchased from Gibco, Eggenstein, Germany) supplemented with 10 % 
fetal calf serum (FCS, purchased from Gibco, Eggenstein, Germany), 100 units/ml penicillin, 
100 µg/ml streptomycin and 2 mM glutamine (all three purchased from Gibco, Eggenstein, 
Germany). HaCaT cells (cell line derived from human keratinocytes, kindly provided by Dr. 
Martin Mempel, Dermatology, TU Munich, Germany) and primary human foreskin 
keratinocytes (kindly provided by Dr. Martin Mempel, Dermatology, TU Munich, Germany) 
were kept under the same conditions but the DMEM medium contained no supplements.  
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2.2.2.2 Transfection 
 
One day prior to addition of DNA complexes, cells were seeded at a density of 20,000 (NIH 
3T3, CHO-K1, HaCaT, RIF-1 and primary human keratinocytes) or 45,000 (HepG2) cells per 
well of a 96-well plate or 250,000 (NIH 3T3 and HeLa) cells per well of a 6-well plate 
(gamma-sterilized and cell culture treated plates; produced by TPP, Switzerland; purchased 
from Peske, Aindling-Pichl, Germany) giving rise to an almost confluent cell layer on the day 
of complex addition. 
Unless otherwise stated, 50 µl and 500 µl of vector formulations were added to cells kept in 
150 µl and 1.5 ml fresh medium, respectively (96 well-plate and six-well plate formats).  
When the magnetofection method was used, cells were incubated with superparamagnetic 
iron oxide nanoparticles (trMAGs; from Chemicell, Berlin, Germany) containing vectors 
(magnetofectins) usually for 10 to 20 min. During the incubation times the culture dishes were 
placed upon sintered Nd-Fe-B magnets (NeoDelta; remanence Br, 1080-1150 mT; purchased 
from IBS Magnet, Berlin, Germany). The dimensions of the magnets for six- and 24-well 
plates were 20 x 10 x 5 mm. For 96-well plates the format was cylindrical (d = 6 mm, h = 5 
mm) and the magnets were inserted in an acrylic glass template in 96-well plate format with 
strictly alternating polarization. The fields of the individual magnets influence each other such 
that the vector dose becomes concentrated in the centers of individual wells. As control 
without magnet, cells in a separate plate were incubated for the same time with the same 
vectors but without application of a magnetic field. 
When a standard transfection method (without magnetic beads) was used, cells were 
incubated with e.g. PEI-DNA complexes usually for 2 to 4 h. 
After the incubation with DNA vectors (with or without magnet) the cells were washed once 
with fresh medium, grown usually for 24 h and subjected to the luciferase or β-galactosidase 
assay as described below. 
 
Preparation of DNA complexes: If not otherwise stated, equal volumes of stock solutions in 
water containing the various components of the complexes were mixed sequentially by 
pipetting or gentle vortexing. After each mixing step, complexes were incubated for 15 min. 
For gene transfer one component had to be plasmid-DNA. Either p55pCMV-IVS-luc+, a 
plasmid coding for the firefly luciferase (kindly provided by Andrew Baker, Bayer, USA) or 
pCMV-β-gal, a plasmid coding for the β-galactosidase (kindly provided by Walter Schmidt, 
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Intercell, Vienna, Austria) was used. Both plasmids were purified by cesium chloride gradient 
centrifugation by Ursula Putz, TU Munich, Germany. The last component was usually NaCl 
to adjust the final concentration to 150 mM NaCl and to start salt induced aggregation or 
glucose to obtain a final concentration of 5 % glucose. 
If one component were trMAG particles, the complex was called magnetofectin and could be 
used for gene transfer with magnetic forces (magnetofection).  
If there was no trMAG component in the complex the transfection was called a standard 
transfection (like e.g. PEI-DNA). 
The sequence of writing like e.g. trMAG / DNA / PEI reflects the sequence of mixing the 
components. In this example, DNA was pipetted to trMAGs, followed by addition of PEI and, 
if desired, finally NaCl or glucose was added. In this type of writing the NaCl or glucose 
component is not mentioned. 
The final volume of a complex solution was calculated for 50 µl and 500 µl per well in 
triplicates or quadruples of a 96-well and 6-well plate, respectively. 
 
2.2.2.3 Luciferase assay 
 
Twenty-four hours after transfection, cells were washed once with phosphate buffered saline 
(PBS) and incubated with 100 µl (96-well plate) or 500 µl (6-well plate) of lysis buffer (0.1 % 
Triton X-100 in 250 mM Tris pH 7.8). Ten to 50 µl each of the cell lysates were transferred to 
black 96-well plates, mixed with 100 µl of luciferin buffer (60 mM dithiothreitol, 10 mM 
magnesium sulfate, 1 mM ATP, 30 µM D(-)-luciferin, in 25 mM glycil-glycine pH 7.8) and 
assayed for bioluminescence using the Microplate Scintillation & Luminescence counter 
“TopCount” (Canberra Packard, Groningen, The Netherlands) with a count time of 12 s and a 
count delay of 10 min. 
To obtain a calibration curve 200, 100, 50, 25, 12.6, 6.25, 3.13, 1.57, 0.78, 0.39, 0.2, 0.1, 
0.05, 0.025, 0.013 and 0 ng luciferase (Roche, Mannheim, Germany) each in 50 µl lysis 
buffer (2-fold dilution series) were measured under the same conditions as the samples. 
The protein content of the cell lysates was determined using the Bio-Rad Protein Assay (Bio-
Rad, Munich, Germany) adapted for use in a 96-well plate format. Five to 10 µl each of the 
cell lysates were transferred to transparent 96-well plates (type “flat bottom”; here: from 
Nunc, Denmark), mixed with 155 to 150 µl aqua dest and 40 µl Bio-Rad Protein Assay dye 
concentrate. The absorbance (at 630 nm) was measured using the absorbance reader 
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“Biolumin 690” and the computer programme “Xperiment” (both from Molecular Dynamics, 
USA). 
To obtain a protein standard curve 9.667, 6.445, 4.296, 2.864, 1.910, 1.273, 0.849, 0.566, 
0.377, 0.252, 0.168 and 0 µg bovine serum albumine (BSA) / 200 µl were measured (1.5-fold 
dilution series). Bio-Rad Protein Assay Standard II was bought as BSA. 
Specific luciferase activity in picograms or nanograms luciferase per milligram of protein 
were calculated from the luciferase and protein calibration curves. 
 
2.2.2.4 β-Galactosidase assay 
 
Cells were usually plated in 6-well plates. Twenty-four hours after transfection the cells were 
washed with phosphate buffered saline (PBS). Subsequently the cells were incubated between 
20 min and 12 h with staining solution (protocol see below) at 37 °C. After staining cells 
were washed with PBS, observed macroscopically and microscopically and eventually 
pictures were taken. 
Staining buffer: 10 mM phosphate buffer pH 7.0, 150 mM NaCl, 1 mM MgCl2, 3.3 mM 
K4Fe(CN)6x3H2O, 3.3 mM K3Fe(CN)6. 
For 10 ml of staining solution 20 mg of 5-bromo-4-chloro-3-indolyl-beta-galactopyranosid 
(X-Gal; Roche, Mannheim, Germany) were dissolved in 1 ml N, N Dimethylformamide 
(DMF; Sigma, Steinheim, Germany), filled up to 10 ml with staining buffer and filtered 
through a 0.22 µm filter (Milipore, Eschborn, Germany). 
 
2.2.3 Preparation of DOTAP-Cholesterol cationic liposomes 
 
In a silanized 15 ml screw cap glass tube a 5 mM DOTAP/5 mM Cholesterol chloroform 
solution was prepared. To generate a regular lipid film on the inner surface of the tube, the 
chloroform was evaporated with a rotary evaporator (Rotavapor-R, Büchi, Switzerland). The 
evaporator was ventilated with Argon gas (Linde, Germany) to exclude oxygen. The tube was 
kept in vacuo overnight. The next day, 15 ml of a 5 % glucose solution were added to the 
tube, vortexed for 30 seconds and exposed for 30 min to ultrasonication (Sonicater: Sonorex 
RK 510 H, from Bandelin, Germany) to produce a stable liposomal suspension. 
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2.2.4 Preparation of polyethylenimine (PEI) 
 
PEI (25 kDa) as supplied by the manufacturer (Sigma-Aldrich, Deisenhofen, Germany) was 
dissolved in water, the pH was adjusted to 7.4 by the addition of HCl (hydrochloric acid) and 
the concentration was adjusted to 10 mg/ml. The material was dialyzed against water by using 
dialysis tubes with a pore size of 12-14 kDa (Serva, Heidelberg, Germany) followed by sterile 
filtration (0.20 µm cellulose acetate CA membrane, Peske, Aindling-Pichl, Germany). The 
concentration of PEI relative to the original solution was determined using the ninhydrin 
assay (analogous to the protocol in “2.4.1.1 Ninhydrin assay to determine the amount of PEI 
in trMAG-PEI particle suspensions”). 
 
2.2.5 Biotinylation of PEI (bPEI) 
 
An aliquot of PEI solution (17.2 mg) was lyophilized and redissolved in 0.5 ml 20 mM 
HEPES pH 7.4. Two equivalents of succinimidyl-6-(biotinamido) hexanoate (NHS-LC-
Biotin; Pierce, Rockford, IL, USA; 68.8 µl of a 20 mM solution in DMSO) were added. After 
reaction at room temperature for 3 hours, the material was purified via gel filtration 
(Sephadex G-25 filled in a HR 10/10 column, Pharmacia, Freiburg, Germany. Flow rate 1 
ml/min with water as eluent). The PEI concentration of the product fraction was 4.39 mg/ml 
according to the ninhydrin assay (performed analogous to the protocol in “2.4.1.1 Ninhydrin 
assay to determine the amount of PEI in trMAG-PEI particle suspensions”). 
 
2.2.6 Coupling of streptavidin to trMAG-PEI (trMAG-PEI-Sta) 
 
Streptavidin-SPDP: Five mg streptavidin (Molecular Probes, Leiden, The Netherlands) were 
dissolved in 500 µl HBS (20 mM HEPES/150 mM sodium chloride pH 7.4) and purified by 
gel filtration (Sephadex G-25; PD-10 columns, Pharmacia, Sweden) using the same buffer. 
The pooled product fractions were concentrated to 520 µl containing 3.4 mg (56 nmol) 
streptavidin using a speed-vac. To this solution, a 3.5-fold excess of succinimidyl-pyridyl-
dithiopropionate (SPDP; 32 mM in 100 % ethanol) was added. After reaction at room 
temperature over night, the material was purified via gel filtration in HBS (Sephadex G-25 
filled in a HR 10/10 column; Pharmacia, Sweden; flow rate 0.5 ml/min). The concentration of 
coupled pyridyl-dithiopropionate was 75 µM, the concentration of streptavidin was 1.6 
mg/ml, corresponding to a substitution of approximately 2.8 PDP per streptavidin molecule. 
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trMAG-PEI-SH: Thiolation of trMAG-PEI was carried out by adding 4 µl SPDP (10 mM in 
ethanol) to 5 mg trMAG-PEI in 250 µl water, followed by addition of 246 µl 20 mM HEPES 
pH 7.4. The reaction was carried out in a microcentrifuge tube which was shaken over night at 
full speed at 37 ˚C in an Eppendorf shaker (Thermomixer 5436). Subsequently, the material 
was washed exhaustively with 0.1 % TFA. After reduction by addition of β-mercaptoethanol, 
the total amount of coupled pyridyl-dithiopropionate was determined to be approximately 13 
nmol. The material was again washed exhaustively with 0.1 % TFA. 
A 3-fold excess of streptavidin-SPDP (thiopyridyl groups over thiol groups) was added to the 
thiolated magnetic particle pellet. After reaction over night, one third of the available 
thiopyridyl groups had reacted, indicating a quantitative reaction. The product was washed 
exhaustively with water. 
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2.3 Characteristics of magnetic nanoparticles (trMAGs) used in this study 
 
2.3.1 Measurement of particle size by dynamic light scattering 
 
The particles listed in table 2 (section 3 “Results”) were diluted to a concentration of 10 µg/ml 
aqua dest. and their size distributions were determined by dynamic light scattering using the 
Zetasizer 3000 HS, Malvern Instruments, Herrenberg, Germany.  
Approximately 1 ml of each sample was filled into a cuvette and measured with the following 
specifications: 10 measurements per sample prepared in water, viscosity of water 0.89 cP, 
temperature 25°C. 
 
2.3.2 Transmission electron microscopy of trMAGs 
 
Preparation of the trMAG particles:  
For electron microscopy aqueous solutions with 10 µg trMAG-PEI and 20 µg trMAG-16/1 
per ml were prepared. 
 
The transmission electron microscopy (TEM) was performed by Jean-Serge Rémy, 
Strasbourg, following the protocol of Erbacher et al. (Erbacher et al., 1998). 
A carbon film was prepared on cleaved mica, using evaporation of carbon rods under vacuum. 
The flotation technique was then used to cover the electron microscope copper/rhodium grids 
(300 Mesh, Touzard and Matignon, Courtaboeuf, France) with carbon film. After drying 
overnight, the grids were kept on a blotting paper placed in a Petri dish. Just before the 
samples were added, the grids were glow discharged (110 mV, 25-30 µA, 25 sec). 
A 5 µl drop of each solution prepared above was then poured onto a grid. Observations of the 
samples containing the electron-dense trMAGs were performed at 80 kV with a Philips EM 
410 transmission electron microscope (Eindhoven, The Netherlands). 
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2.4 Binding of DNA to magnetic particles 
 
2.4.1 Examination of trMAG-PEI as representative for positively charged magnetic 
beads with a monolayer of PEI 
 
2.4.1.1 Ninhydrin assay to determine the amount of PEI in trMAG-PEI particle 
suspensions 
 
The ninhydrin assay enables the quantitative and qualitative analysis of primary and 
secondary amines contained in PEI. 
 
Determination of µg PEI / µg trMAG 
 
Sample: 120 µg trMAG-PEI particles in 6 µl aqueous suspension were pipetted into an 
Eppendorf tube. 
PEI standard row: 0, 3, 6, 9 and 12 µl of an aqueous 1 mg/ml PEI (800 kDa) stock solution 
were added each into an Eppendorf tube. 
The sample and the standard row were prepared and examined in triplicates. 
Ninhydrin assay: 75 µl phenol-ethanol (76 g phenol in 24 g ethanol), 100 µl 1.3 promille 
Kaliumcyanid in pyridine and 75 µl ninhydrin (2.5 g ninhydrin in 50 ml ethanol) were added 
to all the Eppendorf tubes prepared above. All reaction vessels were shaken and incubated for 
5 min at 95 °C. After addition of 1 ml 60 % ethanol (EtOH) to all tubes the magnetic beads 
were centrifuged with 14000 rpm for 3 min in a EBA 12 R centrifuge from Hettich, 
Tuttlingen, Germany. 500 µl of the supernatants and the PEI standard row solutions were used 
to determine the extinction of the produced ninhydrin derivatives (Ruheman’s Purple) 
photometrically at 570 nm with a DU 640 spectrophotometer from Beckmann, Munich, 
Germany. By comparing the extinctions of the samples with the extinctions of the PEI 
standard row the amount of µg PEI per µg trMAG-PEI could be calculated. 
But in PEI bound to iron oxide particles not all primary and seconday amines may be 
accessible for the ninhydrin. Therefore the trMAGs contain probably even more PEI than the 
assay shows. 
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Detection of unbound PEI in trMAG suspension 
 
Sample: 160 µg of trMAG-PEI particles in 1 ml aqueous suspension. 
 
Preparation of supernatants: Approximately 1ml the sample was pipetted into a well of a 
24-well plate (TPP, Switzerland). The trMAGs were sedimented by placing a sintered 20 x 10 
x 5 mm Nd-Fe-B magnet (NeoDelta; remanence Br, 1080-1150 mT; purchased from IBS 
Magnet, Berlin, Germany) underneath the well for 1h. Three times 120 µl of the supernatant 
were pipetted into 3 Eppendorf tubes (for examination in triplicates). 
The ninhydrin assay should detect PEI which was not bound to trMAGs in the supernatants 
in the Eppendorf tubes. The assay was carried out as described above but without 
centrifugation after addition of 60 % EtOH. Further it was not a quantitative but only a 
qualitative analysis: blue staining indicated unbound PEI in the supernatant. 
 
2.4.1.2 DNA-binding curves 
 
The generally used protocol for radioactive (32P) labeling of plasmid DNA by nick translation 
is described in “General methods” (2.2.1). 
The magnets used were sintered Nd-Fe-B magnets (NeoDelta; remanence Br, 1080-1150 mT; 
purchased from IBS Magnet, Berlin, Germany). The magnet format was cylindrical (d = 6 
mm, h = 5 mm) and 96 of such magnets were inserted in an acrylic glass template in 96-well 
plate format with strictly alternating polarization. The fields of the individual magnets 
influenced each other such that the vector dose becomes concentrated in the centers of 
individual wells. 
 
Preparation of trMAG-PEI / DNA complexes: In two separate set-ups, 120 µl each of DNA 
stock solution (124.8 µg cold plasmid plus 1.56 x 107 c.p.m. 32P-labeled plasmid in 3120 µl of 
water) were added to 120 µl each of a dilution series of trMAG-PEI in water. The trMAG-PEI 
dilution series was calculated to result in 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0 and 4.0 µg 
trMAG-PEI/µg DNA after mixing by pipetting. After 15 min of incubation, either 240 µl each 
of water or of 300 mM sodium chloride (for salt-induced aggregation) were added to the 
mixture. After 20 min of incubation the trMAG-PEI / DNA complexes (in water and in 150 
mM NaCl) were ready for the binding studies. 
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Preparation of trMAG-PEI / DNA plus PEI or DOTAP-Chol: In two separate set-ups, 120 
µl each of DNA stock solution (124.8 µg cold plasmid plus 1.56 x 107 c.p.m. 32P-labeled 
plasmid in 3120 µl of water) were added to 120 µl each of a dilution series of trMAG-PEI in 
water. The trMAG-PEI dilution series was calculated to result in 0, 0.2, 0.4, 0.6, 0.8, 1.0, 2.0 
and 4.0 µg trMAG-PEI/µg DNA after mixing by pipetting. After 15 min of incubation, either 
120 µl each of PEI stock solutions (41.7 µg/ml in water) or of DOTAP-Cholesterol liposome 
stock suspensions (121.2 µl 5 mM liposome stock per ml in water) were added to the mixture. 
This resulted in PEI:DNA N/P ratios of 8 or DOTAP:DNA charge ratios of 5. After further 
15-min incubation, 120 µl each of 600 mM sodium chloride (for salt-induced aggregation) 
were added to the complexes. After a 20-min incubation, the trMAG-PEI / DNA / PEI and 
trMAG-PEI / DNA / DOTAP-Chol complexes (both in 150 mM NaCl) were ready for 
studying the DNA association. 
 
Binding studies: 120 µl each of the complexes prepared above were transferred to the wells 
of a U-bottom 96-well plate in triplicates. The plate was positioned upon the 96-well format 
magnetic plate. After 30 min of magnetic sedimentation, 80 µl supernatants were removed 
and mixed with 125 µl each of Microscint 40 (Canberra Packard, Dreieich, Germany) in an 
opaque 96-well plate. The samples were counted using a Topcount instrument (Canberra 
Packard, count delay set to 10 min, count time in triplicates, 5 min each).  
The binding was calculated as: % bound = 100 x c.p.m. (sample) / c.p.m. (reference). 
As reference (100 % of the DNA unbound) the samples with a trMAG/DNA w/w ratio of 0 
were taken. 
 
2.4.1.3 Measurement of zeta potential by laser Doppler velocimetry (LDV) 
 
Preparation of samples in aqua dest.: 
trMAG-PEI: 15 µg trMAG-PEI/1.5 ml 
trMAG-PEI / DNA: 15 µg plasmid DNA in 750 µl water were added to 15 µg trMAG-PEI in 
the same volume of water while vortexing. After a incubation time of 15 min the complexes 
were ready for measurement of the zeta potential.  
 
The zetapotentials of the samples were determined by laser Doppler velocimetry (LDV) 
using the Zetasizer 3000 HS, Malvern Instruments, Herrenberg, Germany. Roughly 50 ml 
aqua dest were injected into the electrophoresis chamber for rinsing by using a syringe before 
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each sample injection of approximately 1.5 ml. Measurements were performed with the 
following specifications: sampling time 5 sec, 10 measurements per sample, viscosity of 
water 0.89 cP, dielectric constant of water 80.4, temperature 25°C, beam mode F(Ka) = 1.50 
(Smoluchowsky equation, for calculation of the zetapotential). After all measurements 50 ml 
ethanol (EtOH, 70%) were injected to keep the instrument sterile. 
 
2.4.1.4 Particle sizes in 150 mM NaCl 
 
Preparation of trMAG-PEI / DNA / PEI (w/w = 1; N/P = 8) complexes: 
10 µg plasmid DNA in 333.3 µl water were pipetted to 10 µg trMAG-PEI in the same volume 
of water, homogenized and incubated. After 15 min 10.4 µg PEI (25 kDa) in 303.3 µl water 
were added to the trMAG plus DNA containing solution. After vortex a 15 min incubation 
time followed. Finally, the ternary complex solution was filled up to 1 ml with 30 µl 5 M 
NaCl (to adjust the ionic strength to 150 mM) and vortexed gently. 
Size measurements were performed with the following specifications: 60 measurements for 
the ternary complex sample prepared in 150 mM NaCl, viscosity of 150 mM NaCl 1.14 cP, 
temperature 25°C. 
 
2.4.1.5 Transmission electron microscopy 
 
Formulation of trMAG-PEI plus PEI-DNA (w/w = 1; N/P = 8): 
4 µg plasmid DNA in 100 µl water were added to 4.2 µg PEI (25 kDa) in the same volume of 
water while vortexing (giving rise to an N/P ratio of 8). After 15 min incubation 4 µg trMAG-
PEI in 100 µl water were pipetted to the PEI-DNA vectors and vortexed gently. After 15 min 
of incubation the solution was filled up to a final volume of 400 µl and the ionic strength was 
adjusted to 150 mM sodium chloride (initialization of salt induced aggregation). 
 
Transmission electron microscopy was performed by Jean-Serge Rémy, Strasbourg, exactly 
as described in 2.3.2, but additionally trMAG-PEI / PEI-DNA complexes were stained with 
30 µl of an aqueous uranyl-acetate solution (1%, w/w) for 20 sec and then excess liquid was 
removed with blotting paper. 
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2.4.2 Examination of trMAG-16/1 as representative for positively charged magnetic 
beads with a multilayer of PEI 
 
2.4.2.1 Ninhydrin assay to determine the amount of PEI in trMAG-16/1 particle 
suspensions 
 
The assay was performed exactly as described in 2.4.1.1. 
 
2.4.2.2 DNA-binding curve 
 
Preparation of trMAG-16/1 / DNA complexes: 120 µl each of DNA stock solution (124.8 
µg cold plasmid plus 1.56 x 107 c.p.m. 32P-labeled plasmid in 3120 µl of water) were added to 
120 µl each of a dilution series of trMAG-16/1 in water. The trMAG-16/1 dilution series was 
calculated to result in 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0 and 4.0 µg trMAG-16/1 / µg DNA 
after mixing by pipetting. After 15 min, 240 µl each of water were added to the mixture and 
the complexes were incubated for further 20 min.  
 
The binding studies were performed exactly as previously described in 2.4.1.2. 
 
2.4.2.3 Measurement of zeta potential by laser Doppler velocimetry (LDV) 
 
Preparation of samples in aqua dest.: 
trMAG-16/1: 60 µg trMAG-16/1 / 1.5 ml 
trMAG-16/1 / DNA: 30 µg plasmid DNA in 750 µl water were added to 60 µg trMAG-16/1 
in the same volume of water while vortexing. After a incubation time of 15 min the 
complexes were ready for measurement of the zeta potential.  
 
The zetapotential was determined exactly as described in 2.4.1.3. 
 
2.4.2.4 Transmission electron microscopy 
 
Formulation of trMAG-16/1 plus DNA: 3 µg plasmid DNA in 100 µl water were added to 6 
µg trMAG-16/1 in 100 µl water while vortexing. After 15 min incubation the solution was 
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filled up to a final volume of 300 µl and the ionic strength was adjusted to 150 mM sodium 
chloride (initialization of salt induced aggregation). 
 
Transmission electron microscopy was performed by Jean-Serge Rémy, Strasbourg, exactly 
as described in 2.3.2. 
 
2.4.3 Examination of trMAG-pAsp as representative for negatively charged magnetic 
beads 
 
2.4.3.1 DNA-binding studies 
 
Preparation of PEI / DNA / trMAG-pAsp: 960 µl of aqueous DNA solution (28.8 µg cold 
plasmid plus 5.31 x 106 c.p.m. 32P-labeled plasmid) were added to 960 µl aqueous PEI 
solution (with 30 µg PEI, to obtain a N/P ratio of 8). The complexes were mixed by pipetting. 
After 15 min of incubation, 960 µl aqueous trMAG-pAsp solution (28.8 µg trMAG-pAsp) 
were added to the mixture, vortexed gently and incubated for further 15 min. 
1396.8 µl of this preparation were transferred into a new reaction vessel and either 43.2 µl of 
water or 43.2 µl of a 5 M NaCl solution were added to obtain PEI / DNA / trMAG-pAsp 
complexes in water or in 150 mM sodium chloride. 
Preparation of DNA / trMAG-pAsp / PEI: 960 µl of aqueous DNA solution (28.8 µg cold 
plasmid plus 5.31 x 106 c.p.m. 32P-labeled plasmid) were added to 960 µl aqueous trMAG-
pAsp solution (28.8 µg trMAG-pAsp) and mixed by pipetting. After a 15-min incubation, 960 
µl aqueous PEI solution (with 30 µg PEI, to obtain a N/P ratio of 8) were added to the 
mixture, vortexed gently and incubated for further 15 min.  
1396.8 µl of this preparation were transferred into a new reaction vessel and either 43.2 µl of 
water or 43.2 µl of a 5 M NaCl solution were added to obtain DNA / trMAG-pAsp / PEI 
complexes in water or in 150 mM sodium chloride. 
 
Binding studies: In two separate set-ups, 200 µl each of the trMAG-pAsp complexes were 
transferred to the wells of a U-bottom 96-well plate in triplicates. One plate was positioned 
upon the 96-well format magnetic plate whereas the other plate was not exposed to a magnetic 
field. All further steps followed the protocol described in 2.4.1.2. As references (with 100 % 
of the DNA unbound) the corresponding samples in the plate without magnetic sedimentation 
were taken. 
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2.5 Magnetofection in cell culture 
 
2.5.1 Transfection with positively charged trMAGs 
 
2.5.1.1 trMAG particles and naked DNA 
 
Cells: NIH 3T3 seeded in 96-well plates. 
General settings: 1 µg DNA/well. 
trMAG/DNA w/w ratios: 0.5, 1, 2, 4, 8, 16, whereas the ratios 8 and 16 were only examined 
with trMAG-PEI and trMAG-13/1 to trMAG-17/1. 
Each preparation examined in triplicates. 
DNA stock: 59.9 µg/ml in water. 
trMAG stocks: each 1 mg/ml in water. 
trMAGs: trMAG-PEI, trMAG-13/1, trMAG-14/1, trMAG-15/1, trMAG-16/1, trMAG-17/1, 
trMAG-18/1, trMAG-19/1, trMAG-20/1, trMAG-21/1, trMAG-22/1, trMAG-23/1, trMAG-
24/1, trMAG-25/1, trMAG-26/1. 
Controls: each preparation without magnet (in triplicates each); naked DNA without trMAGs 
(in triplicates). 
Incubation time: cells were incubated with vectors (with or without magnet) for 20 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG / DNA complexes: 120,3 µl DNA stock each were added to 
120.3 µl of each trMAG suspension (see table). Finally 120.3 µl of 15 % glucose or 120.3 µl 
of 450 mM NaCl, respectively, were added to each vector preparation to obtain final 
concentrations of 5 % glucose or 150 mM NaCl. 
trMAG suspensions: 
trMAG/DNA 
(w/w) 
0 0.5 1 2 4 8 16 
µg trMAG in 
120.3 µl H2O 
0 3.6 7.2 14.4 28.8 57.6 115.2 
 
2.5.1.2 trMAG / DNA complexes and additional PEI 
 
Cells: CHO-K1 seeded in 96-well plates. 
General settings: 0.5 µg DNA/well. 
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trMAG/DNA w/w ratios: 0.4, 0.8, 1, 2, 4, 8. 
PEI/DNA N/P ratio = 8. 
Each preparation examined in quadruples. 
DNA stock: 40 µg/ml in water. 
trMAG stocks: each 1 mg/ml in water. 
PEI (25 kDa) stock: 41.7 µg/ml in water. 
trMAGs: trMAG-DEAE, trMAG-DAEA, trMAG-STARCH-PEI, trMAG-PEI-ethoxylated, 
trMAG-PEI-epichlorohydrin, trMAG-PEI-lowMW, trMAG-PEI-SDS, trMAG-PEI-C1/1. 
Controls: each preparation without magnet (in quadruples each). 
Incubation time: cells were incubated with vectors (with or without magnet) for 15 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG / DNA / PEI complexes: 125 µl DNA stock each were added to 
125 µl of each trMAG suspension (see table). Subsequently 125 µl PEI stock each were 
added. Finally 125 µl of 0.6 M NaCl were added to each vector preparation to obtain final 
concentrations of 150 mM NaCl. After addition of NaCl the complexes were incubated for 45 
min (salt induced aggregation). 
trMAG suspensions: 
trMAG/DNA 
(w/w) 
0.4 0.8 1 2 4 8 
µg trMAG in 
125 µl H2O 
2 4 5 10 20 30 
 
2.5.2 Transfection with negatively charged trMAGs 
 
2.5.2.1 trMAGs and PEI-DNA complexes 
 
Cells: NIH 3T3 and HepG2 seeded in two 96-well plates each. 
General settings: 0.5 µg DNA/well. 
trMAG/DNA w/w ratios: 0, 0.5, 1, 2, 4, 8. 
PEI/DNA N/P ratio = 8. 
Each preparation examined in triplicates. 
DNA stock: 240 µg/7.2 ml in water. 
trMAG stocks: each 1 mg/ml in water. 
PEI (25 kDa) stock: 250.2 µg/7.2 ml in water. 
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trMAGs: trMAG-ARA, trMAG-pACRYL, trMAG-pACRYL-MAL, trMAG-pASP. 
Controls: each preparation without magnet (in triplicates each). 
Incubation time: cells were incubated with vectors (with or without magnet) for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG / PEI-DNA complexes: To preform PEI-DNA, 6545 µl of DNA 
stock were added to 6545 µl of PEI stock.  
 Three times 144 µl (triplicates) of each trMAG suspension containing 38.4 µg trMAGs were 
added consecutively to row A of a round-bottom 96-well plate (Nunc, Denmark). All other 
wells were filled with 72 µl of water. Using a multichannel pipettor, 72 µl each were 
transferred from row A to row B, from row B to row C, and so on. The dilution series finished 
at row F. Then, 144 µl PEI-DNA were pipetted to each well. Finally, 24 µl 50 % glucose 
solution per well were added to obtain a final concentration of 5 % glucose. 
 
2.5.3 Hints to the mechanism of magnetofection 
 
2.5.3.1 Influence of endosomolytic substances in magnetofection 
 
PEI, PEI-bAdv, Lipofectamine and GenePORTER as additives 
 
Cells: NIH 3T3 and CHO-K1 seeded in 96-well plates. 
General settings: 0.1 µg DNA/well at GenePORTER and Lipofectamine, 0.5 µg DNA/well 
at all other formulations. 
50 µl transfection volume/well for each preparation. 
trMAG/DNA w/w ratio: 2. 
PEI/DNA N/P ratio = 8. 
Chemically inactivated adenovirus (inact. adv): 7.2 x 108 inact. adv particles/0.5 µg DNA. 
5 µl GenePORTER (Gene Therapy Systems, La Jolla, CA, USA)/1 µg DNA or 4 µl 
Lipofectamine (Life Technologies, Karlsruhe, Germany)/1 µg DNA. 
Each preparation examined in triplicates. 
DNA stocks: 1.56 µg/0.195 ml in serum-free DMEM for GenePORTER and Lipofectamine, 
11.7 µg/0.2925 ml in HBS for all other formulations. 
trMAG stocks: 1 mg/ml in serum-free DMEM for GenePORTER and Lipofectamine, 1 
mg/ml in HBS for all other formulations. 
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trMAG suspensions: 1.56 µg/0.0975 ml in serum-free DMEM for GenePORTER and 
Lipofectamine, 11.7 µg/0.1463 ml in HBS for all other formulations. 
PEI (25 kDa) stock: 8.1 µg/0.195 ml in HBS. 
Inact. adv stock: 5.59 x 109 virus particles per 0.0975 ml in HBS. 
GenePORTER stock: 3.9 µl/0.0975 ml in serum-free DMEM. 
Lipofectamine stock: 3.1 µl/0.0975 ml in serum-free DMEM. 
trMAGs: trMAG-PEI. 
Controls: corresponding standard vectors without trMAGs and without magnetic field (each 
in triplicates). 
Incubation times: cells were incubated with vectors containing inact. adv for 20 min, 
incubation with all other vectors was 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-PEI / DNA complexes: 45 µl DNA stock were added to 45 µl 
trMAG suspension. Finally, 90 µl HBS were pipetted to the mixture. 
trMAG-PEI / DNA / PEI complexes: 45 µl DNA stock were mixed with 45 µl trMAG 
suspension. Then, 45 µl PEI stock were pipetted to the mixture. Finally, 45 µl HBS were 
added to the complexes. 
PEI-DNA complexes: 45 µl DNA stock were pipetted to 45 µl PEI stock. Finally, 90 µl HBS 
were added to the complexes. 
trMAG-PEI / DNA / PEI / inact. adv complexes (AVET): 45 µl DNA stock were added to 45 
µl trMAG suspension. Subsequently 45 µl PEI stock were added. Finally, 45 µl inact. adv 
stock were pipetted to the complexes and mixed very gently. 
PEI-DNA / inact. adv complexes (AVET): 45 µl DNA stock were added to 45 µl PEI stock. 
Then, 45 µl inact. adv stock were pipetted to the complexes and mixed very gently. Finally, 
45 µl HBS were added. 
trMAG-PEI / DNA / Lipofectamine complexes: 45 µl DNA stock were mixed with 45 µl 
trMAG suspension. Subsequently 45 µl Lipofectamine stock were pipetted to the mixture. 
Finally, 45 µl serum-free DMEM were added to the complexes. 
Lipofectamine-DNA complexes: 45 µl DNA stock were pipetted to 45 µl Lipofectamine 
stock. Finally, 90 µl serum-free DMEM were added to the complexes. 
trMAG-PEI / DNA / GenePORTER complexes: 45 µl DNA stock were mixed with 45 µl 
trMAG suspension. Subsequently 45 µl GenePORTER stock were pipetted to the mixture. 
Finally, 45 µl serum-free DMEM were added to the complexes. 
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GenePORTER-DNA complexes: 45 µl DNA stock were pipetted to 45 µl GenePORTER 
stock. Finally, 90 µl serum-free DMEM were added to the complexes. 
Application of vectors: Fifty µl each of the DNA complexes were added to cells kept in 150 
µl fresh medium (complete). Only when complexes containing GenePORTER or 
Lipofectamine were used cells were freshly supplemented with 50 µl serum-free DMEM and 
50 µl transfection volume/well were applied. 
 
A synthetic influenza virus peptide (INF7) as additive 
 
Cells: NIH 3T3 seeded in a 96-well plate. 
General settings: 1 µg DNA/well. 
trMAG/DNA w/w ratios: 0.5, 1, 2, 4, 8, 16. 
Influenza virus derived peptide INF7: INF7/DNA -/- ratio = 1. 
All formulations prepared in 5 % glucose. 
Each preparation examined in quadruples. 
DNA stock: 93.6 µg/1.17 ml in water. 
trMAG stock: 2 mg/ml in water. 
trMAG suspension: 249.6 µl trMAG stock plus 140.4 µl water. 
trMAG suspension dilution series: Five tubes were filled with 195 µl water. To the first 
tube 195 µl of trMAG suspension were added, mixed and 195 µl from the first tube were 
added to the second tube, mixed and so on. 
INF7 stock: 13.6 µl INF7 solution (13.9 mM with regard to negative charges) plus 766.4 µl 
water. 
Glucose stock: 480 µl 50 % glucose plus 720 µl water. 
trMAGs: trMAG-16/1 
Controls: trMAG-16/1 / DNA without INF7 (each in quadruples). 
Incubation time: cells were incubated with vectors and magnet for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: DNA / INF7 / trMAG-16/1 complexes: In six tubes, 60 µl DNA stock 
each were mixed with 60 µl INF7 stock each. Then, 60 µl each of trMAG suspension or of a 
trMAG suspension dilution were added to the tubes. Finally, 60 µl glucose stock each were 
pipetted to the complexes to obtain a final concentration of 5 % glucose. 
trMAG-16/1 / DNA / INF7 complexes: 60 µl each of the trMAG suspension and of its five 
dilutions were filled into six tubes. Subsequently 60µl DNA stock were pipetted to each tube. 
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Then, 60 µl INF7 stock each were added. Finally, 60 µl glucose stock each were pipetted to 
the complexes. 
trMAG-16/1 / DNA complexes: 60 µl DNA stock each were added to six tubes containing 60 
µl of trMAG suspension or one of its five dilutions. Then, 60 µl water each were pipetted to 
the mixtures. Finally, 60 µl glucose stock each were added to the complexes. 
 
2.5.3.2 The fate of magnetic particles during magnetofection (transmission electron 
microscopy) 
 
Cells and transfections 
Approximately 300 000 HeLa cells were seeded per 35 mm dish. 
The next day the cells were washed with PBS and 1.5 ml fresh complete medium were added 
per dish. Then, each dish was incubated with 500 µl of trMAG-16/1 / DNA complexes (2.5 µg 
DNA/dish, trMAG/DNA w/w ratio = 2, preparation of complexes in 5 % glucose) for 1, 5 and 
15 min. During these times a rectangular Nd-Fe-B magnet of 20 x 10 x 5 mm (Neo Delta; 
remanence Br, 1080-1150 mT; purchased from IBS magnet, Berlin, Germany) was placed 
underneath each dish. One dish was incubated first for 15 min with vectors and with magnet, 
then the medium was changed and the cells were incubated for further 24 h without magnet. 
After the incubation times the cells were fixed immediately. 
 
Preparation of the samples and electron microscopy 
Cells were fixed in 1 % glutaraldehyde in Sorensens buffer (0.1 M KH2PO4, 0.1 M Na2HPO4, 
pH 7.4) for 1 h at room temperature. After fixation the cells were washed once with Sorensens 
buffer. Then the cells were post fixed in 1 % aqueous osmium tetroxide for 1 h and washed 
twice with Sorensens buffer followed by a dehydration series in graded ethanols (30 %, 50 % 
and 70 %). Each step was done two times for 10 min. The samples were stored in 70 % 
ethanol overnight at 4°C. The next day the cells were further dehydrated in 90 %, 95 %, and 
three times in 100 % ethanol, all done at 4°C. One additional 100 % ethanol step was done at 
room temperature. Afterwards a 1:1 mixture of the resin Epon 812 and 100% ethanol was put 
on the cells for two hours. The solution was taken off and the pure Epon mix was put into the 
dishes overnight. The next day the Epon solution was replaced by fresh Epon two times and 
placed in an oven at 50°C for a two day period to polymerize. The sectioning of the 
polymerised blocks was done by a ultramicrotome. For contrast staining 4 % uranyl acetate 
and 0,2 % lead citrate were used. A Philips CM 10 transmission electron microscope 
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(Eindhoven, The Netherlands) located at the Department of Anatomy II, Ludwig-
Maximilians-University, Munich, Germany, was applied for microscopy. 
The fixation, block preparation, sectioning and electron microscopy was performed mainly by 
Jim Lausier (Department of Pediatrics, Ludwig-Maximilians-University, Munich, Germany), 
assisted by Sabine Herzmann (Department of Anatomy II, Ludwig-Maximilians-University, 
Munich, Germany). 
 
2.5.3.3 Reporter gene expression kinetic with magnetofection and standard 
transfection 
 
Cells: NIH 3T3 seeded in 96-well plates. 
General settings: 1 µg DNA/well. 
trMAG/DNA w/w ratio: 4. 
PEI/DNA N/P ratio = 8. 
Each preparation in 0.9 % (150 mM) NaCl. 
Each preparation at each time point examined in triplicates. 
DNA stock: 58.8 µg/0.980 ml in 0.9 % NaCl. 
trMAG stock: 16 mg/ml in water. 
trMAG suspension: 109.2 µg/0.455 ml in 0.9 % NaCl. 
PEI (25 kDa) stock: 61.3 µg/0.980 ml in 0.9 % NaCl. 
trMAGs: trMAG-16/1. 
Controls: PEI-DNA standard transfections without magnet (in triplicates each). 
Incubation time: maximum time of incubation with vectors with or without magnet was 8 h. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-16/1 / DNA / PEI complexes: 455 µl DNA stock were added to 
the 455 µl trMAG suspension. Finally, 455 µl PEI stock were pipetted to the mixture. 
PEI-DNA complexes: 455 µl DNA stock were mixed with 455 µl PEI stock. Finally, 455 µl 
0.9 % NaCl were added to the complexes. 
Cells transfected with each preparation in triplicates were lysed after 1, 2, 4, 8, 24 and 48 h. 
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2.5.3.4 Influence of the magnet on reporter gene expression 
 
Transfections without magnetic particle containing vectors but with application of a 
magnetic field 
 
Cells: NIH 3T3 seeded in 96-well plates. 
General settings: 0.5 µg DNA/well. 
PEI/DNA N/P ratio = 8. 
Streptavidinylated polylysine: 25 ng St-pL/0.5 µg DNA. 
Chemically inactivated adenovirus (inact. adv): 7.2 x 108 inact. adv particles/0.5 µg DNA. 
Liposomes: DOTAP/Cholesterol mol/mol ratio = 1. 
DOTAP-Cholesterol / DNA +/- = 5. 
Protective copolymer P6YE5C: P6YE5C/DNA -/- ratio = 2. 
Each preparation examined in quadruples. 
DNA stock: 28 µg/0.7 ml in HBS. 
PEI (25 kDa) stock: 23.4 µg/0.56 ml in HBS. 
Streptavidinylated polylysine (St-pL) stock: 0.26 µg/0.132 ml in HBS. 
Inact. adv stock: 1.44 x 1010 virus particles per 0.25 ml in HBS. 
DOTAP-Cholesterol stock: 17.4 µl 5 mM DOTAP-Cholesterol plus 126.6 µl HBS. 
P6YE5C stock: 29.6 mM in terms of negative charges (in water). 
P6YE5C solution: 1.2 µl P6YE5C stock plus 142.8 µl HBS. 
Controls: comparison of the vectors with and without magnet (each in quadruples). 
Incubation times: cells were incubated with vectors with or without magnet for 3 h. 
Reporter gene assay: luciferase. 
Vector preparation: PEI-DNA / bAdv complexes: 120 µl DNA stock were mixed with 120 
µl PEI stock. Subsequently 120 µl inact. adv stock were added and mixed very gently. Finally, 
120 µl HBS were pipetted to the complexes. 
bAdv / St-pL / DNA / PEI complexes: 120 µl inact.adv stock were added to 120 µl St-pL 
stock and mixed very gently. Then, 120 µl DNA stock were pipetted to the mixture. Finally, 
120 µl PEI stock were added to the complexes. 
PEI-DNA complexes: 120 µl DNA stock were added to 120 µl PEI stock. Finally, 240 µl HBS 
were pipetted to the mixture. 
DOTAP-Cholesterol / DNA complexes: 120 µl DNA stock were added to 120 µl DOTAP-
Cholesterol stock. Finally, 240 µl HBS were pipetted to the mixture. 
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PEI-DNA / P6YE5C complexes: 120 µl DNA stock were mixed with 120 µl PEI stock. Then, 
120 µl P6YE5C solution wer pipetted to the mixture. Finally, 120 µl HBS were added to the 
complexes. 
 
2.5.4 Critical parameters in optimizing magnetofection 
 
2.5.4.1 Dose-response studies at different trMAG / DNA (w/w) ratios 
 
Magnetofection with trMAG-PEI / DNA / DOTAP-Cholesterol 
 
Cells: CHO-K1 seeded in two 96-well plates. 
General settings: starting concentration of 0.5 µg DNA/well. 
Liposomes: DOTAP/Cholesterol mol/mol ratio = 1. 
DOTAP-Cholesterol / DNA +/- = 5. 
trMAG/DNA w/w ratios: 0, 0.2, 0.4, 0.6, 0.8, 1, 2, 4. 
Each preparation examined in quadruples. 
DNA stock: 92.16 µg/2.304 ml in water. 
trMAG stock: 1 mg/ml in water. 
DOTAP-Cholesterol stock: 279.3 µl 5 mM DOTAP-Cholesterol liposomes in water plus 
2024 µl water. 
trMAGs: trMAG-PEI. 
Controls: DOTAP-Cholesterol / DNA complexes without trMAGs (each in quadruples). 
Incubation time: cells were incubated with vectors and magnet for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-PEI / DNA / DOTAP-Cholesterol complexes: 250 µl DNA 
stock each were added to 250 µl of each trMAG suspension (see table below). Subsequently 
250 µl DOTAP-Cholesterol each were added to the trMAG / DNA mixtures. Further, 250 µl 
600 mM NaCl each were added to the tubes. Then, 4 x 240 µl of each composition 
(quadruples) were added to positions A1, B1, C1, D1 and E1, F1, G1, H1 and A7, B7, C7, D7 
and E7, F7, G7, H7 of two round-bottom 96-well plates (Nunc, Denmark). All other wells 
were filled with 120 µl 150 mM NaCl. Using a multichannel pipettor, 120 µl each were 
transferred from row 1 and 7, respectively, to rows 2 and 8, respectively, to rows 3 and 9, and 
so on. Total handling time was about 20 min. 
MATERIALS AND METHODS  59 
trMAG suspensions: 
trMAG/DNA 
(w/w) 
0 0.2 0.4 0.6 0.8 1 2 4 
µg trMAG in 
250 µl H2O 
0 2 4 6 8 10 20 40 
 
Application of vectors: Fifty µl each of the DNA complex dilution series were added to cells 
kept in 150 µl fresh medium (complete). 
 
Magnetofection with trMAG-PEI / DNA plus GenePORTER or plus Lipofectamine 
 
Cells: CHO-K1 seeded in a 96-well plate. 
General settings: starting concentration of 0.1 µg DNA/well. 
100 µl transfection volume/well in serum-free DMEM. 
5 µl GenePORTER (Gene Therapy Systems, La Jolla, CA, USA)/1 µg DNA or 4 µl 
Lipofectamine (Life Technologies, Karlsruhe, Germany)/1 µg DNA. 
trMAG/DNA w/w ratios: 0, 0.5, 1, 2, 4, 6, 8, 10. 
Each preparation examined in triplicates. 
DNA stock: 6 µg/0.3 ml in DMEM (without supplements). 
trMAG stocks: 0.1 mg/ml in DMEM (without supplements) and 1 mg/ml in DMEM (without 
supplements). 
trMAGs: trMAG-PEI. 
Controls: GenePORTER-DNA or Lipofectamine-DNA complexes without trMAGs (each in 
triplicates). 
Incubation time: cells were incubated with vectors and magnet for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-PEI / DNA / GenePORTER or Lipofectamine complexes: 36 µl 
DNA stock each were added to 36 µl of each trMAG suspension (see table below). Incubation 
was not longer than the required handling time. Subsequently 3.6 µl of GenePORTER or 2.9 
µl of Lipofectamine diluted to 72 µl with DMEM were added to each trMAG / DNA mixture. 
After 20 min incubation, the DNA complexes were filled up to 720 µl with DMEM. Then, 3 x 
230 µl of each composition (triplicates) were added consecutively to rows A and E , 
respectively, of a round-bottom 96-well plate (Nunc, Denmark). All other rows were filled 
with 115 µl DMEM. Using a multichannel pipettor, 115 µl each were transferred from row A 
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and E, respectively, to rows B and F, respectively, to rows C and G, and so on. Total handling 
time was about 20 min. 
trMAG suspensions: 
trMAG/DNA 
(w/w) 
0 0.5 1 2 4 6 8 10 
µg trMAG in 
36 µl DMEM 
0 0.36 0.72 1.44 2.88 3.6 5.76 7.2 
 
Application of vectors: Serum-containing medium was removed from the plate and replaced 
with 100 µl each of the DNA complex dilution series. After a incubation time of 10 min with 
complexes and magnet cells were washed with complete DMEM. 
 
2.5.4.2 Comparison of positively with negatively charged trMAGs regarding the 
transfection efficiency 
 
Cells: NIH 3T3 seeded in 96-well plate. 
General settings: 0.5 µg DNA/well. 
trMAG/DNA w/w ratio: 1. 
PEI/DNA N/P ratio = 8. 
Influenza virus derived peptide INF7: INF7/DNA -/- ratio = 1. 
Each preparation examined in triplicates. 
DNA stock: 25 µg/0.624 ml in HBS. 
trMAG stocks: each 1 mg/ml in HBS. 
PEI (25 kDa) stock: 26 µg/0.624 ml in HBS. 
INF7 stock: 28.3 nmol negative charges/0.234 ml in HBS. 
trMAGs: trMAG-PEI, trMAG-PO4. 
Controls: each preparation without magnet (in triplicates each). 
Incubation time: cells were incubated with vectors (with or without magnet) for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: Preformation of PEI-DNA (N/P = 8) complexes: 520 µl DNA stock 
were added to 520 µl PEI stock. 
PEI-DNA / INF7 / trMAG-PEI or trMAG-PO4 complexes: 195 µl PEI-DNA were added to 
97.5 µl INF7 stock. To this mixture, 97.5 µl trMAG-PEI or trMAG-PO4 suspension (both 
consisting of 3.9 µg trMAG in 97.5 µl HBS) were added. 
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PEI-DNA / trMAG-PEI or trMAG-PO4 complexes: 195 µl PEI-DNA were added to 97.5 µl 
trMAG-PEI or trMAG-PO4 suspension (both consisting of 3.9 µg trMAG in 97.5 µl HBS). 
Further, 97.5 µl HBS were added. 
 
2.5.4.3 Variation of the mixing order during formation of the complexes 
 
DNA complexes including DOTAP-Cholesterol and trMAG-PO4 or trMAG-PEI 
 
Cells: NIH 3T3 seeded in two 96-well plates. 
General settings: starting concentration of 0.5 µg DNA/well. 
Liposomes: DOTAP/Cholesterol mol/mol ratio = 1. 
DOTAP-Cholesterol / DNA +/- = 5. 
trMAG/DNA w/w ratio: 1. 
Each preparation examined in triplicates. 
DNA stock: 30 µg/ml in HBS. 
trMAG stocks: 1 mg/ml in HBS. 
trMAG suspensions: 30 µg/ml in HBS. 
DOTAP-Cholesterol stock: 455 µM in HBS. 
trMAGs: trMAG-PO4, trMAG-PEI. 
Controls: each preparation without magnet (in triplicates each). 
Incubation time: cells were incubated with vectors (with or without magnet) for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: DOTAP-Cholesterol / DNA / trMAG complexes: 260 µl DNA stock 
were added to 260 µl DOTAP-Cholesterol stock followed by mixing with 260 µl trMAG 
suspension.  
trMAG / DNA / DOTAP-Cholesterol complexes: Using the same volumes and reagents, first 
trMAGs and DNA were mixed and then added to DOTAP-Cholesterol. 
Serial dilution series: Three times 240 µl of each composition (triplicates) were added to A1-
3, A7-9, E1-3 and E7-9 of a round-bottom 96-well plate (Nunc, Denmark). Positions 1-3 of B, 
C, D, F, G, H and positions 7-9 of B, C, D, F, G, H were filled with 120 µl HBS. Using a 
multichannel pipettor, 120 µl each were transferred from row A and E, respectively, to rows B 
and F, respectively, to rows C and G, and so on. Total handling time was about 20 min. 
Application of vectors: Fifty µl each of the DNA complex dilution series were added to cells 
kept in 150 µl fresh medium (complete). 
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DNA complexes including PEI and trMAG-PO4 
 
Cells: NIH 3T3 seeded in 96-well plates. 
General settings: 0.5 µg DNA/well. 
trMAG/DNA w/w ratio: 1. 
PEI/DNA N/P ratio = 8. 
Each preparation in HBS. 
Each preparation examined in quadruples. 
DNA stock: 18.7 µg/0.468 ml in HBS. 
trMAG stock: 1 mg/ml in HBS. 
trMAG suspension: 18.7 µg/0.468 ml in HBS. 
PEI (25 kDa) stock: 19.5 µg/0.468 ml in HBS. 
trMAGs: trMAG-PO4. 
Controls: each preparation without magnet (in quadruples each). 
Incubation time: cells were incubated with vectors (with or without magnet) for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: PEI-DNA / trMAG-PO4 complexes: 120 µl DNA stock were mixed 
with 120 µl PEI stock. Subsequently 120 µl trMAG-PO4 suspension were added to the 
mixture. Finally, 120 µl HBS were pipetted to the complexes. 
trMAG-PO4 / PEI / DNA complexes: 120 µl trMAG-PO4 suspension were mixed with 120 µl 
PEI stock. Subsequently 120 µl DNA stock were added to the mixture. Then, 120 µl HBS 
were pipetted to the complexes. 
trMAG-PO4 / DNA / PEI complexes: 120 µl DNA stock were mixed with 120 µl trMAG-PO4 
suspension. Then, 120 µl PEI stock were added. Finally, 120 µl HBS were pipetted to the 
complexes. 
 
DNA complexes including PEI, trMAG-PO4 and chemically inactivated adenovirus 
 
Cells: NIH 3T3 seeded in 96-well plates. 
General settings: 0.5 µg DNA/well. 
trMAG/DNA w/w ratio: 1. 
PEI/DNA N/P ratio = 8. 
Chemically inactivated adenovirus (inact. adv): 7.2 x 108 inact. adv particles/0.5 µg DNA. 
Each preparation in HBS. 
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Each preparation examined in quadruples. 
DNA stock: 49.9 µg/1.248 ml in HBS. 
trMAG stock: 1 mg/ml in HBS. 
trMAG suspension: 49.9 µg/1.248 ml in HBS. 
PEI (25 kDa) stock: 52 µg/1.248 ml in HBS. 
Inact. adv stock: 7.16 x 1010 virus particles per 1.248 ml in HBS. 
trMAGs: trMAG-PO4. 
Controls: each preparation without magnet (in quadruples each). 
Incubation time: cells were incubated with vectors (with or without magnet) for 10 min. 
Reporter gene assay: luciferase. 
Vector preparation: inact. adv / trMAG-PO4 / DNA / PEI complexes: 120 µl inact. adv 
stock were added to 120 µl trMAG-PO4 suspension and mixed very gently by pipetting. 
Subsequently 120 µl of DNA stock were added. Finally, 120 µl PEI stock were pipetted to the 
mixture. 
All other vector preparations were performed with the same components and volumes but 
with different mixing orders. 
 
2.5.4.4 Kinetics of magnetofection 
 
Cells: NIH 3T3 seeded in 96-well plates. 
General settings: 0.1 µg DNA/well. 
100 µl transfection volume/well in serum-free DMEM. 
4 µl Lipofectamine (Life Technologies, Karlsruhe, Germany)/1 µg DNA or 5 µl 
GenePORTER (Gene Therapy Systems, La Jolla, CA, USA)/1 µg DNA. 
trMAG/DNA w/w ratio: 2. 
Each preparation examined in triplicates. 
DNA stock: 17.8 µg/0.9 ml in DMEM (without supplements). 
trMAG stock: 1 mg/ml in DMEM (without supplements). 
Lipofectamine (LF) solution: 41.5 µl LF plus 995.3 µl DMEM. 
GenePORTER (GP) solution: 51.8 µl GP plus 985 µl DMEM. 
trMAGs: trMAG-PEI. 
Controls: Lipofectamine-DNA or GenePORTER-DNA complexes without trMAGs in the 
presence and absence of a magnet (each in triplicates) and trMAG-PEI / DNA / 
Lipofectamine or GenePORTER without magnet (each in triplicates). 
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Incubation time: cells were incubated with vectors for 5, 10, 20, 40 and 240 min and the 
magnet was applied for 240 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-PEI / DNA / Lipofectamine (LF) complexes: 216 µl DNA stock 
were added to 216 µl trMAG-PEI suspension containing 8.64 µg trMAGs. Subsequently 432 
µl LF solution were pipetted to this mixture. Finally, the complexes were filled up with 
DMEM to a final volume of 4320 µl. 
trMAG-PEI / DNA / GenePORTER (GP) complexes: 216 µl DNA stock were added to 216 µl 
trMAG-PEI suspension containing 8.64 µg trMAGs. Then, 432 µl GP solution were pipetted 
to this mixture. Finally, the complexes were filled up with DMEM to a final volume of 4320 
µl. 
DNA / Lipofectamine (LF) or DNA / GenePORTER (GP) complexes: exactly the preparation 
of trMAG-PEI / DNA / LF or GP complexes but instead of 216 µl trMAG-PEI suspension 
216 µl DMEM were used. 
Application of vectors: Serum-containing medium was removed from the plate and replaced 
with 100 µl each of the DNA complexes. After incubation with complexes cells were washed 
with complete DMEM. 
 
2.5.5 Comparison of magnetofection and conventional transfection methods with 
regard to their gene transfer efficiency 
 
2.5.5.1 Transfection of NIH 3T3 and CHO-K1 cells with different vector formulations 
 
Cells: NIH 3T3 and CHO-K1 seeded in 96-well plates. 
General settings: 0.5 µg DNA/well (with PEI), 0.25 µg DNA/well (with AVET-PEI), 0.1 µg 
DNA/well (with GenePORTER and Lipofectamine). 
50 µl transfection volume/well for each preparation. 
trMAG/DNA w/w ratios: 1 (with AVET-PEI) and 2 (with PEI, GenePORTER and 
Lipofectamine). 
PEI/DNA N/P ratio = 8. 
Chemically inactivated adenovirus (inact. adv): 3.6 x 108 inact. adv particles/0.25 µg DNA. 
5 µl GenePORTER (Gene Therapy Systems, La Jolla, CA, USA)/1 µg DNA or 4 µl 
Lipofectamine (Life Technologies, Karlsruhe, Germany)/1 µg DNA. 
Each preparation examined in triplicates. 
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DNA stocks: 40 µg/ml in water (for PEI), 40 µg/ml in HBS (for AVET-PEI), 20 µg/ml in 
serum-free DMEM (for GenePORTER and Lipofectamine). 
trMAG stocks: 1 mg/ml in water (for PEI), 1 mg/ml in HBS (for AVET-PEI), 1 mg/ml in 
serum-free DMEM (for GenePORTER and Lipofectamine). 
trMAG suspensions: 0 and 80 µg/ml in water (for PEI), 0 and 40 µg/ml in HBS (for AVET-
PEI), 0 and 40 µg/ml in serum-free DMEM (for GenePORTER and Lipofectamine). 
PEI (25 kDa) stocks: 41.7 µg/ml in water (for PEI) and in HBS (for AVET-PEI). 
Inact. adv stock: 5.74 x 1010 virus particles per ml in HBS. 
GenePorter stock: 50 µl/ml in serum-free DMEM. 
Lipofectamine stock: 40 µl/ml in serum-free DMEM. 
NaCl stock: 600 mM in water. 
trMAGs: trMAG-PEI. 
Controls: standard vectors without magnetic field with 10 min and 4 h incubation time (each 
in triplicates) and magnetofectins without magnetic field with 10 min incubation time (each in 
triplicates). 
Incubation times: cells were incubated with magnetofectins with and without magnet for 10 
min and with standard vectors without magnet for 10 min and 4 h. 
Reporter gene assay: luciferase. 
Vector preparation: DNA / trMAG-PEI / PEI complexes: 195 µl DNA stock were mixed 
with 195 µl trMAG suspension (80 µg/ml in water). Subsequently 195 µl PEI stock were 
added to the mixture. Finally, 195 µl NaCl stock were pipetted to the complexes to obtain a 
concentration of 150 mM NaCl. A final 30-min incubation step was performed for salt-
induced aggregation. 
PEI-DNA complexes: exactly the preparation of DNA / trMAG-PEI / PEI complexes but 
instead of 195 µl trMAG-PEI suspension with 80 µg/ml in water, 195 µl trMAG-PEI 
suspension with 0 µg/ml in water were used. 
DNA / PEI / trMAG-PEI / inact. adv complexes (AVET-PEI): 97.5 µl DNA stock were mixed 
with 97.5 µl PEI stock. Subsequently 97.5 µl trMAG-PEI suspension (40 µg/ml in HBS) were 
added to the mixture. Then, 97.5 µl inact. adv stock were pipetted to the complexes and mixed 
very gently. Finally, 390 µl HBS were added for a 1:1 dilution. 
DNA / PEI / inact. adv complexes (AVET-PEI): exactly the preparation of DNA / PEI / 
trMAG-PEI / inact. adv complexes but instead of 97.5 µl trMAG-PEI suspension with 40 
µg/ml in HBS, 97.5 µl trMAG-PEI suspension with 0 µg/ml in HBS were used. 
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DNA / trMAG-PEI / GenePORTER or Lipofectamine complexes: 78 µl DNA stock were 
mixed with 78 µl trMAG-PEI suspension (40 µg/ml in serum-free DMEM). Subsequently 156 
µl GenePORTER or Lipofectamine stock were added. After 20 min incubation, the complexes 
were diluted 2.5-fold with serum-free DMEM (which means addition of 468 µl medium). 
Cells were freshly supplemented with 50 µl serum-free DMEM, incubated with 50 µl 
transfection volume/well, followed by washing and cultivation with serum-containing 
medium. 
DNA / GenePORTER or Lipofectamine complexes: exactly the preparation of DNA / 
trMAG-PEI / GenePORTER or Lipofectamine complexes but instead of 78 µl trMAG-PEI 
suspension with 40 µg/ml in serum-free DMEM , 78 µl trMAG-PEI suspension with 0 µg/ml 
in serum-free DMEM were used. 
 
2.5.5.2 Transfection of NIH 3T3 and CHO-K1 cells with different DNA doses 
 
Lipofectamine as transfection reagent 
 
Cells: NIH 3T3 and CHO-K1 seeded in two 96-well plates each. 
General settings: starting concentration of 0.1 µg DNA/well. 
50 µl transfection volume/well. 
trMAG/DNA w/w ratios: 2. 
4 µl Lipofectamine (Life Technologies, Karlsruhe, Germany)/1 µg DNA. 
Each preparation examined in triplicates. 
DNA stock: 20.7 µg/ 1.296 ml in serum-free DMEM. 
trMAG stock: 1 mg/ml in serum-free DMEM. 
trMAG suspension: 27.6 µg/0.864 ml in serum-free DMEM. 
Lipofectamine stock: 41.4 µl/0.648 ml in serum-free DMEM. 
trMAGs: trMAG-PEI. 
Controls: standard vectors without magnetic field with 10 min and 4 h incubation time (each 
in triplicates) and magnetofectins without magnetic field with 10 min and 4h incubation time 
(each in triplicates). 
Incubation times: cells were incubated with magnetofectins with and without magnet for 10 
min and 4 h and with standard vectors without magnet for 10 min and 4 h. 
Reporter gene assay: luciferase. 
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Vector preparation: DNA / trMAG-PEI / Lipofectamine complexes: The positions A1-6 of a 
round-bottom 96-well plate (Nunc, Denmark) were filled with 60 µl trMAG suspension each 
and then 60 µl DNA stock each were added. Further, 60 µl Lipofectamine stock each were 
pipetted to the mixtures. Finally, 60 µl serum-free DMEM each were added. 
Lipofectamine-DNA complexes: The positions A7-9 were filled with 60 µl Lipofectamine 
stock each and then 60 µl DNA stock each were added. Finally, 120 µl serum-free DMEM 
each were pipetted to the complexes. 
Serial dilution series: Well 1-9 of row B, C and D were filled with 120 µl serum-free DMEM 
each. Using a multichannel pipettor, 120 µl each were transferred from row A to row B, to 
row C, and to row D. The surplus of 120 µl in the wells of row D was dicarded. Then, 120 µl 
serum-free DMEM were added to the wells of row A-D. 
Application of vectors: Cells were freshly supplemented with 50 µl serum-free DMEM and 
50 µl transfection volume/well were applied. 
 
2.5.6 Localization of gene transfer using the magnetofection method 
 
Cells: NIH 3T3 seeded in a 6-well plate. 
General settings: 6 µg DNA/well. 
trMAG/DNA w/w ratio: 1. 
Biotinylated PEI (bPEI): bPEI/DNA N/P ratio = 8. 
Chemically inactivated and biotinylated adenovirus (inact. bAdv): 8.625 x 109 inact. adv 
particles/6 µg DNA. 
Each preparation in HBS. 
DNA stock: 48 µg/ml in HBS. 
trMAG stock: 1 mg/ml in HBS. 
trMAG suspension: 57.6 µg/ml in HBS. 
bPEI (25 kDa) stock: 50 µg/ml in HBS. 
Inact. bAdv stock: 6.9 x 1010 virus particles per ml in HBS. 
trMAGs: streptavidinylated trMAG-PEI (trMAG-PEI-Sta). 
Controls: same complexes but without magnet and complexes lacking trMAGs and no 
magnet. 
Incubation time: cells were incubated with vectors (with or without magnet) for 15 min. 
Reporter gene assay: . β-galactosidase. 
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Vector preparation: bPEI / DNA / inact. bAdv / trMAG-PEI-Sta complexes: 300 µl DNA 
stock were mixed with 300 µl bPEI stock. Then, 300 µl inact. bAdv stock were added and 
mixed very gently. Finally, 300 µl trMAG suspension were pipetted to the complexes. 
bPEI /DNA / inact. bAdv complexes: 150 µl DNA stock were mixed with 150 µl bPEI stock. 
Then, 150 µl inact. bAdv stock were added and mixed very gently. Finally, 150 µl HBS were 
pipetted to the complexes. 
X-gal staining: After 24 h, the cells were washed with PBS and subjected to X-gal staining 
for 45 min. 
 
2.5.7 Magnetofection of other cells 
 
2.5.7.1 HaCaT cells 
 
Cells: HaCaT cells (cell line derived from human keratinocytes, kindly provided by Dr. 
Martin Mempel, Dermatology, TU Munich, Germany) seeded in 96-well plates. Medium: 
DMEM without supplements. 
General settings: 1 µg DNA/well at PEI containing vectors and 0.1 µg DNA/well at 
GenePORTER containing vectors. 
50 µl transfection volume/well at PEI containing vectors and 100 µl transfection volume/well 
at GenePORTER containing vectors. 
trMAG/DNA w/w ratio: 4. 
PEI/DNA N/P ratio = 8. 
5 µl GenePORTER (Gene Therapy Systems, La Jolla, CA, USA)/1 µg DNA. 
Each preparation examined in triplicates. 
DNA stocks: 8.4 µg/0.140 ml in 0.9 % NaCl for PEI containing vectors and 0.84 µg/0.280 ml 
in serum-free DMEM for GenePORTER containing vectors. 
trMAG stocks: 16 mg/ml in 0.9 % NaCl for PEI containing vectors and 1 mg/ml in serum-
free DMEM for GenePORTER containing vectors. 
trMAG suspensions: 15.6 µg/0.065 ml in 0.9 % NaCl for PEI containing vectors and 1.56 
µg/0.130 ml in serum-free DMEM for GenePORTER containing vectors. 
PEI (25 kDa) stock: 8.1 µg/0.130 ml in 0.9 % NaCl. 
GenePORTER stock: 3.9 µl/0.260 ml in serum-free DMEM. 
trMAGs: trMAG-16/1. 
Controls: corresponding standard vectors without trMAGs (each in triplicates). 
MATERIALS AND METHODS  69 
Incubation times: cells were incubated with vectors and magnet for 4h. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-16/1 / DNA / PEI complexes: 60 µl DNA stock were mixed 
with 60 µl trMAG suspension. Finally, 60 µl PEI stock were added to the mixture. 
PEI-DNA complexes: 60 µl DNA stock were mixed with 60 µl PEI stock. Finally, 60 µl 0.9 % 
NaCl were added. 
trMAG-16/1 / DNA / GenePORTER complexes: 120 µl DNA stock were mixed with 120 µl 
trMAG suspension. Finally, 120 µl GenePORTER stock were added to the mixture. 
GenePORTER-DNA complexes: 120 µl DNA stock were mixed with 120 µl GenePORTER 
stock. Finally, 120 µl serum-free DMEM were added to the mixture. 
Application of vectors: Fifty µl each of the PEI containing complexes were added to cells 
kept in 150 µl fresh medium. 
Hundred µl each of the GenePORTER containing complexes were added to cells from which 
the medium was removed before. 
 
2.5.7.2 Primary human keratinocytes 
 
Cells: primary human foreskin keratinocytes (kindly provided by Dr. Martin Mempel, 
Dermatology, TU Munich, Germany) seeded in 96-well plates. Medium: DMEM without 
supplements. 
General settings: 1 µg DNA/well. 
trMAG/DNA w/w ratio: 2. 
PEI/DNA N/P ratio = 8. 
Preparation in 0.9 % NaCl. 
The various incubation times were examined in triplicates each. 
DNA stock: 25.7 µg/0.429 ml in 0.9 % NaCl. 
trMAG stock: 5 mg/ml in water. 
trMAG suspension: 51.5 µg/0.429 ml in 0.9 % NaCl. 
PEI (25 kDa) stock: 26.8 µg/0.429 ml in 0.9 % NaCl. 
trMAGs: trMAG-16/1. 
Controls: 10’ with vectors but no magnet and 4 h with vectors but no magnet (in triplicates 
each). 
Incubation times: 10’ with vectors and 4 h with magnet, 4 h with vectors and 4 h with 
magnet, 10’ with vectors and 10’ with magnet, 4 h with vectors and only the first 10’ with 
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magnet. Incubation with vectors and application of a magnetic field always started 
simultaneously. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-16/1 / DNA / PEI complexes: 390 µl DNA stock were mixed 
with 390 µl trMAG suspension. Finally, 390 µl PEI stock were added to the mixture. 
 
2.5.7.3 RIF-1 cells 
 
Cells: RIF-1 cells (mouse radiation-induced fibrosarcoma cell line, kindly provided by Ellen 
Kolbe, Experimental Oncology, TU Munich, Germany) seeded in a 96-well plate. Medium: 
DMEM with supplements. 
General settings: 1 µg DNA/well. 
trMAG/DNA w/w ratio: 4. 
PEI/DNA N/P ratio = 8. 
Preparations in 0.9 % NaCl. 
Each preparation was examined in triplicates. 
DNA stock: 12.6 µg/0.210 ml in 0.9 % NaCl. 
trMAG stock: 16 mg/ml in water. 
trMAG suspension: 33.6 µg/0.140 ml in 0.9 % NaCl. 
PEI (25 kDa) stock: 8.8 µg/0.140 ml in 0.9 % NaCl. 
trMAGs: trMAG-16/1. 
Control: Incubation with the standard vector PEI-DNA for 2 h (in triplicates). 
Incubation times: cells were incubated with magnetofectins for 30 min. 
Reporter gene assay: luciferase. 
Vector preparation: trMAG-16/1 / DNA / PEI complexes: 65 µl DNA stock were mixed 
with 65 µl trMAG suspension. Finally, 65 µl PEI stock were added to the mixture. 
trMAG-16/1 / DNA complexes: 65 µl DNA stock were mixed with 65 µl trMAG suspension. 
Finally, 65 µl 0.9 % NaCl were added to the mixture. 
PEI-DNA complexes: 65 µl DNA stock were mixed with 65 µl PEI stock. Finally, 65 µl 0.9 % 
NaCl were added to the complexes. 
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2.6 Magnetofection in animal experiments 
 
2.6.1 Injection into the ear veins of five pigs 
 
Preparation of vectors: trMAG-PEI / DNA / PEI complexes per animal (2 ears): 1200 µg 
DNA (plasmid: p55pCMV-IVS-luc+) in 3 ml water were mixed with 1200 µg trMAG-PEI 
beads in 3 ml water and incubated for 15 min. Subsequently 1250.9 µg PEI (25 kDa) in 3 ml 
water were added to the mixture, vortexed and incubated for further 15 min. Finally, 360 µl 5 
M NaCl in 3 ml water were pipetted to the complexes (to obtain a final concentration of 150 
mM), mixed and left for 20 min to allow salt induced aggregation. 
 
Application of vectors: An i.v. cannula (VenflonTM, 22G, Becton Dickinson, Helsingborg, 
Sweden) was laid as far distal as possible into the Vena auricularis lateralis of each ear. For 
anesthesia 6 mg Propofol 1 % (Fresenius, Bad Homburg) per kg body weight were injected 
into one ear. During anesthesia medical oxygen was supplied. Approximately 5 cm 
downstream of the cannula in the right ear a permanent Neodymium-Iron-Boron magnet 
(NeoDelta; remanence Br, 1080-1150 mT; purchased from IBS Magnet, Berlin, Germany) 
with 20 x 10 x 5 mm was placed lengthways above the vein. Subsequently 5 ml of complexes 
were infused within 3 min. The magnet was attached for 1 h above the vein. Then, 5 ml of 
complexes were injected within 3 min into the left ear vein but no magnet was applied 
(control ear without magnet). 
 
Preparation of tissue and blood samples: Twenty-four hours after injection of complexes 
the animals were sacrificed by intracardiac injection of 1.5 g Pentobarbital (Narcoren, Merial, 
Hallbergmoos) and 20 ml of KCl (1 M KCl solution, Delta-Pharma, Pfullingen) each. Both 
ears were removed and the ear veins and 2 samples each of other major organs (heart, lung, 
liver, spleen and kidney) were isolated. Each ear vein was divided in two samples: first the 
area of injection and second the area of the vein underneath the magnet (or no magnet). 
Additionally, blood samples of 5 ml each were taken. 
The tissue samples were washed with PBS and added to tubes (conical 2.0 ml screw cap tubes 
with cap, VWR scientific products, West Chester, USA) which were filled with beads for 
homogenization (Zirconia beads, 2.5 mm diameter, Biospec Products Inc., Bartlesville, USA) 
and 500 (for veins) or 750 µl (for organs) lysis buffer (10 ml of 5 x Reporter Lysis Buffer 
from Promega Corporation, Madison, USA plus 40 ml water plus 1 tablet Complete protease 
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inhibitor from Boehringer, Mannheim, Germany). Fivehundred µl of blood sample each were 
pipetted into an empty tube. Each tube was weighed before and after the tissue sample was 
added. Tubes plus samples were kept on ice all the time. The samples in the tubes were 
homogenized 3 x 20 seconds by using a Mini-beadbeater (Biospec Products Inc., Bartlesville, 
USA) and subsequently centrifuged for 10 min at 14000 rpm and 4 °C (centrifuge: EBA 12 R, 
Hettich, Tuttlingen). Each blood sample was centrifuged for 5 min at 3000 rpm and 4 °C and 
only the serum was used for luciferase assay. 
 
Luciferase assay: Fifty µl from each prepared sample tube were transferred to a well of a 
black 96-well plate, mixed with 100 µl of luciferin buffer (Luciferase Assay System, Promega 
Corporation, Madison, USA) and assayed for bioluminescence using the Microplate 
Scintillation & Luminescence counter “TopCount” (Canberra Packard, Groningen, The 
Netherlands) with a count time of 12 s and a count delay of 1 min. 
To obtain a calibration curve 200, 100, 50, 25, 12.6, 6.25, 3.13, 1.57, 0.78, 0.39, 0.2, 0.1, 
0.05, 0.025, 0.013 and 0 ng luciferase (Roche, Mannheim, Germany) each in 50 µl lysis 
buffer (2-fold dilution series) were measured under the same conditions as the samples. 
After luciferase assay the sample tubes (now lacking 50 µl) were weighed again. 
The reporter gene expressions were expressed in pg luciferase/g tissue. 
 
This animal experiment was performed in collaboration with Ulrike Schillinger (veterinarian), 
Experimental Oncology, TU Munich, Germany. 
 
2.6.2 Injection into the ear arteries of two rabbits 
 
Preparation of vectors: trMAG-16/1 / DNA complexes for two animals (4 ears): 960 µg 
DNA (plasmid: p55pCMV-IVS-luc+) in 3.6 ml 5 % glucose were mixed with 3840 µg 
trMAG-16/1 beads in 3.6 ml 5 % glucose and incubated for 10 min. 
 
Application of vectors: An i.v. cannula (VenflonTM, 22G, Becton Dickinson, Helsingborg, 
Sweden) was laid as far proximal as possible into the ear artery of each ear. For anesthesia 50 
mg Ketamin and 4 mg Xylazin per kg body weight were injected intramuscular (i.m.). During 
anesthesia medical oxygen was supplied. Approximately 5 cm downstream of the cannula in 
the right ear a permanent Neodymium-Iron-Boron magnet (NeoDelta; remanence Br, 1080-
1150 mT; purchased from IBS Magnet, Berlin, Germany) with 20 x 10 x 5 mm was placed 
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lengthways above the artery. Subsequently 1.5 ml of complexes were injected within 1 min. 
The magnet was attached for 1 h above the artery. Then, 1.5 ml of complexes were injected 
within 1 min into the left ear artery but no magnet was applied (control ear without magnet). 
 
Preparation of the artery samples: Approximately 24 hours after injection of complexes the 
animals were sacrificed by i.v. injection of 120 mg Pentobarbital (Narcoren, Merial, 
Hallbergmoos) per kg body weight. Both ears were removed and the ear arteries were 
isolated. Each ear artery was divided in different samples: the area proximal of the magnet, 
the area underneath the magnet, the area distal of the magnet, and an area remote distal of the 
magnet; ear arteries without magnet were divided in the corresponding areas.  
The different samples were washed with PBS and added to tubes (conical 2.0 ml screw cap 
tubes with cap, VWR scientific products, West Chester, USA) which were filled with beads 
for homogenization (Zirconia beads, 2.5 mm diameter, Biospec Products Inc., Bartlesville, 
USA) and 500 µl lysis buffer (10 ml of 5 x Reporter Lysis Buffer from Promega Corporation, 
Madison, USA plus 40 ml water plus 1 tablet Complete protease inhibitor from Boehringer, 
Mannheim, Germany). Each tube was weighed before and after a sample was added. Tubes 
plus samples were kept on ice all the time. The samples in the tubes were homogenized 3 x 20 
seconds by using a Mini-beadbeater (Biospec Products Inc., Bartlesville, USA) and 
subsequently centrifuged for 10 min at 14000 rpm and 4 °C (centrifuge: EBA 12 R, Hettich, 
Tuttlingen).  
 
Luciferase assay: followed exactly the protocol described in the animal experiment above 
“Injection into the ear veins of five pigs”. 
 
This animal experiment was performed in collaboration with Ulrike Schillinger (veterinarian), 
Experimental Oncology, TU Munich, Germany. 
 
2.6.3 Injection into the ilea of rats 
 
Preparation of vectors: trMAG-16/1 / DNA complexes for six animals: 1250 µg DNA 
(plasmid: pCMV-β-gal) in 3125 µl 5 % glucose were mixed with 2500 µg trMAG-16/1 beads 
in 3125 µl 5 % glucose and incubated at room temperature. 
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Application of vectors: After laparatomy of anesthetized Wistar rats in the linea alba region, 
ileum and caecum were exposed and the guts was clamped off 8 cm in oral direction of the 
ileo-caecal junction. Ingested material was carefully rinsed towards the caecum by application 
of 1 ml of isotonic saline. Then, a second clamp was placed 3 cm aborally from the first 
clamp. One ml of the vector preparation was injected with a 20G needle (Braun, Melsungen, 
Germany) adjacent to the first clamp. The injection site was closed with surgical suture 
(Ethilon 3/0 black monofil, from Ethicon, Norderstedt, Germany) while a sterile permanent 
Neodymium-Iron-Boron magnet (NeoDelta; remanence Br, 1080-1150 mT; purchased from 
IBS Magnet, Berlin, Germany) with 20 x 10 x 5 mm was placed under the clamped-off 
section. Five min post injection both clamps were removed. The magnet was left for a total of 
20 min. Subsequently, the guts was returned carefully into the abdominal cavity which was 
closed with surgical suture. Altogether 3 animals with magnet and 3 animals without magnet 
(controls) were treated. 
 
Preparation of the samples: The animals were sacrificed after 48 hrs. The treated section of 
the guts and adjacent areas were isolated, rinsed exhaustively with PBS and fixed for 30 min 
with 2 % formaldehyde (Sigma-Aldrich, Deisenhofen, Germany) and 0.2 % glutaraldehyde 
(Sigma-Aldrich, Deisenhofen, Germany) in PBS. The tissue was rinsed again with PBS 
followed by 4 hrs X-Gal staining at 37°C. Subsequently, the tissue was again rinsed 
exhaustively with PBS and stored over night at 4°C in 2 % formaldehyde/PBS followed by 
embedding for paraffin and cryosections. Sections were stained with eosin. 
 
This animal experiment was performed in collaboration with Julia Henke and Ulrike 
Schillinger (veterinarians), Experimental Oncology, TU Munich, Germany. 
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3 RESULTS 
 
In this chapter the characteristics of the magnetic particles used are shown and the results of 
experiments which examined the binding of DNA to magnetic beads, transfections with 
different types of magnetic particles (magnetofections), the mechanism of magnetofection, 
optimization of magnetofection, the gene transfer efficiency of magnetofections compared to 
standard transfections, magnetic field-guided localzation of gene transfer, magnetofection of a 
variety of cells and the applicability of magnetofection in vivo, are presented. 
 
3.1 Characteristics of magnetic nanoparticles (trMAGs) used in this study 
 
The beads used in this study were superparamagnetic iron oxide nanoparticles. This kind of 
particles is usually derived by precipitation from acidic iron(II)/iron(III)-salt solutions upon 
addition of bases (Schwertmann and Cornell, 1991). To stabilize the particles, they are coated 
with polymers. Every commercial supplier follows his own special protocol. The particles 
used in this thesis were synthesized by Chemicell GmbH, Berlin and they differed in their 
coatings and their sizes. The exact coating procedures were not disclosed by Chemicell. 
However, the information included in table 2 was provided. 
To create paramagnetic gene vectors, the DNA needs to be bound to the magnetic beads. 
Possible ways of binding are biological binding (e.g. via streptavidin-biotin), chemical-
covalent binding and physical binding (via electrostatic or van der Waals interactions). In this 
thesis physical binding was chosen and Christian Bergemann from Chemicell developed iron 
oxide nanoparticles coated with cationic or anionic polymers which enable binding of 
negatively charged DNA or positively charged DNA vectors to the particles via electrostatic 
interactions or via salt induced aggregation. In the beginning, particles were coated with a 
monolayer of the cationic polymer polyethylenimine (PEI). PEI is a well known transfection 
reagent, it is able to compact DNA and it has endosomolytic activities as it acts as a “proton 
sponge”, that means protonation of PEI within endosomes and endosomal Cl¯ entry triggers 
osmotic swelling and destabilization of the endosomal vesicle (Boussif et al., 1995; Sonawane 
et al., 2003). Based on results in gene delivery (presented in section 3.3.1.1), which showed 
that a monolayer coating did not promote transfection of naked plasmid DNA to a sufficient 
extent, the idea of a multilayer coating with PEI arose. Christian Bergemann (Chemicell) 
synthesized such particles and he also produced iron oxides coated with PEI of different 
molecular weights, linear PEI (known to be very efficient in gene transfer), chemically 
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modified PEI, diethylaminoethyl-dextran (DEAE-dextran, forms massive precipitates when 
added to DNA and leads to enhanced gene transfer) and other cationic and anionic polymers.  
 
3.1.1 Surface coating and size of magnetic particles 
 
In the following table, all magnetic particles used, their surface coatings and the results of size 
measurements by dynamic light scattering are presented. 
 
Positively charged magnetic particles 
Name of magnetic particle Coating average diameter 
nm +/- 
trMAG-PEI trMAGs coated with a monolayer of 
polyethylenimine, (PEI, Mw 800 kDa, 
Fluka, Neu-Ulm, Germany). PEI is a well 
known transfection reagent. 
221.8 +/- 2.3 
trMAG-13/1 trMAGs coated with a monolayer of PEI 2 
kDa (Sigma-Aldrich, Deisenhofen, 
Germany). 
195.6 +/- 1.5 
trMAG-14/1 trMAGs coated with a monolayer of PEI 
60 kDa (Sigma-Aldrich, Deisenhofen, 
Germany). 
223.1 +/- 2.9 
trMAG-15/1 trMAGs coated with a monolayer of PEI 
750 kDa (Fluka, Neu-Ulm, Germany). 
327.1 +/- 8.6 
trMAG-16/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany). * 
236.9 +/- 4.0 
trMAG-17/1 trMAGs coated with linear PEI (Aldrich, 
USA). Linear PEI is an efficient 
transfection reagent. 
n.d. 
trMAG-18/1 trMAGs coated with a multilayer of PEI 
2000 kDa (Aldrich, USA). * 
205.8 +/- 6.4 
trMAG-19/1 trMAGs coated with a multilayer of PEI 
2000 kDa (Aldrich, USA) but with a 
different coating procedure than at trMAG-
18/1. * 
267.8 +/- 18.1 
trMAG-20/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany), but 
with a different coating procedure than at 
trMAG-16/1. * 
356.2 +/- 12.5 
trMAG-21/1 trMAGs ultraloaded with layers of PEI 800 
kDa (Fluka, Neu-Ulm, Germany). * 
390.6 +/- 30.1 
trMAG-22/1 trMAGs coated with a commercially 
available polyamine from Merck, 
Darmstadt, Germany. 
n.d. 
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trMAG-23/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany) but 
with a different coating procedure than at 
trMAG-16/1. * 
328.3 +/- 20.0 
trMAG-24/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany) but 
with a different coating procedure than at 
trMAG-16/1. * 
322.2 +/- 13.5 
trMAG-25/1 trMAGs coated with a multilayer of PEI 
800 kDa (Fluka, Neu-Ulm, Germany) but 
with 50% less PEI than at trMAG-16/1. * 
279.1 +/- 11.1 
trMAG-26/1 trMAGs coated with poly(bis(2-
chlorethyl)ether-alt-1,3 bis(3-dimethyl-
amino)propyl)urea, quaternized. The 
positive charges should enable DNA 
binding. 
n.d. 
trMAG-DEAE trMAGs with a dextran monolayer coating, 
introduction of end-standing DEAE groups 
with 2-diethylamino-ethyl chloride-
hydrochloride. DEAE-dextran is known to 
increase gene transfer. 
n.d. 
trMAG-DAEA trMAGs coated with a polymer prepared 
from dimethylamine, epichlorohydrine and 
ethylene diamine. The positive charges 
should enable DNA binding. 
175.8 +/- 2.8 
trMAG-STARCH-PEI trMAGs with a multilayer coating of 
starch, Mw 60 kDa (Fluka, Neu-Ulm, 
Germany) followed by covalent coupling 
of PEI via amino groups to the periodate-
oxidized starch layer. 
197.0 +/- 2.5 
trMAG-PEI-ethoxylated trMAGs with a monolayer coating of PEI 
50 kDa (Aldrich, USA) which has been 
ethoxylated (80 %). 
239.4 +/- 6.0 
trMAG-PEI-
epichlorhydrin 
trMAGs with a monolayer coating of PEI 
20 kDa (Aldrich, USA) modified with 
epichlorohydrin. 
191.6 +/- 4.1 
trMAG-PEI-lowMW trMAGs with a monolayer coating of PEI, 
Mw 1.7 kDa (Aldrich, USA). 
152.8 +/- 1.2 
trMAG-PEI-SDS trMAGs with a monolayer coating of PEI 
800 kDa (Aldrich, USA) modified by a 
covalent coupling of sodium dodecyl 
sulfate (SDS) by carbodiimide activation 
(N-Ethyl-N’-(dimethylaminopropyl)-
carbodiimide). SDS should enhance 
transport through cellular membranes. 
n.d. 
trMAG-PEI-C1/1 trMAGs coated with a commercially 
available PEI, should result in relativly 
small particles. 
97.2 +/- 2.4 
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Negatively charged magnetic particles 
Name of magnetic particle Coating average diameter 
nm +/- 
trMAG-ARA trMAGs coated with arabinic acid, sodium 
salt, Mw 250 kDa. Negative charges 
should enable the binding of positively 
charged gene vectors. 
230.2 +/- 2.6 
trMAG-pACRYL trMAGs coated with polyacrylic acid, 
sodium salt, Mw 20 kDa. Negative charges 
should enable the binding of positively 
charged gene vectors. 
158.1 +/- 3.0 
trMAG-pACRYL-MAL trMAGs coated with polyacrylic acid-co-
maleic acid, sodium salt, Mw 50 kDa. 
Negative charges should enable the 
binding of positively charged gene vectors.
221.1 +/- 3.5 
trMAG-pASP or trMAG-
pAsp 
trMAGs coated with polyaspartic acid, 
sodium salt, Mw 3000 kDa. Negative 
charges should enable the binding of 
positively charged gene vectors. 
110.1 +/- 1.5 
trMAG-PO4 trMAGs coated with starch-phosphate, Mw 
20 kDa. Negative charges should enable 
the binding of positively charged gene 
vectors. 
n.d. 
Table 2 Overview of all magnetic particles used, description of their coatings and the results of size 
measurements in aqua dest. by dynamic light scattering using a Malvern 3000 HS Zetasizer. The different 
coating procedures and further details are only known by Christian Bergemann, Chemicell, Berlin, Germany. 
The coated iron oxides are in this thesis called “trMAGs” which is only the short form of “transMAGs”, the 
name usually used in publications. The nomenclature of the various trMAGs was established by Christian 
Bergemann, Berlin, Germany. 
Abbreviations: PEI = polyethylenimine, kDa = kiloDalton, Mw = Molecular weight in g/mol or Dalton, n.d. = 
not determined because aggregated after long-term storage. 
 
* trMAGs labeled with a star are trMAGs coated with a multilayer of PEI and their suspensions contain 
unbound PEI which is a result of the multilayer coating procedure. 
 
3.1.2 Transmission electron microscopy of trMAGs 
 
To illustrate with examples what such magnetic particles look like one electron micrograph of 
trMAGs with a monolayer coating of PEI and one electron micrograph of trMAGs with a 
multilayer coating of PEI (taken by Jean-Serge Rémy, Strasbourg) are presented below. 
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The iron oxide beads coated with a monolayer of PEI (trMAG-PEI) and the ones coated with 
a multilayer of PEI (trMAG-16/1) show both an organization in multi-domain structures. 
Discrepancies in size between light scattering and transmission electron microscopy 
measurements are probably due to the irregular shape of the structures. Further it has to be 
considered that with the sample preparation method used here, non-aggregated particles may 
be washed off through a washing procedure. Additionally, the particles are not studied in 
suspension but they are allowed to dry on a grid which could change their appearance as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Transmission electron micrographs of magnetic beads coated with a monolayer of PEI (trMAG-PEI, 
left picture) and a multilayer of PEI (trMAG-16/1, right picture). The samples applied had concentrations of 10 
µg trMAG-PEI per ml water and 20 µg trMAG-16/1 per ml water, respectively. No stain was used and therefore 
only the electron-dense iron oxide crystals but no PEI molecules are visible. The magnetic particles are 
organized in multi-domain structures of irregular shape.  
The electron micrographs were produced by Jean-Serge Rémy, Strasbourg. 
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3.2 Binding of DNA to magnetic particles 
 
As shown above, all trMAGs are nanoparticles and they have either a positive or a negative 
surface coating. Therefore, in terms of shape and charge, they have similar characteristics as 
nonviral gene vectors which can associate with other charged particles via electrostatic 
interactions or via salt-induced colloid aggregation, a phenomenon well known in colloid 
chemistry (Hiemenz, 1986). 
The question was now if trMAGs could be bound to DNA (vectors) by such physical 
interactions. 
DNA-binding curves were obtained when magnetic particle / DNA (vector) preparations (with 
less than 1% of the DNA molecules 32P-labeled) were magnetically sedimented as described 
in “Materials and methods”. Non-sedimented radioactivity was determined in the 
supernatants. From this, the percentage of bound radio-labeled DNA (which is assumed to be 
directly proportional to the percentage of bound unlabeled DNA) was calculated.  
 
3.2.1 Examination of trMAG-PEI as representative for positively charged magnetic 
beads with a monolayer of PEI 
 
The trMAG-PEI particles are coated with a monolayer of of PEI 800 kDa. Determination of 
the PEI content of trMAG-PEI particles by ninhydrin assay revealed that one µg trMAG-PEI 
contained 0.07 µg PEI and there was no unbound PEI in suspension. It has to be 
considered that when PEI is bound to iron oxides not all primary and secondary amines may 
be accessible for the ninhydrin reaction and therefore it can be assumed that the actual PEI 
content is higher than the one determined. 
 
3.2.1.1 DNA-binding curves 
 
Magnetic particle / DNA (vector) associates were prepared at increasing particle / DNA 
weight ratios. The complexes were either formulated and left in water (aqua dest.-curves) or 
they were formulated in water and then the the ionic strength was adjusted to 150 mM NaCl 
(150 mM NaCl-curves). 
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Figure 2 Percentage of radio-labeled DNA which was bound to trMAG-PEI beads in dependence of the 
particle / DNA weight ratio.  
trMAG-PEI / DNA complexes in aqua dest. and 150 mM NaCl [DNA (aqua dest.), DNA (150mM 
NaCl)]: The resulting DNA binding curves for complexes in water and in 150 mM NaCl were very similar. 
A saturation with more than 90 % of the DNA bound was achieved at a trMAG-PEI / DNA (w/w) ratio of 
2. Approx. 85 % of the DNA dose was associated with beads at a ratio of 1. 
trMAG-PEI / DNA / PEI and trMAG-PEI / DNA / DOTAP-Cholesterol complexes in 150 mM NaCl 
[DNA / PEI (150 mM NaCl), DNA / DOTAP-Chol (150 mM NaCl)]: A saturation with almost 100 % of 
the DNA bound was achieved at a trMAG / DNA (w/w) ratio of 4 when first DNA and then PEI (N/P = 8) 
or DOTAP-Cholesterol (+/- = 5) was added to trMAG-PEI. Both binding curves showed a similar shape but 
the trMAG-PEI / DNA / PEI complexes were more effective in DNA association than the trMAG-PEI / 
DNA / DOTAP-Cholesterol aggregates. 
 
 
Measurements with laser Doppler velocimetry (LDV) using a Malvern 3000 HS Zetasizer 
showed that the average zetapotential of trMAG-PEI in aqua dest. was +38.4 +/- 0.8 mV and 
of trMAG-PEI / DNA (w/w = 1) in aqua dest. was –35.6 +/- 3.0 mV. This change of the 
zetapotential from strongly positive to strongly negative when DNA was added to trMAG-PEI 
beads confirms that DNA is bound to the trMAGs. This binding has to occur via electrostatic 
interactions.  
When trMAG-PEI / DNA / PEI or DOTAP-Chol complexes are formed, first DNA binds 
electrostatically to trMAG-PEI. But it is assumed that after addition of free PEI or DOTAP-
Chol the trMAGs are displaced (free PEI and DOTAP-Chol is assumed to have a higher 
binding affinity to DNA than PEI bound to iron oxides) and through electrostatic interactions 
PEI-DNA or DOTAP-Chol-DNA complexes can be formed. A further assumption suggests 
that these positively charged polyplexes or lipoplexes can aggregate with the positively 
charged trMAGs upon salt addition. 
Compared to using only naked DNA, additional free PEI or DOTAP-Cholesterol moved the 
point of saturation to higher magnetic beads / DNA (w/w) ratios. At a weight ratio of 2, 92 % 
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(naked DNA, saturation), 83 % (DNA + PEI) and 72 % (DNA + DOTAP-Chol), 
respectively, of the DNA dose were associated with the magnetic beads. 
Further binding studies in our lab with iodine-125 labeled DNA revealed that the trMAG-PEI 
particles did not associate with PEI-DNA complexes (N/P = 8) in water but that they did in 
150 mM NaCl. (Plank et al., 2003c). This finding demonstrates that for the association of 
gene vectors with magnetic beads, salt-induced aggregation can be very important. 
 
3.2.1.2 Partcle sizes in 150 mM NaCl 
 
In addition to the DNA-binding curve of trMAG-PEI / DNA / PEI in 150 mM NaCl, the 
corresponding particle sizes up to 2 hours after adjustment of the ionic strength to 150 mM 
NaCl were measured by dynamic light scattering.  
 
 
It is assumed that in the beginning DNA binds electrostatically to trMAG-PEI but after 
addition of free PEI the trMAGs are displaced and through electrostatic interactions PEI-DNA 
complexes (positively charged) are formed. After addition of salt, the trMAGs can aggregate 
with PEI-DNA particles and with increasing time the aggregates get larger and larger. In 
dynamic light scattering, the particles are assumed to be spherical and therefore the obtained 
size values of aggregates with irregular shape are only an approximation whereas the time-
dependent growth of aggregates can be monitored with reliability.  
  
 
 
Figure 3 Time-dependent growth of 
particles resulting from trMAG-PEI 
beads plus DNA (w/w = 1/1) plus PEI 
(N/P = 8) in 150 mM NaCl.  
This phenomenon can be explained by 
salt-induced aggregation. The 
particles aggregated with 
approximately linear kinetics starting 
at 217 ± 2 and remaining in the sub-
micrometer range within two hours. 
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3.2.1.3 Transmission electron microscopy 
 
To illustrate what such associates produced by salt-induced aggregation look like an electron 
micrograph of trMAG-PEI particles mixed with PEI-DNA complexes followed by adjustment 
to 150 mM NaCl was taken by Jean-Serge Rémy, Strasbourg. 
 
 
Salt induced aggregation enables the binding of positively charged PEI-DNA vectors to 
positively charged trMAG-PEI. This finding is in accordance with the already mentioned 
results of binding studies with iodine-125. 
The electron micrograph gives an impression of the shape of such aggregates although it has 
to be considered that with the sample preparation method used here, the particles are not in 
suspension but they are allowed to dry on a grid and this could change their appearance. 
 
3.2.2  Examination of trMAG-16/1 as representative for positively charged magnetic 
beads with a multilayer coating with PEI 
 
The trMAG-16/1 particles are coated with a multilayer of PEI 800 kDa. Determination of the 
PEI content of trMAG-16/1 beads by ninhydrin assay revealed that one µg trMAG-16/1 
contained 0.37 µg PEI (approximately 5.3 times more than trMAG-PEI) and parts of it are 
unbound PEI in suspension. It has to be considered that with PEI bound to iron oxides not 
all primary and secondary amines may be accessible for the ninhydrin reaction and therefore 
it can be assumed that the actual PEI content is higher than the one determined. 
 
 
 
 
 
 
 
 
 
 
Figure 4 Associates of trMAG-PEI and PEI-DNA 
(w/w = 1; N/P = 8) vectors produced by salt-induced 
aggregation. 
Staining of the complexes with an aqueous uranyl-
acetate solution (1%, w/w) made PEI-DNA complexes 
electrondense and therefore visible as grey spherical or 
worm-like structures. 
The micrograph shows a tight association of PEI-DNA 
(more gray spherical or worm-like structures) with iron 
oxide particles (black crystals). 
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3.2.2.1 DNA-binding curve 
 
Magnetic particle / DNA associates were prepared at increasing particle / DNA weight ratios 
in aqua dest. and the binding of DNA to trMAG-16/1 was examined.  
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Figure 5 Percentage of radio-labeled DNA which was bound to trMAG-16/1 beads in aqua dest. in dependence 
of the particle / DNA weight ratio. 
DNA binding was only possible with relatively low trMAG/DNA (w/w) ratios from 0.1 to 0.8. Maximum 
binding was achieved at a trMAG/DNA (w/w) ratio of 0.4 with a relatively low value of 26 %. The negative 
values for trMAG/DNA (w/w) ratios of 1.5 and 4 can only be explained by experimental fluctuation. 
A possible explanation for this binding curve could comprise two overlaping effects:  
First effect: As mentioned before trMAG-16/1 particles contain free unbound PEI in their suspension and it is 
assumed that DNA binds preferentially to free PEI (to form PEI-DNA complexes) and not to PEI from the 
trMAG layers as free PEI is better accessible and more flexible. The amount of DNA remains constant but the 
amount of trMAGs and unbound PEI increases with increasing trMAG/DNA (w/w) ratios. Therefore at low 
trMAG/DNA ratios where not sufficient unbound PEI is provided to bind all the DNA, the remaining DNA is 
bound to the trMAGs present and there is still unbound DNA. Thus an increase in trMAGs and unbound PEI 
leads to an increase of DNA bound to trMAGs until a peak is reached. Further increase of trMAGs and unbound 
PEI results in less binding of DNA to trMAGs as more and more unbound PEI is provided. At trMAG/DNA 
(w/w) ratios higher than 0.8 there is so much unbond PEI in solution that it binds all the DNA to form positively 
charged PEI-DNA complexes and there is no DNA left which could bind to trMAGs. The PEI-DNA complexes 
formed at trMAG/DNA (w/w) ratios higher than 0.8 have to be positively charged because negatively charged 
complexes could bind to trMAGs. 
Second effect: At low trMAG/DNA (w/w) ratios the PEI-DNA complexes formed are probably negatively 
charged as there is not so much unbound PEI in suspension. These negatively charged complexes could bind 
electrostatically to trMAGs. With increasing amounts of trMAGs and unbound PEI more negatively charged 
PEI-DNA complexes are formed and get bound to the magnetic beads until maximum binding is achieved. If the 
amount of trMAGs plus unbound PEI is further increased the PEI-DNA complexes get less negatively charged 
and their binding to trMAGs decreases until even positively charged trMAGs are formed which were not able to 
bind to trMAG-16/1 particles. 
 
When trMAG-16/1 / DNA mixtures were prepared in water maximum binding of DNA to 
magnetic beads was obtained at a trMAG/DNA (w/w) ratio of 0.4 with only 26 % which 
indicates inefficient binding. With trMAG/DNA (w/w) ratios higher than 0.8 there is 
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even no binding of DNA to trMAGs possible. Measurements with laser Doppler 
velocimetry (LDV) using a Malvern 3000 HS Zetasizer showed that the average zetapotential 
of trMAG-16/1 in aqua dest. was +64.2 +/- 6.3 mV and of trMAG-16/1 / DNA (w/w = 2) in 
aqua dest. was +56.6 +/- 1.4 mV which means that there was no significant change of the 
zetapotential when DNA was added to trMAG-16/1 beads. This result confirms that at higher 
trMAG/DNA (w/w) ratios no DNA can be bound to trMAG-16/1 particles. 
Recent binding studies in our lab with trMAG-16/1 / DNA complexes (including iodine-125 
labeled DNA) prepared in 150 mM NaCl showed that more than 90% of the DNA is 
associated with trMAG-16/1 particles at trMAG/DNA w/w ratios from 0.5 to 1.1. It is 
assumed that DNA binds preferentially to free PEI and the resulting PEI-DNA complexes 
aggregate with trMAG-16/1 particles by salt-induction. But in the same experiment with 
trMAG/DNA w/w ratios higher than 1.1 a dramatic decrease in DNA binding was obtained 
and at a ratio of 2 and 4, only 20% and no DNA binding, respectively, was monitored. An 
explanation for the strong decrease in DNA binding at higher trMAG/DNA w/w ratios could 
be that higher amounts of free PEI inhibit salt-induced aggregation of PEI-DNA and trMAG-
16/1 particles.  
 
3.2.2.2 Transmission electron microscopy 
 
TrMAG-16/1 particles and DNA (trMAG/DNA w/w = 2) were mixed in water, the ionic 
strength was adjusted to 150 mM NaCl and for illustration an electron micrograph was taken 
by Jean-Serge Rémy, Strasbourg. 
 
  
Figure 6 Associates of trMAG-16/1 particles and PEI-
DNA complexes (both positively charged) produced 
by salt-induced aggregation (trMAG/DNA w/w = 2). 
The aggregate shown has a size of several hundred 
nanometers (see scale bar in the right lower corner). 
The PEI forming the PEI-DNA complexes was 
originally free unbound PEI which was contained in 
trMAG-16/1 suspension. 
Staining of the complexes with an aqueous uranyl-
acetate solution (1%, w/w) made PEI-DNA complexes 
electron-dense and therefore visible as grey and black 
structures (see the two lower arrows). 
The micrograph shows a tight association of PEI-DNA 
(grey and black structures indicated by the two lower 
arrows) with iron oxide particles ( much smaller black 
crystals indicated by the longer upper arrow). 
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Despite recent binding studies in our lab which revealed that in salt with a trMAG/DNA w/w 
ratio of 2 only 20% of the DNA is bound to trMAG-16/1 particles, this electron micrograph 
shows efficient salt-induced aggregation of trMAG-16/1 particles and PEI-DNA complexes at 
this ratio of 2. An explanation for more efficient aggregation in electron microscopy 
experiments could be that through a washing step in the sample preparation free PEI (which 
could inhibit aggregation) is removed. Further, the addition of uranyl-acetate for staining 
could promote salt-induced aggregation and also drying of the samples on a grid could 
enhance aggregation.  
 
3.2.3 Examination of trMAG-pAsp as representative for negatively charged magnetic 
beads 
 
The trMAG-pAsp particles are coated with polyaspartic acid (sodium salt, 3000 kDa). 
 
3.2.3.1 DNA-binding studies 
 
The binding of DNA complexes to negatively charged poly aspartic acid coated particles 
(trMAG-pAsp) in water and after adjustment of the ionic strength to 150 mM NaCl was 
examined. 
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Figure 7 Percentage  of DNA 
bound to negatively charged  
trMAG-pAsp particles (w/w = 1) 
in water and after adjustment of 
the ionic strength to 150 mM 
NaCl. 
Additionally the mixing order of 
the complex components was 
varied: 
Firstly PEI-DNA (N/P = 8) 
complexes with a positive net 
charge were preformed and 
subsequently trMAG-pAsp beads 
(negatively charged) were added.  
Secondly the PEI (N/P = 8) was 
added to a solution containing 
DNA and trMAG-pAsp particles. 
Independent of the mixing 
sequence in water there was no 
binding of DNA to the magnetic 
beads possible but in 150 mM 
NaCl approximately 70 % of the 
DNA complexes were associated 
with magnetic particles via salt-
induced aggregation. 
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Mixing negativly charged DNA and trMAG-pAsp and subsequent addition of positively 
charged PEI did not lead to electrostatic binding of DNA to the magnetic beads in water. 
Surprisingly, even positively charged PEI-DNA complexes (N/P = 8) could not bind 
electrostatically to negatively charged poly aspartic acid coated beads in aqua dest. An 
explanation could be that with a N/P ratio of 8 there is an excess of PEI that is not complexed 
to DNA (Boeckle et al., 2004) but could bind to trMAG-pAsp instead of PEI-DNA. 
In contrast, after adjustment of the ionic strength to 150 mM NaCl with any mixing order, 
more than 70 % of the DNA dose is bound to trMAG-pAsp particles. Similarly as positively 
charged trMAG-PEI or trMAG-16/1 particles and positively charged PEI-DNA complexes 
(see figure 2, 4 and 6) can aggregate in 150 mM NaCl, the trMAG-pAsp beads with 
electrostatically bound PEI (resulting in net positively charged particles) can bind to 
positively charged PEI-DNA complexes via salt induced colloid aggregation. 
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3.3 Magnetofection in cell culture 
 
In cell culture it was examined if gene transfer with magnetic beads (positively or negatively 
charged) plus DNA and eventually PEI is possible, which type of magnetic particle is the 
most efficient in transfections, if a magnetic field would enhance gene transfer, what the 
mechanism of magnetofection is, what the critical parameters for magnetofection are (e.g. 
DNA dose-response profiles or the kinetics of magnetofection), the comparison of 
magnetofection with standard transfection methods, if a distinct localization of paramagnetic 
gene vectors via magnetic field is possible and if magnetofection is applicable to different cell 
types. 
If not otherwise stated, all transfections were performed in 96-well plates in triplicates. 
Sintered Nd-Fe-B magnets (Neo Delta; remanence Br, 1080-1150 mT; purchased from 
IBS Magnet, Berlin, Germany) were used. For 96-well plates, the magnet shape was 
cylindrical (d = 6 mm, h = 5 mm) and the magnets were inserted in an acrylic glass template 
in 96-well plate format with strictly alternating polarization. The fields of the individual 
magnets influence each other such that the vector dose becomes concentrated in the centers of 
individual wells. If not otherwise stated, all luciferase and β-galactosidase assays were 
performed 24 hours after transfection of the cells. 
 
3.3.1 Transfection efficiency with positively charged trMAGs 
 
In the following experiments, it was examined if gene transfer with magnetic particles is 
possible, if a permanent magnet placed underneath the cell culture plate could enhance 
transfections with magnetic particles, which type of magnetic beads is the most successful in 
gene transfer, which trMAG/DNA (w/w) ratios show maximum transfection efficiencies and 
if smaller complexes (prepared in salt-free medium) or larger complexes (which aggregate in 
150 mM NaCl) lead to higher reporter gene expression. Complexes formed in salt-free 
medium (e.g. water or 5% glucose) are small and their size is stable for hours. Originally the 
idea has been that small particles are taken up by cells more easily (e.g. through endocytosis) 
and therefore lead to more efficient gene transfer. But Ogris et al. showed that larger gene 
vectors resulting from salt-induced aggregation are more efficient in transfections (Ogris et 
al., 1998). 
First, positively charged trMAGs, most of them loaded with PEI in mono- or multilayers, 
were examined.  
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3.3.1.1 trMAG particles and naked DNA 
 
trMAG-PEI and trMAG-13/1 – trMAG-26/1 are all superparamagnetic iron oxide beads 
coated with cationic polymers. Most of these particles are coated with PEI and they differ in 
the type of coating (monolayer or multilayer) and in the molecular weight of PEI (see table 2). 
The beads were mixed with naked plasmid DNA coding for the firefly luciferase at increasing 
trMAG/DNA (w/w) ratios. The efficiency of the complexes in luciferase gene transfer into 
NIH3T3 mouse fibroblasts (using 1 µg DNA / well) with and without application of a 
magnetic field was determined. 
 
Preparation in water and subsequent adjustment to 5% glucose 
 
The particles were mixed with DNA in water and subsequently glucose was added to obtain a 
final concentration of 5% glucose. The glucose does not alter the electrostatic binding 
behaviour but in contrast to aqua dest.; the 5% glucose solution can be added to the cells 
without causing osmotic stress. In the previously shown binding studies with trMAG-16/1 
particles in water (figure 5) at trMAG/DNA (w/w) ratios higher than 0.8; there was no 
electrostatic binding of DNA to PEI multilayer coated trMAGs possible as the entire DNA 
dose associated with unbound PEI which is contained in the suspensions of all multilayer 
beads. Therefore it was assumed that transfections with PEI multilayer coated particles 
formulated in water and adjusted to 5% glucose would only lead to reporter gene expression 
at low trMAG/DNA (w/w) ratios. The cells (kept in serum-containing medium) were 
incubated with complexes for 20 minutes and during this time either a magnet was applied or 
not (control). After incubation the cells were washed and fresh medium was added. 
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Figure 8 Transfection with trMAG-PEI. The par-
ticles are coated with a monolayer of PEI 800kDa 
(Fluka). 
Figure 9 Transfection with trMAG-13/1. The 
particles are coated with a monolayer of PEI 2 kDa 
(Sigma-Aldrich). 
Figure 10 Transfection with trMAG-14/1. The 
particles are coated with a monolayer of PEI 60  
kDa (Sigma-Aldrich). 
Figure 11 Transfection with trMAG-15/1. The 
particles are coated with a monolayer of PEI 750  
kDa (Fluka). 
Figure 12 Transfection with trMAG-16/1. The 
particles are coated with a multilayer of PEI 800  
kDa (Fluka). 
Figure 13 Transfection with trMAG-17/1. The 
particles are coated with linear PEI (Aldrich).  
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Figure 14 Transfection with trMAG-18/1. The 
particles are coated with a multilayer of PEI 2000  
kDa (Aldrich). 
Figure 15 Transfection with trMAG-19/1. The 
difference between trMAG-19/1 and trMAG-18/1 
(fig. 12) is only the coating procedure. 
Figure 16 Transfection with trMAG-20/1. The 
difference between trMAG-20/1 and trMAG-16/1 
(fig. 10) is only the coating procedure. 
Figure 17 Transfection with trMAG-21/1. The 
difference between trMAG-21/1 and trMAG-16/1 
(fig. 10) is that trMAG-21/1 is ultraloaded with PEI. 
Figure 18 Transfection with trMAG-22/1. The 
particles are coated with a commercially available 
polyamine from Merck, Darmstadt. 
Figure 19 Transfection with trMAG-23/1. The 
difference between trMAG-23/1 and trMAG-16/1 
(fig. 10) is only the coating procedure. 
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Figure 20 Transfection with trMAG-24/1. The 
difference between trMAG-24/1 and trMAG-16/1 
(fig. 10) is only the coating procedure. 
Figure 21 Transfection with trMAG-25/1 which is an 
analogue to trMAG-16/1 (fig. 10) but is coated with 
50 % less PEI. 
Figure 22 Transfection with trMAG-26/1. The par-
ticles are coated with poly(bis(2-chlorethyl)ether-alt-
1,3 bis(3-dimethylamino)propyl)urea, quaternized. 
Figure 23 Transfection with naked DNA (1 µg/well) 
without trMAG particles (control).  
 
The highest efficiency in gene transfer (approx. 370 pg luciferase/mg protein) was observed 
at a trMAG/DNA (w/w) ratio of 2 with trMAG-18/1 particles (fig.14) which are coated with 
a multilayer of PEI 2000 kDa (Aldrich) and as is the case with all multilayer coated particles 
their suspension contains unbound PEI. The trMAG-19/1 particles (fig.15) differ from 
trMAG-18/1 only in the coating procedure and showed with more than 130 pg luciferase/mg 
protein the second highest value. Transfection efficiencies roughly around 100 pg 
luciferase/mg protein were reached by using trMAG-16/1 (fig. 12), trMAG-24/1 (fig. 20) and 
trMAG-25/1 (fig. 21) beads, all with a multilayer of PEI 800 kDa (Fluka) and unbound PEI in 
suspension. These relatively high transfection efficiencies of trMAGs coated with multilayers 
of PEI and unbound PEI in suspension at trMAG/DNA ratios of 2 or higher may seem 
surprising at first glance. From binding studies (figure 5) we know that unbound PEI in 
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suspension inhibits electrostatic binding of DNA to the trMAGs at higher trMAG/DNA (w/w) 
ratios. Yet trMAG-16/1 particles showed their peak transfection at a trMAG/DNA (w/w) ratio 
of 2 although the binding studies revealed no association of DNA with magnetic particles 
when complexes were prepared in water. In contrast, with a trMAG/DNA (w/w) ratio of 0.5 
where DNA is bound electrostatically to trMAG-16/1 beads no gene transfer was detected. A 
simple explanation for this apparent contradiction is that association of DNA, PEI and 
magnetic particles is initiated as soon as the complexes are added to the serum-containing cell 
culture medium. At least a fraction of the DNA dose would then be associated with magnetic 
particles by the time these are sedimented on the cells. The relatively sharp optimum in 
dependence of magnetic particle to DNA ratio can be explained by the fact that a minimum 
amount of PEI (free or in complexes) per endosome may be required to exert the proton 
sponge effect. This would explain the low transfection at weight ratios below 2. On the other 
hand, ratios above 2 may lead to a situation where DNA is entirely bound to free PEI. These 
pre-formed complexes would be opsonized with serum in the culture medium and would in 
this manner be inhibited from interacting with magnetic particles. In addition, the binding 
studies in 150 mM NaCl demonstrate that there is no binding between magnetic particles and 
DNA at weight ratios of 4 or higher and thus also in serum-containing medium magnetic 
particle/DNA association may be strongly reduced at this ratios. Further, higher amounts of 
trMAGs may be cell-toxic and therefore reduce the transfection efficiency. 
Under conditions where an association of DNA with magnetic particles can be assumed, 
strong enhancements by applying a magnetic field were observed. 
The trMAG-PEI (fig. 8), trMAG-13/1 (fig. 9) and trMAG-14/1 (fig. 10) beads (all with a 
monolayer of PEI) showed only increased transfection values (trMAG-13/1 even more than 
100 pg luciferase/mg protein) at a trMAG/DNA (w/w) ratio of 16. At this ratio the trMAGs 
settled already during complex preparation in water, probably because such a high amount of 
trMAGs could not be suspended in the given volume. Application of a magnetic field during 
transfection did not play a major role anymore because the visible large heavy aggregates 
which were formed in cell culture medium sedimented very quickly anyway. 
Transfection with trMAG-20/1 (fig. 16), coated with a multilayer of PEI 800 kDa (Fluka) and 
unbound PEI in suspension, resulted in nearly no gene transfer. The difference to trMAG-16/1 
particles which showed relatively high transfection efficiencies was only the coating 
procedure. This result indicates the importance of the type of coating procedure on gene 
transfer efficiency. Unfortunately, the coating procedure was not disclosed by the 
manufacturer. 
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The trMAG-17/1 particles (fig. 13), coated with linear PEI (Aldrich), showed no significant 
gene expression which means that linear PEI (a successful transfection reagent in 
transfections without magnetic beads) is not as suitable as branched PEI for coating iron oxide 
crystals. 
The high standard deviations observed in transfections with the iron oxide beads are a 
phenomenon that occurs generally in experiments with relatively low transfection efficiencies 
(compared to standard polyfections or lipofections). 
In transfections with trMAG-22/1 (fig. 18), coated with a commercially available polyamine, 
and trMAG-26/1 (fig. 22), coated with poly(bis(2-chlorethyl)ether-alt-1,3 bis(3-
dimethylamino)propyl)urea quaternized, absolutely no gene expression was detectable. 
Transfection without any iron oxide beads only with naked DNA (fig. 23) resulted in no gene 
transfer, no matter if a magnetic field was applied or not. This was a control to show that the 
presence of trMAGs enhances gene transfer. 
 
Preparation in water and subsequent adjustment of the ionic strength to 150 mM NaCl 
 
The particles were mixed with DNA and the ionic strength was adjusted to 150 mM NaCl. 
The cells (kept in serum-containing medium) were incubated with complexes for 20 minutes 
and during this time either a magnet was applied or not (control). After incubation, the cells 
were washed and fresh medium was added. 
 
Figure 24 Transfection with trMAG-PEI. The 
particles are coated with a monolayer of PEI 800  
kDa (Fluka). 
Figure 25 Transfection with trMAG-13/1. The 
particles are coated with a monolayer of PEI 2  
kDa (Sigma-Aldrich). 
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Figure 26 Transfection with trMAG-14/1. The 
particles are coated with a monolayer of PEI 60  
kDa (Sigma-Aldrich). 
Figure 27 Transfection with trMAG-15/1. The 
particles are coated with a monolayer of PEI 750  
kDa (Fluka). 
Figure 28 Transfection with trMAG-16/1. The 
particles are coated with a multilayer of PEI 800  
kDa (Fluka). 
Figure 29 Transfection with trMAG-17/1. The 
particles are coated with linear PEI (Aldrich).  
Figure 30 Transfection with trMAG-18/1. The 
particles are coated with a multilayer of PEI 2000  
kDa (Aldrich). 
Figure 31 Transfection with trMAG-19/1. The 
difference between trMAG-19/1 and trMAG-18/1 
(fig. 28) is only the coating procedure. 
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Figure 32 Transfection with trMAG-20/1. The 
difference between trMAG-20/1 and trMAG-16/1 
(fig. 26) is only the coating procedure. 
Figure 33 Transfection with trMAG-21/1. The 
difference between trMAG-21/1 and trMAG-16/1 
(fig. 26) is that trMAG-21/1 is ultraloaded with PEI. 
Figure 34 Transfection with trMAG-22/1. The 
particles are coated with a commercially available 
polyamine from Merck, Darmstadt. 
Figure 35 Transfection with trMAG-23/1. The 
difference between trMAG-23/1 and trMAG-16/1 
(fig. 26) is only the coating procedure. 
Figure 36 Transfection with trMAG-24/1. The 
difference between trMAG-24/1 and trMAG-16/1 
(fig. 26) is only the coating procedure. 
Figure 37 Transfection with trMAG-25/1 which is  
an analogue to trMAG-16/1 (fig. 26) but is coated 
with 50 % less PEI. 
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Figure 38 Transfection with trMAG-26/1. The par-
ticles are coated with poly(bis(2-chlorethyl)ether-alt-
1,3 bis(3-dimethylamino)propyl)urea, quaternized. 
Figure 39 Transfection with naked DNA (1 µg/well) 
without trMAG particles (control).  
 
When the complexes were aggregated in 150 mM NaCl the highest efficiency in gene 
transfer (approx. 3000 pg luciferase/mg protein) was observed at a trMAG/DNA (w/w) ratio 
of 2 with trMAG-16/1 particles (fig.28) which are coated with a multilayer of PEI 800 kDa 
(Fluka) and unbound PEI in suspension (for explanation of the sharp transfection optimum at 
trMAG/DNA w/w = 2, see the same arguments as used previously for the preparation in 5% 
glucose). Similar to the results with complexes in 5% glucose, particles covered with a 
multilayer of high molecular weight PEI (here 800 kDa) and unbound PEI in suspension 
(trMAG-16/1 [fig. 28], trMAG-21/1 [fig. 33], trMAG-23/1 [fig. 35], trMAG-24/1 [fig. 36] 
and trMAG-25/1 [fig. 37]) at trMAG/DNA (w/w) ratios of 1 or 2 were the most successful in 
gene transfer. 
When the preparations were allowed to aggregate in salt solution their efficiency in 
transfecting cells was strongly increased. An explanation could be that the addition of salt 
directly after mixing the components gives the trMAGs and PEI-DNA complexes more time 
to aggregate compared to preparations in 5% glucose. The latter can only aggregate during the 
short period of time in salt and serum-containing cell culture medium before the magnet is 
placed underneath the well and when trMAGs get in contact with PEI-DNA during magnetic 
sedimentation. In the larger aggregates more DNA is bound to magnetic beads, larger 
aggregates are sedimented by magnetic force more efficiently and in previous work Ogris et 
al. showed that larger vectors are more efficient in gene transfer (Ogris et al., 1998). 
trMAG-18/1 (fig. 30) and trMAG-19/1 (fig. 31), with their 2000 kDa PEI multilayer the most 
successful particles in the 5 % glucose series, showed after aggregation in NaCl solution with 
peak values of little more than 150 pg luciferase/mg protein much poorer transfection 
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efficiencies than 800 kDa PEI multilayer beads like trMAG-16/1. This finding indicates that 
one has to consider the medium for complex preparation before choosing the type of particle. 
From the results with preparations in glucose and with salt-induced aggregates it can be 
concluded that the most efficient particles in gene transfer were iron oxides coated with a 
multilayer of high molecular weight branched PEI plus free PEI in suspension at 
trMAG/DNA (w/w) ratios of 1 or 2 (eventually 4, but higher amounts of trMAGs may already 
be cell-toxic and therefore reduce the transfection efficiency). 
Especially when the most successful particles (e.g. trMAG-18/1 and trMAG-19/1 in 5% 
glucose or trMAG-16/1 prepared in NaCl) were used gene transfer was increased strongly by 
applying a magnetic field. This indicates that magnetic sedimentation of paramagnetic 
vectors is possible and that the association of DNA with magnetic particles is compatible 
with gene delivery. 
The trMAG-PEI (fig. 24), trMAG-13/1 (fig. 25) and trMAG-14/1 (fig. 26) beads, coated with 
a monolayer of 800, 2 and 60 kDa PEI, respectively, showed only transfection values around 
75 pg luciferase/mg protein at a trMAG/DNA (w/w) ratio of 16. As already observed in the 5 
% glucose experiments, there were visible precipitates at this high ratio, probably because 
such a high amount of trMAGs could not be suspended in the given volume. The aggregation 
may even be enhanced by salt. Application of a magnetic field during transfection did not 
play a major role anymore because the visible heavy aggregates sedimented very quickly 
anyway and enhanced transfection. 
All experiments revealed that for each type of particle a optimum w/w ratio of beads/DNA 
can be determined. But the optimum ratio can differ for the same particles in 5 % glucose or 
in 150 mM NaCl, as seen e.g. with trMAG-18/1 beads in figure 14 and figure 30. 
The trMAG-17/1 particles (fig. 29), coated with linear PEI (Aldrich), showed only poor gene 
expression which means that linear PEI (a successful transfection reagent in transfections 
without magnetic beads) is not as suitable as branched PEI for coating iron oxide crystals. 
In transfections with trMAG-15/1 (fig. 27), coated with a monolayer of 750 kDa PEI, and 
trMAG-22/1 (fig. 34), coated with a commercially available polyamine, absolutely no gene 
expression was detectable when the complexes were formed in salt solution. 
In all gene transfer experiments with the superparamagnetic particles, the NIH3T3 mouse 
fibroblasts appeared to be healthy and were proliferating as usual. 
In the control experiment without magnetic particles (naked DNA dissolved in 150 mM NaCl, 
fig. 39), a very low value of 0.05 pg luciferase/mg protein could be detected when no 
magnetic field was applied. 
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In summary, particles were found that lead to transfection only with naked DNA and 
their transfection efficiency was even enhanced by application of a magnetic field. This 
means that the proof of principle for magnetofection is shown, but compared to 
standard transfections with polyplexes or lipoplexes, the gene transfer efficiency 
obtained by magnetofection was low. As iron oxide beads coated with multilayers of high 
molecular weight branched PEI and unbound PEI in suspension were the most 
successful particles, it can be speculated that addition of free PEI (or other 
endosomolytic standard transfection reagents) to the beads may improve their 
transfection efficiency. Addition of salt to vector preparations increases the gene 
transfer efficiency as well. 
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3.3.1.2 trMAG / DNA complexes and additional PEI 
 
The eight different types of trMAGs presented below are iron oxides coated with cationic 
polymers and incubation of CHO-K1 cells with these beads associated with naked plasmid 
DNA in 5 % glucose led to no gene transfer. As seen in the experiments before, iron oxide 
beads with unbound high molecular weight PEI in suspension were the most successful in 
transfections and therefore PEI 25 kDa (N/P = 8) was added to the trMAG / DNA complexes 
in the hope to enable gene transfer. The ionic strength of all vector solutions was adjusted to 
150 mM NaCl to allow salt-induced aggregation which had turned out essential in the 
previous experiments. 
The efficiency of these aggregates with increasing bead / DNA (w/w) ratio in luciferase gene 
transfer into CHO-K1 cells (using 0.5 µg DNA / well) with and without application of a 
magnetic field was determined. The incubation time of the cells (kept in serum-containing 
medium) with aggregates in the presence or absence of a magnetic field was 15 min. Then the 
cells were washed and fresh medium applied. 
 
Figure 40 Transfection with trMAG-DEAE. The 
particles are coated with a monolayer of dextran. 
Endstanding DEAE groups were introduced with 2-
diethylamino-ethyl chloride-hydrochloride. 
Figure 41 Transfection with trMAG-DAEA. The 
particles are coated with a polymer prepared from 
dimethylamine, epichlorohydrine and ethylene 
diamine. 
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Figure 42 Transfection with trMAG-STARCH-PEI. 
The particles were coated with a multilayer of starch, 
followed by covalent coupling of PEI via amino 
groups to the periodate-oxidized starch layer. 
Figure 43 Transfection with trMAG-PEI-ethoxylated. 
Monolayer coating of the particles with PEI 50 kDa 
(Aldrich) which has been ethoxylated (80 %). 
 
Figure 44 Transfection with trMAG-PEI-epichloro-
hydrin. Monolayer coating of particles with PEI 20 
kDa (Aldrich) modified with epichlorohydrin. 
Figure 45 Transfection with trMAG-PEI-lowMW. 
Monolayer coating of the particles with PEI 1.7 kDa 
(Aldrich). 
 
Figure 46 Transfection with trMAG-PEI-SDS. 
Monolayer coating with PEI 800 kDa modified by a 
covalent coupling of sodium dodecyl sulfate (SDS). 
Figure 47 Transfection with trMAG-PEI-C1/1.  
Particles coated with a commercially available PEI. 
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No transfection was detected when CHO-K1 cells were incubated with these beads associated 
with naked plasmid DNA in 5 % glucose. But with additional PEI 25 kDa (N/P = 8) and 
adjusting ionic strength 150 mM NaCl, all particles showed efficient gene transfer into 
CHO-K1 cells. 
The highest transfection (on the average 400 ng luciferase/mg protein) was monitored with 
trMAG-STARCH-PEI (fig. 42) at a beads/DNA (w/w) ratio of 0.4, although this was not 
significantly higher than with the other particles. 
Transfection with all other particles at their optimum w/w ratio including smaller trMAG-
PEI-C1/1 ( fig. 47) resulted in values between approx. 200-380 ng luciferase/mg protein. 
It has to be emphasized that here the gene expression values are given in ng luciferase/mg 
protein and not as in 3.3.1.1 in pg luciferase/mg protein. This means that with trMAG / DNA 
complexes plus PEI 25 kDa (N/P = 8) plus salt-induced aggregation 100 to 1000-fold higher 
efficiencies were achieved than with the best transfections of section 3.3.1.1 with only naked 
DNA plus salt-induced aggregation. This indicates the strong enhancing effect of additional 
free PEI (probably due to endosomolytic activities) in magnetofection and that with PEI, 
transfection efficiencies comparable to those usually obtained with standard nonviral 
transfection reagents are possible.  
The optimum beads/DNA (w/w) ratio for all beads was relatively low ranging from 0.4-1. 
Without application of a magnetic field, the gene expression remained below 10 ng 
luciferase/mg protein with all particles tested (most of these low values cannot be seen at the 
scales used in the graphs). The increase in transfection by applying a magnetic field ranged 
from 3 to 1292148-fold.  
In all transfections with these superparamagnetic particles, the cells appeared to be healthy 
and were proliferating as usual. 
 
3.3.2 Transfection efficiency with negatively charged trMAGs 
 
3.3.2.1 trMAGs and PEI-DNA complexes 
 
In the previously shown binding studies (figure 7), there was no electrostatic binding of 
negatively charged trMAG-pAsp particles to PEI-DNA complexes in water. But it might be 
possible that the PEI-DNA complexes and trMAGs with electrostatically bound surplus PEI 
(resulting in net positively charged particles) could aggregate when they meet each other by 
Brownian motion during the short period of time in salt-containing cell culture medium before 
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the magnet is placed underneath the well and when trMAGs get in contact with PEI-DNA 
during magnetic sedimentation. This would be the same effect as already monitored with 
trMAGs coated with a multilayer of PEI and unbound PEI in suspension. 
The four different trMAGs used are iron oxide beads coated with anionic polyelectrolytes. 
The negatively charged trMAGs were mixed with net positively charged PEI-DNA (N/P = 8) 
complexes in water at increasing trMAG / DNA (w/w) ratios and subsequently the solution 
was adjusted to 5% glucose. The efficiency of the complexes in luciferase gene transfer into 
NIH3T3 and HepG2 cells (using 0.5 µg DNA / well) with and without application of a 
magnetic field was determined. 
 
Transfection of NIH3T3 cells with complexes in 5% glucose 
 
NIH3T3 mouse fibroblasts (kept in serum-containing medium) were incubated with 
complexes for 10 minutes and during this time either a magnet was applied or not (control). 
After incubation the cells were washed and fresh medium was added. 
 
Figure 48 Transfection with trMAG-ARA. The 
particles are coated with arabinic acid, sodium salt, 
250 kDa. 
Figure 49 Transfection with trMAG-pACRYL. The 
particles are coated with polyacrylic acid, sodium salt, 
20 kDa. 
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Figure 50 Transfection with trMAG-pACRYL-MAL. 
The particles are coated with polyacrylic acid-co-
maleic acid, sodium salt, 50 kDa. 
Figure 51 Transfection with trMAG-pASP. The 
particles are coated with polyaspartic acid, sodium 
salt, 3000 kDa. 
 
All four types of particles tested showed gene expression in NIH 3T3 cells although in figure 
7 there is no electrostatic binding of PEI-DNA to trMAG-pAsp particles in water. An 
explanation may be that PEI-DNA complexes and negatively charged trMAGs with 
electrostatically bound surplus PEI (resulting in net positively charged particles) could 
aggregate in salt and serum-containing cell culture medium.  
The highest transfection efficiency (approx. 270 pg luciferase/mg protein) was observed at a 
trMAG/DNA (w/w) ratio of 0.5 with trMAG-pASP particles (fig. 51). 
In general, gene transfer into NIH3T3 cells with negatively charged beads (plus PEI-
DNA) was roughly as effective as with positively charged particles (plus naked DNA) in 
5 % glucose (see 3.3.1.1, preparation in water and subsequent adjustment to 5 % glucose). 
The optimum trMAG/DNA (w/w) ratios for all the negatively charged particles ranged from 
0.5-2. 
Application of a magnetic field enhanced gene transfer with all particles except with trMAG-
pACRYL-MAL (fig.50) indicating that with most negatively charged particles the principle of 
magnetic sedimentation works. The polyacrylic acid-co-maleic acid covered beads showed 
the poorest transfection efficiency (approx. 30 pg luciferase/mg protein) and the magnetic 
force did not play any role in transfecting cells. 
In all transfections with the negatively charged particles, the NIH3T3 cells appeared to be 
healthy and were proliferating as usual. 
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Transfection of HepG2 cells with complexes prepared in 5% glucose 
 
HepG2 cells (kept in serum-containing medium) were incubated with complexes for 10 
minutes and during this time either a magnet was applied or not (control). After incubation the 
cells were washed and fresh medium was added. 
 
Figure 52 Transfection with trMAG-ARA. The par-
ticles are coated with arabinic acid, sodium salt, 250 
kDa. 
Figure 53 Transfection with trMAG-pACRYL. The 
particles are coated with polyacrylic acid, sodium salt, 
20 kDa. 
 
Figure 54 Transfection with trMAG-pACRYL-MAL. 
The particles are coated with polyacrylic acid-co-
maleic acid, sodium salt, 50 kDa. 
Figure 55 Transfection with trMAG-pASP. The 
particles are coated with polyaspartic acid, sodium 
salt, 3000 kDa. 
 
All four types of particles tested showed gene expression in HepG2 cells. The explanation is 
again aggregation in the salt and serum-containing cell culture medium. 
The highest efficiency in transfecting HepG2 cells (approx. 110 pg luciferase/mg protein) 
was obtained at a trMAG/DNA (w/w) ratio of 2 with trMAG-pASP particles (fig. 55) which 
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were already the most efficient negatively charged beads for gene transfer into NIH3T3 cells 
(fig. 51). 
The lowest transfection efficiency in HepG2 cells (peak transfection: 19 pg luciferase/mg 
protein) was achieved with trMAG-pACRYL-MAL particles (fig. 54) similarly as in NIH3T3 
(fig. 50). But in HepG2 cells, the application of a magnetic field strongly enhanced gene 
transfer with trMAG-pASP-MAL, whereas in NIH3T3 cells the magnet did not play an 
important role (fig. 50). 
Application of a magnetic field increased the gene transfer into HepG2 cells with all 
negatively charged particles indicating one more time that magnetic sedimentation is possible. 
Gene transfer in HepG2 was usually slightly less efficient than in NIH3T3 cells except with 
trMAG-ARA beads which showed an average peak value of 100 pg luciferase/mg protein 
(fig.52) in HepG2 but only 60 pg luciferase/mg protein in NIH3T3 cells (fig.48). 
The optimum trMAG/DNA (w/w) ratios for transfecting HepG2 and NIH3T3 cells were 
identical, only trMAG-pASP particles had a optimum ratio of 2 and 0.5 for HepG2 (fig. 55) 
and NIH3T3 (fig. 51), respectively. 
In all transfections with the negatively charged particles, the HepG2 cells appeared to be 
healthy and were proliferating as usual. 
 
In summary, negatively charged trMAGs were found (especially trMAG-pAsp) which 
showed similar gene expression values as positively charged particles when both are in 
5% glucose. Additionaly, their transfection efficiencies were usually enhanced by application 
of a magnetic field which means that the principle of magnetic sedimentation is applicable 
to negatively charged beads as well.  
Further it is assumed that an adjustment of the ionic strength to 150 mM NaCl directly after 
the mixing of components would significantly improve the transfection efficiencies of 
negatively charged trMAGs (as already shown for positively charged trMAGs). 
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3.3.3 Hints to the mechanism of magnetofection 
 
The experiments with positively and negatively charged trMAGs showed that gene transfer 
with magnetic particles is possible and that application of a magnetic field improved the 
transfection efficiencies. Further, the addition of free PEI, an endosomolytic polymer 
commonly used as transfection reagent, enhanced gene expression. All these findings show 
that magnetofection works but now the question arises what the mechanism of 
magnetofection is. Are the paramagnetic vectors pulled into the cell (or even into the nucleus) 
by magnetic force? Does endocytosis play any role? Is it possible that the permanent magnet 
alone (without magnetic beads) has an enhancing effect on the reporter gene expression? 
 
3.3.3.1 Influence of endosomolytic substances in magnetofection 
 
The transfections with positively charged trMAGs showed that free PEI, which harbours 
endosomolytic activities, improved the gene transfer efficiencies. This could mean that release 
of gene vectors from endosomes is an important step in magnetofection. The uptake 
mechanism which captures vectors in endosomes is called endocytosis. Therefore in the 
following experiments it was examined if magnetofectins containing substances which 
enhance endosomal relase are generally more efficient in gene transfer than magnetofectins 
without endosomolytic additives. The influence of endosomolytic substances on 
magnetofection gives a hint if endocytosis plays a role in magnetofection. 
 
PEI, PEI-bAdv, Lipofectamine and GenePORTER as additives 
 
In the following experiments, trMAG-PEI were chosen as magnetic particles because they are 
only coated with a monolayer of PEI (800 kDa) and their suspension does not harbour 
unbound free PEI. As endosomolytic additives PEI, PEI plus biotinylated chemically 
inactivated adenoviruses (PEI-bAdv), Lipofectamine (LF) and GenePORTER (GP) were 
taken. PEI (25 kDa, from Sigma-Aldrich, Deisenhofen, Germany) acts as a “proton sponge”, 
that means protonation of PEI within endosomes and endosomal Cl¯ entry triggers osmotic 
swelling and destabilization of the endosomal vesicle (Boussif et al., 1995; Sonawane et al., 
2003). Biotinylated chemically inactivated adenoviruses (b-Adv, kindly provided by Ernst 
Wagner, Vienna University Biocenter, Austria) expose in acidified endosomes hydrophobic 
domains of the adenoviral capsid proteins and these domains interact with the endosomal 
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membrane in a fashion that leads to vesicle rupture (Curiel et al., 1991). Lipofectamine 
(transfection reagent from Life Technologies, Karlsruhe, Germany) is a cationic lipid and 
cationic lipid-DNA complexes destabilize endosomal membranes facilitating the release of 
DNA into the cytoplasm (Xu and Szoka, 1996). GenePORTER (transfection reagnet from 
Gene Therapy Systems, La Jolla, CA, USA) is a formulation of a cationic lipid and the neutral 
“helper” lipid DOPE (dioleoylphosphatidylethanolamine) which supports cationic lipids in the 
formation of an inverted hexagonal phase and thus facilitates endosomal membrane 
destabilization (Hafez et al., 2001). 
PEI, PEI plus b-Adv (PEI-bAdv), Lipofectamine (LF) and GenePORTER (GP) were added to 
trMAG-PEI / DNA (w/w ratio = 2) complexes and their transfection efficiency was compared 
to trMAG-PEI / DNA particles without additives. All single components were dissolved in 
150 mM NaCl and the complexes were prepared in 150 mM NaCl to allow salt-induced 
aggregation. During incubation with trMAG containing vectors, a permanent magnet was 
applied. Further, the gene transfer efficiency of the corresponding standard vectors (DNA-
PEI, DNA / PEI / bAdv, DNA-LF and DNA-GP) without magnetic beads and without 
magnetic field was determined. 
NIH 3T3 or CHO-K1 cells were incubated with vectors in the presence or absence of a 
magnetic field for 10 or 20 min, followed by a medium change and the gene expression (in ng 
luciferase/mg protein) was determined after 24 hours. 
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Figure 56 Facilitating magnetic 
field-guided gene transfer by 
addition of endosomolytic 
substances to trMAG-PEI / DNA 
(w/w ratio = 2) complexes. 
The complexes were prepared in 
150 mM NaCl to allow salt-
induced aggregation. 
Transfection with trMAG-PEI / 
DNA (w/w ratio = 2) complexes in 
the presence of a magnetic field 
resulted in no gene expression in 
NIH 3T3 or CHO-K1 cells (see 
column “Additives No”). But 
addition of membrane 
destabilizing substances (see 
columns PEI, PEI-bAdv, 
Lipofectamine and GenePORTER) 
enabled magnetic field-guided 
gene transfer into NIH 3T3 or 
CHO-K1 cells (blue bars, 
paramagnetic vectors). 
Standard vectors with the same 
endosomolytic additives but 
without magnetic beads and 
without magnetic field (yellow 
bars) showed reporter gene 
expression as well but significantly 
lower than the corresponding 
paramagnetic vectors. 
 
The magnetofectin additive PEI enabled gene transfer into NIH 3T3 and Lipofectamine or 
GenePORTER into CHO-K1 cells with a short incubation time of 10 min with complexes and 
magnet. PEI plus an inactivated biotinylated adenovirus (bAdv) facilitated magnetofection of 
NIH 3T3 cells as well but the complexes were left for 20 min on the cells. One might argue 
that an incubation time of 20 min is not comparable with a incubation time of 10 min which 
was used for trMAG-PEI / DNA without additives. But nevertheless it can be concluded that 
only the endosomolytic substances made gene transfer possible, as in figure 24 trMAG-PEI / 
DNA complexes with a trMAG/DNA w/w ratio of 2 and a 20 min incubation with complexes 
and magnet showed no gene expression. 
The importance of membrane-destabilizing additives for successful magnetofection 
indicates that magnetofectins are captured in endosomes and that paramagnetic vectors are 
taken up by the cell via endocytosis. 
Another result of these experiments was that vectors including magnetic particles 
(paramagnetic vectors or magnetofectins) and an applied magnetic field increased gene 
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expression values up to 9400-fold (Lipofectamine) compared to standard vectors without 
beads and without magnet. 
A further result was that not only the adjustment of the ionic strength to 150 mM NaCl after 
mixing of the components results in salt-induced aggregation which associates e.g. trMAG-
PEI and PEI-DNA particles, but that mixing of the components from the beginning in 150 
mM NaCl forms similar aggregates as they show enhanced transfection efficiencies compared 
to trMAG-PEI / DNA alone or to corresponding standard vectors. 
 
A synthetic influenza virus peptide (INF7) as additive 
 
In the following experiments, trMAG-16/1 were chosen as magnetic particles. They are 
coated with a multilayer of PEI 800 kDa and unbound PEI is in suspension. As already shown 
in fig. 12, trMAG-16/1 alone (prepared in 5% glucose) showed gene transfer. Now it should 
be examined if addition of a further endosomolytic substance could increase the transfection 
efficiency. As membrane-destabilizing additive the influenza virus hemagglutinin HA-2 N-
terminal fusogenic peptide INF7 was used. Protonation of the acidic residues of INF7 
promotes its transition to a α-helical structure concomittant with endosomal membrane 
binding and destabilization (Wagner et al., 1992a). 
INF7 was added to complexes containing trMAG-16/1 and DNA and their efficiency in gene 
transfer was compared to trMAG-16/1 / DNA particles without INF7. For the vector 
formulations in water, 1 µg DNA/well, an increasing trMAG/DNA (w/w) ratio, a constant 
DNA/INF7 charge/charge ratio (-/- = 1) and two different sequences of mixing (DNA / INF7 / 
trMAG-16/1 and trMAG-16/1 / DNA / INF7) were used. After preparation of the complexes, 
glucose was added to obtain a final concentration of 5% glucose. 
NIH 3T3 cells (kept in serum-containing medium) were incubated with these vectors for 10 
min in the presence of a magnetic field, followed by a medium change and determination of 
gene expression (in pg luciferase/mg protein) after 24 hours. 
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Figure 57 Enhancement of magnetofection 
efficiency by adding the endosomolytic peptide 
INF7 to vectors containing trMAG-16/1 and 
DNA with increasing trMAG/DNA (w/w) 
ratios.  
The complex solutions were adjusted to 5% 
glucose. 
At all trMAG/DNA (w/w) ratios, vectors 
harbouring INF7 were more efficient in gene 
transfer than particles lacking this peptide. 
With a w/w ratio of 2, the enhancement by 
INF7 was up to 1129-fold and the maximum  
efficiency in magnetofection was obtained.  
The sequence of mixing the components for 
INF7 containing vectors did not influence the 
transfection efficiencies very strongly 
(maximum difference between two mixing 
sequences was about 5-fold at a trMAG/DNA 
w/w ratio of 0.5) but up to a w/w ratio of 4 the 
mixing sequence trMAG-16/1 / DNA / INF7 
was more succesful and at higher ratios the 
mixing sequence DNA / INF7 / trMAG-16/1. 
3.3.3.1.1.1  
 
Addition of the synthetic endosome disruptive peptide INF7 (from Influenza virus) to 
vectors containing trMAG-16/1 and DNA increased the magnetofection efficiency up to 
1129-fold.  
In 5% glucose, electrostatic interactions are responsible for complex formations. It is assumed 
that DNA binds preferentially to free PEI and not to PEI from the trMAG layers, as free PEI 
is better accessible and more flexible. Therefore, in both mixing sequences, unbound PEI 
from the trMAG-16/1 suspension could form PEI-DNA associates (see trMAG-16/1 binding 
studies in figure 5). The negatively charged INF7 could act as glue between PEI-DNA 
(positively charged at trMAG/DNA w/w ratios higher than 0.8) and the positively charged 
trMAG-16/1 particles. The preferential formation of PEI-DNA complexes and the function of 
INF7 as glue would also explain why the mixing sequence does not play an important role for 
the transfection efficiency. 
Without INF7, electrostatic binding of DNA to trMAG-16/1 is only possible at the 
trMAG/DNA (w/w) ratio of 0.5 (see trMAG-16/1 binding studies in figure 5). The mixing of 
trMAG-16/1 and DNA at trMAG/DNA (w/w) ratios of 1 or higher without INF7 generates 
positively charged PEI-DNA and separate trMAG-16/1 particles which are not able to bind to 
each other. But as trMAG-16/1 plus DNA mixed at trMAG/DNA (w/w) ratios higher than 0.8 
resulted in gene transfer after magnetic sedimentation, it is assumed that trMAGs and PEI-
DNA aggregate when they get in contact with the salt and serum-containing cell culture 
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medium. Probably salt-induced aggregation plays an important role for all INF7 containing 
vectors as well.  
INF7 containing complexes with a trMAG/DNA (w/w) ratio of 2 (maximum transfection) 
formed visible large aggregates when pipetted into the wells harbouring salt and serum-
containing medium. An explanation for this phenomenon could be that in salt plus serum, 
complexes turned to electroneutrality. Large and heavy aggregates often increase transfection 
efficiencies (Ogris et al., 1998) and the magnetic force acts stronger on paramagnetic 
associates with a larger volume (Zborowski et al., 1995). Nevertheless the NIH 3T3 cells 
appeared to be healthy and were proliferating as usual. 
 
All the endosomolytic additives used enabled or enhanced gene transfer via magnetofection. 
This was shown for vectors in 150 mM NaCl (with PEI, PEI-bAdv, LF and GP) and for 
vectors in 5% glucose (with INF7). The results indicate that the magnetofectins are captured 
in endosomes which is typical for the cellular uptake mechanism of endocytosis. 
Endosomolytic substances facilitate the escape of gene vectors from endosomal vesicles 
which is necessary for reporter gene expression. The enhancement of gene expression in 
magnetofection by endosome disruptive peptides makes it more likely that paramagnetic 
vectors are transferred into the cell by endocytosis than that they are pulled by magnetic 
force through the cellular membrane. 
 
3.3.3.2 The fate of magnetic particles during magnetofection 
 
A further important question about the mechanism of magnetofection was if trMAGs would 
be taken up by the cell (like DNA) or if they would be left outside. If the magnetic beads 
would enter the cell, is the uptake mechanism endocytosis? Is there a magnetic field-guided 
rapid concentration of magnetofectins on the surface of the cell? Or is the magnet even able to 
pull trMAGs directly into the cells circumventing endocytosis? 
To find answers to these questions, HeLa cells (kept in serum-containing medium) were 
incubated with trMAG-16/1 / DNA complexes (2.5 µg DNA/35 mm dish, trMAG/DNA w/w 
= 2, preparation in 5% glucose) and a rectangular Nd-Fe-B magnet of 20 x 10 x 5 mm (Neo 
Delta; remanence Br, 1080-1150 mT; purchased from IBS Magnet, Berlin, Germany) was 
placed underneath each dish. After exposure to vectors and magnet for 1 min, 5 min, 15 min 
and 15 min with further 24 h incubation in fresh complete medium without magnet, the cells 
were fixed and electron micrographs were taken by Jim Lausier, LMU Munich. 
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Figure 58 Electron microscopy of HeLa cells transfected with trMAG-16/1 / DNA vectors. Exposure to 
complexes and magnetic field for (a) 1 min, (b) 5 min, (c) 15 min and (d) 15 min with further 24 h incubation  
without magnet in fresh complete medium. Arrows indicate the electron dense trMAG-16/1 beads. The DNA 
is not electron dense and is not visible in these micrographs. The scale bars indicate 5 µm. The insets show a 
higher magnification of the labeled areas. 
(a) After 1 min one can see a few particles around the cell. (b) After 5 min trMAGs start to accumulate on the 
cell surface. (c) Already after 15 min there is a strong accumulation of magnetic particles on the cell surface 
and beads are found within the cell. (d) After 15 min plus medium change and 24 h magnet-free incubation, a 
dramatic increase of beads within the cell, mainly in cytoplasmic endosomal structures and eventually some in 
the nucleus, was observed. 
The magnifications of a-d (insets) show magnetic particles during their internalization process and d (inset) 
particles captured in endocytotic vesicles. Sometimes there are small finger shaped extensions or narrow 
lamellae in areas where trMAGs are attached to the cellular surface. These cellular protrusions could indicate 
a special uptake mechanism of HeLa cells or the protrusions could be artifacts from sectioning. 
a
c
b
d
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Accumulation of trMAGs (mixed with DNA in 5% glucose) around the cell increased 
significantly from 1 to 5 min and from 5 to 15 min. It might be that complexes prepared in 
150 mM NaCl would accumulate on the cellular surface even more rapid as they form larger 
and heavier aggregates than trMAGs plus DNA prepared in 5% glucose. Larger trMAG-
containing aggregates are more susceptible to magnetic forces and heavier aggregates 
generally sediment more rapidly.  
Efficient uptake of magnetic beads into cells was only obtained when the cells were incubated 
for further 24 hours without magnetic field in fresh complete medium. Micrograph d shows 
that magnetic particles were definitely taken up by the cell. 
The accumulation of trMAGs in endosomal structures suggests endocytosis as cellular 
uptake mechanism and not a direct traction of complexes into the cell by the magnetic field. 
These results were confirmed by Huth et al (Huth et al., 2004) and they showed by electron 
microscopy with trMAG-PEI / gold-labeled DNA complexes (prepared in HBS) that the 
magnetic particles and the DNA are co-internalized into the cell. Further experiments of this 
group lead to the assumption that clathrin-dependent and caveolae-mediated endocytosis are 
involved in magnetofection but their extent of involvement is cell line-dependent. Rejman et 
al found out that particles smaller than 200 nm are taken up by the clathrin-dependent 
pathway, but with increasing particle size there is a shift to the caveolae-mediated 
internalization which becomes the predominant pathway of entry for particles of 500 nm in 
size (Rejman et al., 2004).  
 
3.3.3.3 Reporter gene expression kinetic with magnetofection and standard 
transfection 
 
The aim was to find out if the rapid sedimentation of gene vectors with the magnetofection 
method leads to a different time course of reporter gene expression than in standard 
transfection. 
NIH 3T3 cells were incubated with trMAG-16/1 / DNA / PEI (1 µg DNA/well, trMAG/DNA 
w/w = 4, N/P = 8, preparation in 150 mM NaCl) or PEI-DNA (1 µg DNA/well, N/P = 8, 
preparation in 150 mM NaCl) complexes for maximum 8 hours and during this time a magnet 
was placed underneath the trMAG-vector containing wells. Cells in triplicate wells each were 
lysed after 1, 2, 4, 8, 12, 24 and 48 hours. After 8 hours the remaining cells were washed and 
fresh complete medium was added. The reporter gene expressions (in ng luciferase/mg 
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protein) of magnetofected and standard transfected cells at the different time points were 
determined and the two kinetics compared. 
 
 
Figure 59 Luciferase gene expression kinetics of magnetofected or standard PEI-transfected NIH 3T3 cells.  
The different time points indicate hours after addition of gene vectors to the cells. 
(a) Complete time course over 50 hours. Maximum gene expression with both transfection methods was 
detected after 24 hours. Magnetofection consistently leads to higher expression than the standard transfection 
(enhancement of 9 to 18-fold). 
(b) Initial gene expression during the first 14 hours. With magnetofection, gene expression was already detected 
after 2 hours, with standard transfection only after 8 hours. 
 
Reporter gene expression in magnetofected cells started earlier than in standard transfected 
cells. An explanation could be that the magnetic field leads to a more rapid and synchronized 
concentration of paramagnetic gene vectors on the cell surface, an earlier and synchronized 
(and eventually even accelerated) uptake of complexes into the cell and subsequently into the 
nucleus and finally an earlier and synchronized onset of reporter gene expression. In the 
course of time, the number of transcription and translation events increases and thus a 
continuous increase of luciferase protein was monitored until after 24 hours the maximum 
was detected. The real maximum could also be a bit earlier or later than after 24 hours but 
with the measurement time intervals chosen peak amounts of luciferase were detected after 24 
hours. The following decrease may be due to intracellular plasmid degradation and 
simultaneous breakdown of the luciferase protein. 
An explanation for the later start of gene expression in standard transfected cells could be 
that there is no synchronized sedimentation of gene vectors but in the beginning standard 
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complexes only get in contact with cells by Brownian motion (later sedimentation of 
aggregates may occur as well). Thus it may take between 4 and 8 hours until enough PEI per 
endosome is accumulated to exert the proton sponge effect. Further, it is possible that the 
minute amounts of luciferase protein produced after 4 hours could not be detected by the 
luciferase assay used. Unfortunately, in this time course the beginning of detectable gene 
expression can not be shown as there was no time point for measurement between 4 and 8 
hours. The peak amount of luciferase in standard transfected cells could in reality be achieved 
later than in magnetofected cells as the reporter gene expression processes had a delay 
compared to the ones in magnetofected cells. But in the graph shown, the maximum amount 
of luciferase in standard transfected cells appears to be after 24 hours as well probably 
because the next time point for measurement was not until 48 hours where plasmids and 
luciferase protein were already strongly degraded. Further, the maximum amount of luciferase 
in standard transfected cells was not as high as the one in magnetofected cells. An explanation 
for this phenomenon could be that the sedimentation of trMAG-containing complexes via 
magnetic force results in more vector-cell contacts than than Brownian motion or 
sedimentation of standard complexes. Additionally, the on the average longer time span that 
standard vectors remain in serum-containing cell culture medium could lead to increased 
vector inactivation and therefore a decrease in gene expression. 
 
3.3.3.4 Influence of the magnet on reporter gene expression 
 
Transfections with non-magnetic standard vectors and simultaneous application of a 
magnetic field 
 
The experiments with positively and negatively charged trMAGs showed that application of a 
magnetic field improved the transfection efficiencies of paramagnetic vectors. The 
explanation so far is that the magnet enables or accelerates the sedimentation of trMAG 
containing complexes, consequently more cells get in contact with the complexes, their 
cellular uptake is increased and the result is enhanced reporter gene expression.  
Another explanation would be that not (alone) the magnetic sedimentation is the cause for 
increased gene expression but that the permanent static neodymium-iron-boron (Nd-Fe-B) 
magnet (1080-1150 mT) used could influence cell physiology in a manner that enhances 
transfection and/or reporter gene expression.  
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To examine if the permanent static Nd-Fe-B magnet alone (without magnetic beads) 
influences the measured reporter gene expression, NIH 3T3 cells were incubated for 3 hours 
with various complexes lacking trMAGs (0.5 µg DNA/well) and meanwhile either the 
permanent magnet or no magnet was applied. Subsequently the cells were washed and fresh 
complete medium was added. As gene vectors, PEI-DNA / biotinylated inactivated 
adenovirus (bAdv), bAdv / streptavidinylated polylysine (St-pL) / DNA / PEI, PEI-DNA, 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP)-Cholesterol / DNA and PEI-DNA / 
P6YE5C (a protective copolymer) were used. Polylysine is a cationic polymer commonly 
used in transfections (here streptavidinylated to enable biological linkage to the biotinylated 
inactivated adenovirus), out of DOTAP-Cholesterol solution cationic liposomes are formed 
with a molar ratio of 1/1 (commonly used in transfections) and P6YE5C is a protective 
copolymer of polyethylene glycol 6000Da and the negatively charged peptide YE5C ([Ac-
YE5]2K-ε-C). Polylysine (pL) is a high molecular weight cationic polymer which is very 
effective in DNA condensation and nuclease protection but which is lacking endosomolytic 
activities (Wagner et al., 1992a). 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) is a 
cationic lipid which is able to condense DNA and to protect DNA from nucleases (Leventis 
and Silvius, 1990) whereas the neutral lipid cholesterol (Felgner et al., 1994) is assumed to 
enhance endosomal release. P6YE5C stabilizes polycation / DNA complexes in their minimal 
size, prevents salt- and serum albumin-induced aggregation, and strongly reduces complement 
activation and the interaction with serum proteins (Finsinger et al., 2000). To show all these 
features, P6YE5C has to be added to polycation / DNA complexes in salt-free solution 
whereas in the following experiment PEI-DNA / P6YE5C was prepared in salt-containing 
solution. All vectors were prepared in HEPES (N-2-hydroxyethyl-piperazine-N’-2-
ethanesulphonic acid) buffered saline (20 mM HEPES, pH 7.3, 150 mM NaCl), called HBS. 
The reporter gene expressions (in ng luciferase/mg protein) with and without magnet were 
compared. 
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1  PEI-DNA / bAdv 
2  bAdv / St-pL / DNA / PEI 
3  PEI-DNA 
4  DOTAP-Cholesterol / DNA 
5  PEI-DNA / P6YE5C 
 
Figure 60 Luciferase gene expressions after transfections with various gene vectors lacking trMAGs with and 
without magnetic field. 
The numbers in the gray bars indicate the fold enhancement when a magnet was applied. The magnet did not 
influence significantly the reporter gene expression in transfections with vector 1-4. Only with vector 5 the 
magnetic field lead to a two-fold increase. 
 
Only transfection with vector 5 (PEI-DNA / P6YE5C) was enhanced two-fold by a magnetic 
field. But a two-fold increase is small, so an inaccuracy in the experiment can be the 
explanation for the difference. 
In summary, application of a permanent static magnetic field did not affect the measured 
reporter gene expression in transfections with trMAG-free complexes.  
It can be concluded that the enhancement of transfection by a permanent static neodymium-
iron-boron (Nd-Fe-B) magnet (1080-1150 mT) shown in previous experiments is not a result 
of magnetic influence on cell physiology or activation of gene expression, but is the 
consequence of magnetic sedimentation of trMAG containing gene vectors.  
 
In summary, all experiments to identify the mechanism of magnetofection justify the 
following conclusion:  
The paramagnetic gene vectors are concentrated efficiently by magnetic force on the cell 
surface within minutes and immediately the endocytotic uptake of complexes into cells starts. 
Further steps leading to gene expression probably proceed similar as with standard vectors 
(lacking trMAGs and a magnetic field) but earlier. Higher efficiency in gene transfer with 
magnetofection is probably a result of more efficient sedimentation and therefore higher 
availability of gene vectors on the cellular surface for endocytosis. 
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3.3.4 Critical parameters in optimizing magnetofection 
 
As shown in previous experiments, various types of positively and negatively charged 
magnetic particles are useful for magnetic field-guided gene transfer. It turned out that 
adjustment of the ionic strength to 150 mM NaCl after mixing of the vector components (or 
alternatively already the mixing in 150 mM NaCl) results in higher transfection efficiencies 
than the preparations in salt-free solution. The cellular uptake mechanism is assumed to be 
endocytosis and the addition of endosomolytic substances (like e.g. PEI, bAdv, cationic lipids, 
INF7) to trMAG-containing gene vectors leads to an increase in gene expression. 
To optimize magnetofection, dose-response studies were carried out at different magnetic 
particle to DNA ratios, positively and negatively charged particles were used, mixing orders 
were varied systematically and transfection kinetics (optimum incubation time of cells with 
vectors plus magnet) was examined. Two types of magnetic particles were chosen: trMAG-
PEI beads (coated with a monolayer of PEI 800 kDa and therefore positively charged) which 
showed efficient gene transfer in all previous experiments when an endosomolytic substance 
was added and trMAG-PO4 beads (coated with starch-phosphate Mw 20 kDa and therefore 
negatively charged). Haim et al. (Haim et al., 2005) recently used trMAG-PO4 beads (in the 
reference called TransMAG-PD particles) to form complexes between lentivirus (negatively 
charged) and magnetic particle by colloidal clustering (facilitated by positively charged ions) 
and with an applied magnetic field the complexes could efficiently infect cells. In previous 
work, Lübbe et al. (Lubbe et al., 1996a; Lubbe et al., 1996b) and Alexiou et al. (Alexiou et al., 
2000) used the same magnetic particles (in the references called magnetic fluids or 
ferrofluids) to bind electrostatically positively charged chemotherapeutic agents and the 
complexes were directed to tumors by application of a magnetic field. 
 
3.3.4.1 Dose-response studies at different trMAG / DNA (w/w) ratios 
 
DNA complexes containing increasing trMAG-PEI / DNA (w/w) ratios and a constant 
amount of the cationic lipids DOTAP-Cholesterol, GenePorter or Lipofectamine were serially 
diluted in order to obtain various doses of DNA. The cationic lipids are frequently used 
commercially available transfection reagents. To obtain dose-response profiles at different 
trMAG / DNA (w/w) ratios, CHO-K1 cells were incubated with these vector formulations for 
10 min in the presence of a magnetic field, washed and fresh serum-containing medium was 
added. The luciferase gene expression was determined as usual after 24 hours. 
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Figure 61 Magnetofection of CHO-K1 cells with trMAG-PEI / DNA / DOTAP-Cholesterol complexes. 
Vectors were prepared in aqua dest., subsequently the ionic strength was adjusted to 150 mM NaCl and they 
were added to the cells kept in serum-containing medium. The gene expression (in ng luciferase/mg protein) 
was examined in dependence of the DNA dose and the trMAG / DNA (w/w) ratio. 
The data points represent the averages of quadruples ± standard deviations. 
To obtain high gene expression (up to 17 ng luciferase/mg protein) the optimum trMAG / DNA (w/w) ratio 
was 4 and the optimum DNA dose was 0.5 µg DNA / well. With decreasing amounts of DNA, the gene 
transfer values decreased at all w/w ratios. Only at the ratio of 4, already with 0.1 µg DNA / well a relatively 
high transfection efficiency (13 ng luciferase/mg protein) was monitored. The lowest efficiency in gene 
transfer was obtained without trMAG-PEI particles (w/w = 0). 
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Figure 62 Magnetofection of CHO-K1 cells with trMAG-PEI / DNA / GenePorter complexes. Vectors were 
prepared in serum-free medium, serum-containig medium was removed from the cells and the complexes 
were added. The gene expression (in ng luciferase/mg protein) was examined in dependence of the DNA dose 
and the trMAG / DNA (w/w) ratio. 
The data points represent the averages of triplicates ± standard deviations. 
The highest efficiency in gene transfer (up to approx. 100 ng luciferase/mg protein) was obtained with trMAG 
/ DNA (w/w) ratios of 2, 4 and 6. The lower ratios 1 and 0.5 showed lower transfection efficiencies and the 
higher ratios 8 and 10 were even less efficient than the lower ratios probably due to cell toxicity. The lowest 
efficiency in gene transfer was monitored without trMAG-PEI particles (w/w = 0). 
With increasing amounts of DNA, the transfection efficiency increased as well. Up to more than 100 ng 
luciferase/mg protein were obtained with the highest DNA dose used (0.1 µg DNA / well). Only with a w/w 
ratio of 2 and 1 at 0.05 µg DNA / well there was a saturation point. The w/w ratio 2 enables even a peak 
transfection of nearly 100 ng luciferase/mg protein with 0.05 µg DNA / well. 
In comparison to transfections with DOTAP-Cholesterol complexes (fig. 61), higher reporter gene expression 
was obtained throughout the dose range. 
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Figure 63 Magnetofection of CHO-K1 cells with trMAG-PEI / DNA / Lipofectamine complexes. Vectors 
were prepared in serum-free medium, serum-containig medium was removed from the cells and the 
complexes were added. The gene expression (in ng luciferase/mg protein) was examined in dependence of the 
DNA dose and the trMAG / DNA (w/w) ratio. 
The data points represent the averages of triplicates ± standard deviations. 
The highest efficiency in gene transfer (more than 500 ng luciferase/mg protein) was obtained with the highest 
trMAG / DNA (w/w) ratio of 10. With decreasing w/w ratio the peak transfection values decreased. The only 
exception from this tendency was the w/w ratio of 2 showed the third highest transfection efficiency (approx. 
370 ng luciferase/mg protein). The lowest gene transfer efficiency was monitored with a ratio of 0.5 (data not 
seen in this scale) and 0 (without trMAG-PEI). 
With increasing amounts of DNA, generally gene expression was increasing. But at a w/w ratio of 10 and 8 
the optimum transfection efficiency (approx. 520 and 480 ng luciferase/mg protein) was obtained with only 
0.05 µg DNA / well and using more DNA resulted in a strong decrease in gene transfer probably due to toxic 
effects. 
In general, Lipofectamine complexes were more efficient in transfecting CHO-K1 cells than GenePorter (fig. 
62) or DOTAP-Cholesterol (fig. 61). 
 
 
The three graphs (fig. 61, 62, 63) revealed that each type of complex (with DOTAP-
Cholesterol, GenePorter or Lipofectamine) used for magnetofection has its individual 
optimum trMAG-PEI / DNA (w/w) ratio and DNA dose to obtain maximum transfection 
efficiency. But on the average, a magnetic particle to DNA ratio of 2 and higher DNA-doses 
appeared to be useful. 
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3.3.4.2 Comparison of positively with negatively charged trMAGs regarding the 
transfection efficiency 
 
To answer the question if positively or negatively charged magnetic beads are more efficient 
in magnetofection, gene transfer experiments with trMAG-PEI particles as representative for 
positively charged trMAGs and with trMAG-PO4 particles as representative for negatively 
charged trMAGs were performed under identical conditions (mixing order, buffers, cell line). 
The complexes were formed either of PEI plus DNA plus trMAGs or of PEI plus DNA plus a 
synthetic endosome-disruptive Influenza peptide (INF7) plus trMAGs. The cells (kept in 
serum-containing medium) were incubated with these aggregates for 10 min. with or without 
application of a magnetic field, subsequently medium was changed and as usual after 24 hours 
the gene transfer efficiency (in ng luciferase/mg protein) was determined. 
 
 
Figure 64 Transfection of NIH3T3 cells with positively charged trMAG-PEI (columns 1 and 3) and negatively 
charged trMAG-PO4 (columns 2 and 4). 
Comparing columns of 1 and 2 (PEI-DNA, INF7 and trMAGs) reveals that with magnet the trMAG-PEI  
complexes (1) were slightly superior in transfecting cells whereas without magnet there was no difference. 
Comparing column 3 and 4 (PEI-DNA and trMAGs) shows that with magnet the trMAG-PEI complexes (3) 
were slightly more effective whereas without magnet the values of trMAG-PO4 aggregates (4) were slightly 
higher. 
In summary, there were no significant differences between trMAG-PEI and trMAG-PO4 particles 
regarding the transfection efficiency. 
With all complexes harbouring the INF7 peptide (1 and 2) a slightly higher transfection efficiency was obtained 
than with complexes lacking this peptide. The magnetic field led to significantly enhanced gene transfer in all 
four cases. 
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The graph reveals that there is no significant difference in gene transfer (maximum 1.5-fold 
between 1 and 2, with magnet) when positively charged trMAG-PEI or negatively charged 
trMAG-PO4 particles were used for transfection. trMAG-PEI beads are known to be very 
efficient in magnetofection when combined with endosomolytic substances (like e.g. PEI or 
INF7) and here it is shown that the negatively charged trMAG-PO4 particles are equally 
efficient. 
The influenza peptide added to trMAGs enhanced the transfection efficiency at least 2-fold 
(between 1 and 3 and between 4 and 2, with magnet). 
 
3.3.4.3 Variation of the mixing order of vector components during formation of the 
complexes 
 
DNA-complexes including DOTAP-Cholesterol and trMAG-PO4 or trMAG-PEI 
 
To examine if the sequence of mixing influences the magnetofection efficiency, complexes 
were either prepared in the mixing order DOTAP-Cholesterol plus DNA plus trMAGs (fig. 65 
and 67) or DNA plus trMAGs plus DOTAP-Cholesterol (fig. 66 and 68). The trMAGs used 
were trMAG-PO4 (coated with starch-phosphate, fig. 65 and 66) or trMAG-PEI (coated with 
a monolayer of PEI, fig. 67 and 68). DOTAP-Cholesterol and DNA was formulated with a 
charge ratio of +/- = 5 and the w/w ratio of trMAGs / DNA was 1. All preparations were 
mixed in HBS. A serial dilution series was carried out to obtain a DNA dose-response profile. 
NIH 3T3 cells (kept in serum-containing medium) were incubated for 10 min with complexes 
in the presence or absence of a magnetic field, followed by a medium change and as usual 
after 24 hours the gene expression (in ng luciferase/mg protein) was determined. 
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Figure 65 Transfection of NIH3T3 cells with 
trMAG-PO4 containing complexes prepared in the 
mixing order: DOTAP-Cholesterol plus DNA plus 
trMAG-PO4. The highest magnetofection 
efficiencies were obtained with 0.25 (maximum) and 
0.5 µg DNA/well. 
Figure 66 Transfection of NIH3T3 cells with 
trMAG-PO4 containing complexes prepared in the 
mixing order: DNA plus trMAG-PO4 plus DOTAP-
Cholesterol. The resulting peak magnetofection (at a 
dose of 0.5 µg DNA/well) was approx. 1.5-fold 
higher than the maximum value obtained with the 
mixing sequence used in fig. 65. 
 
  
Figure 67 Transfection of NIH3T3 cells with 
trMAG-PEI containing complexes prepared in the 
mixing order: DOTAP-Cholesterol plus DNA plus 
trMAG-PEI. The highest magnetofection efficiency 
was obtained with the highest DNA dose used (0.5  
µg DNA/well). 
Figure 68 Transfection of NIH3T3 cells with 
trMAG-PEI containing complexes prepared in the 
mixing order: DNA plus trMAG-PEI plus DOTAP-
Cholesterol. Peak magnetofection (at 0.5 µg 
DNA/well) was approx. 1.5-fold higher than the peak 
value observed with the mixing order used in fig. 67. 
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Gene transfer with trMAG-PO4 and with trMAG-PEI particles in both mixing orders 
resulted in similar magnetofection efficiencies and there were no significant differences. 
Only the peak transfection values with trMAG-PO4 (fig. 66) and trMAG-PEI (fig. 68) were 
approximately 1.5-fold higher with the mixing order DNA plus trMAGs plus DOTAP-
Cholesterol when a magnetic field was applied (magnetofection). But a 1.5-fold enhancement 
is not very significant. trMAG-PO4 beads with the mixing sequence DOTAP-Cholesterol plus 
DNA plus trMAG-PO4 showed their maximum transfection efficiency in the presence of a 
magnet with 0.25 µg DNA/well (fig. 65), but with the highest DNA dose of 0.5 µg DNA/well 
(where peak transfection is obtained in the other 3 formulations) almost the same efficiency 
was obtained and the difference between the two is not significant.  
With increasing amounts of DNA, reporter gene expression (in ng luciferase/mg protein) 
increased (only exception: 0.5 µg DNA/well with magnet in fig. 65). But it has to be 
mentioned that for the absolute amount of luciferase produced per well there was no 
pronounced DNA dose-response relationship in the dose range tested. The higher DNA doses 
tended to be toxic by visual inspection. 
Generally, transfections with magnet resulted in significantly higher gene transfer efficiencies 
than transfections without magnet. 
Magnetofections with trMAG-PEI particles were slightly more efficient than with trMAG-
PO4 beads, but the difference was not significant. 
 
DNA-complexes including PEI and trMAG-PO4 
 
Complexes were prepared in HBS with the mixing order PEI-DNA plus trMAG-PO4 or 
trMAG-PO4 plus PEI plus DNA or trMAG-PO4 plus DNA plus PEI to examine if the 
sequence of mixing influences the magnetofection efficiency. For the formulation, 0.5 µg 
DNA/well, a w/w ratio trMAG/DNA of 1 and PEI/DNA with a N/P ratio of 8 were used. NIH 
3T3 cells (kept in serum-containing medium) were incubated with the aggregates for 10 min 
with or without application of a magnetic field. Subsequently the medium was changed and 
after 24 hours reporter gene expression was determined. All transfections were performed in 
quadruples. 
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Figure 69 DNA-complexes including PEI and trMAG-PO4 particles were prepared in three different mixing 
sequences and their efficiency in transfecting NIH 3T3 cells was determined. In the presence of a magnet, 
mixing order 3 (trMAG-PO4 / DNA / PEI) showed the highest gene transfer efficiency followed by mixing 
order 2 (trMAG-PO4 / PEI / DNA). In general, application of a magnetic field during incubation with complexes 
strongly enhanced the transfection efficiency. 
 
The sequence of mixing influenced the efficiency of gene transfer with magnet 
(magnetofection). Mixing order 3 was 1.2 and 3.4-fold more efficient than mixing order 2 
and 1, respectively, but only the 3.4-fold enhancement is assumed to be significant. Mixing 
order 2 showed significantly (2.8-fold) higher gene expression than mixing order 1 as well. 
An explanation for the reduced magnetofection efficiency with mixing order 1 could be that 
PEI in complexes with preformed PEI-DNA and negatively charged trMAGs might be less 
efficient in its endosomolytic activity. 
 
DNA-complexes including PEI, trMAG-PO4 and chemically inactivated adenovirus 
 
The complexes for magnetofection were prepared in HBS in eight different mixing orders 
(fig. 70). 0.5 µg DNA/well, a w/w ratio trMAG/DNA of 1, PEI/DNA with a N/P ratio of 8 
and 7.2 x 108 chemically inactivated adenovirus particles/0.5 µg DNA were used to formulate 
the aggregates. NIH 3T3 cells (kept in serum-containing medium) were incubated with these 
complexes for 10 min in the presence or absence of a magnetic field. Each transfection was 
carried out in quadruples. After a medium change and after further 24 hours the gene 
expression (in ng luciferase/mg protein) was determined. 
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Figure 70 DNA-complexes including PEI, trMAG-PO4 and psoralen-treated adenovirus particles were prepared 
in eight different mixing sequences and their efficiency in transfecting NIH 3T3 cells was determined. Mixing 
order 4 showed the highest gene transfer efficiency whereas with mixing order 5 the lowest value was obtained. 
Mixing sequences 2, 5 and 8 (all with preformed PEI-DNA complexes) resulted in significantly lower 
transfection efficiencies than the mixing sequences 1, 3, 4, 6 and 7 which showed no significant efficiency 
differences among each other. Generally, the transfections with magnet resulted in much higher gene expression 
than the transfections without magnet. 
 
Similar as in fig. 69 aggregates harbouring preformed PEI-DNA complexes (mixing order 
2, 5 and 8) showed significantly lower magnetofection efficiencies than the other 
formulations. E.g. mixing order 5 was 11 times less efficient in magnetofection than mixing 
order 4. And even with application of a magnetic field mixing order 5 showed a 4-fold lower 
transfection efficiency than mixing order 4 without magnet.  
The sequence of mixing had a minor impact on the gene transfer efficiency with magnet when 
mixing order 1, 3, 4, 6 and 7 were used. These formulations showed all similarly high gene 
expression values of more than 3000 ng luciferase/mg protein.  
Addition of chemically inactivated adenovirus particles to the complexes strongly enhanced 
the gene transfer efficiency. E.g. the peak magnetofection value in fig. 70 (with inact. 
adenovirus) was 45-fold higher than the peak magnetofection value in fig. 69 (same 
components but without inact. adenovirus).  
These transfections with inactivated adenoviruses may provide valuable hints for the use of 
active adenoviral gene vectors in magnetofection. At least it was shown that adenoviral 
particles, PEI and negatively charged trMAGs can be successfully combined in a complex and 
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also the amounts of each component used could serve as a guide line for magnetofections with 
active adenoviruses. 
 
In summary, in most cases the mixing order does not influence the magnetofection 
efficiency significantly when the complexes are prepared in salt-containing solution (here 
HBS). An explanation could be that in salt-solution aggregates are formed which usually 
harbour all components added. But the preformation of PEI-DNA complexes in 
combination with negatively charged particles (like e.g. in fig. 69 and 70) can lead to 
reduced magnetofection efficiencies, eventually because PEI might be less efficient in its 
endosomolytic activity in such associates. 
 
3.3.4.4 Kinetics of magnetofection 
 
In the magnetofection experiments presented before, cells were usually incubated with vectors 
for 10-20 min. The aim of the following two experiments was to find out the optimum time 
of incubation of NIH 3T3 cells with DNA-complexes including cationic lipids in 
magnetofection and the comparison to usual standard transfections. 
As vectors in the first experiment (fig. 71) trMAG-PEI / DNA / Lipofectamine (LF) and DNA 
/ LF and in the second experiment (fig. 72) trMAG-PEI / DNA / GenePorter (GP) and DNA / 
GP were chosen. For the formulations 0.1 µg DNA/well, a trMAG/DNA (w/w) ratio of 2 and 
4 µl of Lipofectamine (LF) or 5 µl of GenePorter (GP) per µg of DNA were used. The 
complexes were prepared in serum-free medium, serum-containig medium was removed from 
the cells and the complexes were added. After 5, 10, 20, 40 and 240 minutes of incubation, 
the vector formulations were removed from the cells and cells were washed. The cells were 
positioned upon a magnetic plate for 240 min or were kept without magnet (standard 
conditions) during incubation with complexes. Luciferase gene expression was determined 20 
hours after the start of the experiment in ng luciferase/mg protein. 
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Figure 71 Kinetics of transfections in NIH 3T3 cells 
using the cationic lipid Lipofectamine (LF) with or 
without trMAG particles in the presence or absence  
of a magnetic field. 
Maximum gene expression was found already after  
5 min of incubation with trMAG-PEI / DNA / LF 
complexes and an applied magnetic field 
(magnetofection). The following decrease in this 
curve is probably not significant. 
Figure 72 Kinetics of transfections in NIH 3T3 cells 
using the cationic lipid GenePorter (GP) with or 
without trMAG particles in the presence or absence  
of a magnetic field. 
The highest efficiency in gene transfer was obtained 
with trMAG-PEI / DNA / GP complexes and an 
applied magnetic field (magnetofection). Approx. 42 
% of the final reporter gene expression level was 
already achieved after 5 min. The transfection 
efficiency increased over time with a moderate slope. 
 
In fig. 71 with trMAG-PEI / DNA / LF complexes and an applied magnetic field 
(magnetofection) maximum gene expression was found after 5 min of incubation. Longer 
incubation times led even to a slight but not significant decrease in transfection efficiency. An 
explanation for this curve could be that already after 5 min of incubation the main proportion 
of gene vectors was magnetically sedimented and was in tight contact with the cells so that it 
was not removed by the washing step. The proportion which was sedimented only with longer 
incubation times could be not significant for the gene transfer efficiency. Another possible 
explanation for this curve could be that with the proportion of complexes sedimented after 5 
min the cells are saturated and longer times of incubation and more sedimented aggregates 
have no enhancing effect on transfection efficiency or they could even be toxic. 
In fig. 72 with trMAG-PEI / DNA / GP complexes and an applied magnetic field 
(magnetofection), 42 % of the final reporter gene expression level was achieved after 5 min of 
incubation. With longer incubation, the transfection efficiency increased over time with a 
moderate slope and maximum gene expression after 4 h of incubation was only 2.4-fold 
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higher than gene expression after 5 min of incubation. If it is assumed that this 2.4-fold 
increase is significant, then an explanation for this curve in comparison with fig. 71 could be 
that the proportion of gene vectors which was magnetically sedimented after 5 min was not as 
high as for trMAG-PEI / DNA / LF complexes plus magnet in fig 71. It might be possible that 
GP leads to slower salt-induced aggregation than LF, thus paramagnetic GP aggregates could 
grow slowlier, consequently their magnetic susceptibility might increase slowlier (Voltairas et 
al., 2002) and therefore with increasing incubation time in salt-containing culture medium the 
proportion of gene vectors which is magnetically sedimented still increases.  
From these two experiments it can be concluded that with magnetofection already 5 min of 
incubation with complexes prepared in salt-containing solution can lead to optimum 
gene transfer efficiency or to a transfection efficiency close to the optimum. But still, 
optimum incubation time has to be found out individually for each vector and cell type. 
Magnetic sedimentation was also examined in the electron microscopy studies in fig. 58. Cells 
were incubated with complexes for 1, 5 and 15 min and an incubation time of 15 min was 
necessary for tight association of complexes with cells. It has to be considered that the 
complexes for electron microscopy were prepared in 5% glucose and therefore smaller 
associates were formed which need more time to magnetically sediment than larger 
aggregates of salt-preparations. Additionally, in the experiment in fig. 57 complexes prepared 
in 5% glucose showed efficient magnetofection after a 10 min-incubation. From these results 
it can be assumed that with complexes prepared in salt-free solution an incubation time of 10-
15 min is necessary for efficient magnetofection.  
A further result of the two kinetics experiments (fig. 71 and 72) was that the the highest gene 
expression was obtained with the magnetofection method (complexes including trMAG-PEI 
particles and a magnetic field applied).  
But also adding trMAGs to the complexes without application of a magnetic field enhanced 
the transfection efficiency compared to using the standard vector formulations, especially 
when longer incubation times were used. An explanation for this phenomenon could be that 
the trMAG containing aggregates are heavier due to the iron oxide component and therefore 
settle more efficiently. Consequently there were more contacts between cells and gene vectors 
and therefore the cellular uptake and the transfection efficiency was increased. This 
interpretation is supported by the results of magnetofection experiments shown later in figure 
75. 
At any time point, GenePorter formulations (fig. 72) were more efficient than Lipofectamine 
formulations (fig. 71). 
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3.3.5 Comparison of magnetofection and conventional transfection methods with 
regard to their gene transfer efficiency 
 
As shown in the experiments before, the principle of magnetofection works and magnetic 
particles combined with standard transfection reagents lead to high magnetofection 
efficiencies. Gene transfer efficiencies of optimized magnetofections and of standard 
transfection protocols were compared in the following experiments. 
 
3.3.5.1 Transfection of NIH 3T3 and CHO-K1 cells with different vector formulations 
 
Aim of the following experiments was to compare the gene transfer efficiency of 
magnetofection and the corresponding standard transfection methods (without trMAG 
particles / without magnetic field / long incubation times). In this context, four different 
vector types and two different cell lines were examined. As standard vectors PEI-DNA, DNA 
/ PEI / inactivated adenovirus (adenovirus enhanced transfection with PEI or AVET-PEI), 
GenePorter-DNA and Lipofectamine-DNA complexes were used. The corresponding vectors 
for magnetofection included additional trMAG-PEI particles (trMAG/DNA w/w ratio = 2). 
The formulations were prepared in HBS (AVET-PEI), in serum-free but salt-containing cell 
culture medium (GenePorter-DNA and Lipofectamine-DNA complexes) or in water with 
subsequent adjustment of the ionic strength to 150 mM NaCl (PEI-DNA). NIH 3T3 and 
CHO-K1 cells were incubated with vectors for 10 min or 4 hours in the presence or absence 
of a magnetic field. Subsequently the cells were washed and fresh complete medium was 
added. The gene expression (in ng luciferase/mg protein) was determined in triplicates as 
usually after 24 hours. 
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Figure 73 Efficacy of magnetofectins (magnetic particle containing vectors) in NIH 3T3 and CHO-K1 cells 
upon short-time (10 min) incubation in the presence (black bars) and in the absence (light gray bars) of a 
magnetic field compared with standard transfections with the parent vectors (dark gray bars, 4-h incubation; 
white bars, 10-min incubation). The table below the graph specifies the enhancements that were achieved 
upon the influence of the magnetic field on paramagnetic vectors compared with transfections in the absence 
of the magnetic field with paramagnetic vectors or the parent standard vectors which did not contain trMAG-
PEI. The data demonstrate that magnetofection can strongly enhance transfection efficiencies over standard 
transfection protocols. The relative enhancements are dependent on vector type, cell line and incubation time. 
 
With all vector types except GenePorter, the magnetofection method showed 
significantly higher gene expression in both cell lines than the corresponding 
transfections without magnet. As explanation for this phenomenon it is assumed that due to 
magnetic sedimentation more gene vectors get in tight contact with cells (even within a 
relatively short period of time) and consequently the cellular uptake and the transfection 
efficiency are enhanced. Without magnetic field, the chance for gene vectors to get in contact 
with cells is limited by Brownian motion and only larger aggregates efficiently sediment 
within the incubation time. But it has to be mentioned that with GenePorter containing vectors 
magnetofection in NIH 3T3 and CHO-K1 cells was only 1.4 and 2-fold, respectively, more 
efficient than the standard transfection with a 4 h incubation time. As a 1.4 and 2-fold 
enhancement is not assumed to be significant it can be concluded that in dependence on the 
parental vector, standard transfections with longer incubation times (4 h) can result in 
equally high transfection efficiencies than magnetofections with 10 min incubation time. 
As explanation it is assumed that high concentrations of some gene vectors (like e.g. 
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GenePorter) on cellular surfaces can lead to saturation of uptake processes or even toxicity 
and therefore the higher number of vector-cell contacts achieved with magnetic sedimentation 
does not lead to a further improvement. The results do vary between experiments. E.g. in fig. 
72 the same 10 min-magnetofection of NIH 3T3 cells with GenePorter was up to 5 times 
more efficient in gene transfer than the 4 h incubation with standard GenePorter-DNA. This 
may be explained by slight variations in transfection parameters such as incubation times 
during vector preparation, cell density and passage number at the time of transfection. 
Maximum enhancement by magnetofection was obtained with Lipofectamine containing 
complexes in CHO-K1 cells: 10 min incubation with magnetofectins and a simultaneously 
applied magnetic field resulted in a 971-fold higher gene transfer efficiency than 4 h 
incubation with standard vectors. 
The magnetofection with Lipofectamine complexes (with only 0.1 µg DNA/well) was the 
most efficient in NIH 3T3 and CHO-K1 cells followed by magnetofections with GenePorter 
(also 0.1 µg DNA/well). 
Independent of variability between experiments, magnetofection was always at least as 
efficient as the parent vector, in most cases substantially more efficient. 
 
3.3.5.2 Transfection of NIH 3T3 and CHO-K1 cells with different DNA doses 
 
In fig. 73 magnetofection with Lipofectamine (LF) showed strong enhancement of gene 
transfer efficiency over 4 h-incubation with standard LF-DNA vectors. In the following 
experiments the LF-magnetofection was examined more in detail by establishing a dose-
response profile. 
Vectors for magnetofection included trMAG-PEI particles with a trMAG/DNA (w/w) ratio of 
2. The formulations were prepared in serum-free cell culture medium. In addition to 
magnetofection and standard transfection the efficiency of gene transfer with complexes 
containing trMAGs but without application of a magnetic field was examined. All 
transfections were performed in triplicates. 
NIH 3T3 and CHO-K1 cells were incubated with vectors for 10 min or 4 hours, followed by a 
medium change, and the next day gene expression was determined. 
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Transfection of NIH 3T3 cells 
 
 
 
 
 
Figure 74 Transfection with 
Lipofectamine (LF)-DNA 
complexes and increasing 
amounts of DNA. 
Magnetofections (10’ or 4h + 
trMAGs and magnet) showed 
higher gene expression than 
standard LF-DNA transfections 
(4h – trMAGs, no magnet) at all 
doses of DNA. 
 
Transfection of CHO-K1 cells 
 
 
 
 
Figure 75 Transfection with 
Lipofectamine (LF)-DNA 
complexes and increasing 
amounts of DNA. 
Magnetofections (10’ or 4h + 
trMAGs and magnet) showed 
higher gene expression than 
standard LF-DNA (4h – trMAGs, 
no magnet) at all DNA doses. At 
0.05 µg DNA/well 
magnetofections and standard LF-
DNA approached saturation. 
 
Using NIH 3T3 and CHO-K1 cells, the magnetofection method with Lipofectamine (LF)-
DNA was more efficient under all settings than the corresponding standard method (4h 
– trMAGs, no magnet). A maximum enhancement of 180-fold was achieved in NIH 3T3 cells 
with 4h LF-DNA magnetofection at 0.025 µg DNA (fig. 74) and a maximum enhancement of 
970.9 and 1037.2-fold in CHO-K1 cells with 10’ and 4h LF-DNA magnetofection, 
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respectively, at 0.1 µg DNA (fig. 75). As explanation it is proposed that magnetic 
sedimentation increases the number of vector-cell contacts at all DNA-doses used. 
In NIH 3T3 cells (fig. 74), the enhancements of LF-magnetofection over the corresponding 
standard transfection did not correlate with the DNA-dose. But Plank et al. found out that in 
NIH 3T3 cells the enhancements of 4 h GenePorter-magnetofection over 4 h standard 
GenePorter transfection increased with decreasing DNA-doses (unpublished data). In contrast, 
in CHO-K1 cells (fig. 75), the enhancements of the 10 min and 4 h LF-magnetofection over 
the corresponding standard transfection increased with higher amounts of DNA/well. From 
these results it can be concluded that correlations between enhancement and DNA-dose can 
be obtained in some cases but they depend on the type of vector and the cell line used. 
Figure 74 shows an example where the 10’ LF-DNA magnetofection is with the comparably 
low DNA doses of 0.025 and 0.050 µg DNA/well 4.1 and 9.6-fold, respectively, more 
efficient in transfecting NIH 3T3 cells than the standard LF-DNA method with 0.1 µg 
DNA/well (the highest dose used) and a 4h incubation time with complexes. Figure 75 gives 
an example with CHO-K1 cells where the 10’ LF-DNA magnetofection achieved with 
0.0125, 0.025 and 0.05 µg DNA/well 6.3, 43.2 and 336.8-fold higher gene expression than the 
standard LF-transfection using the much higher dose of 0.1 µg DNA/well and the much 
longer incubation time of 4 hours. Obviously, even if higher DNA-doses and longer 
incubation times significantly increase the number of vector-cell contacts by Brownian 
motion and by sedimentation in standard transfections, in some cases with magnetic 
sedimentation with low DNA-doses and shorter incubation times still more vectors get in 
contact with the cells. In contrast to the results in fig. 74 and 75, Plank et al. (Plank et al., 
2003c) showed (in fig 6 D) that 10 min GenePorter-magnetofection of NIH 3T3 cells was not 
significantly more efficient in gene transfer than 4 h standard GenePorter transfection due to 
toxicity at higher DNA doses (0.05 and 0.1 µg DNA/well of a 96-well plate).  
In all transfection methods used, gene transfer efficiency increased with DNA dose. Only in 
figure 75 at 0.05 µg DNA/well, LF-DNA magnetofections and the standard LF-DNA 
transfection seemed to approach a point of saturation. 
The lowest efficiencies were observed in the absence of a magnetic field. Efficiency improved 
with incubation time, explained by the correlation of incubation time and the number of 
vector-cell contacts. 
In summary, from the experiments with different DNA-doses it can be concluded that in 
dependence on the vector type and probably other factors (like e.g. the cell line used and 
the confluency of cells during experimentation) in many cases magnetofection is much 
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more efficient than standard transfection and DNA-doses and incubation times can be 
reduced significantly. In other cases, especially at higher DNA-doses, standard 
transfection can be as efficient in gene transfer as magnetofection, but only with longer 
incubation times. 
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3.3.6 Localization of gene transfer using the magnetofection method 
 
As shown in the previous experiments, magnetofection is a very efficient method for 
transfections in cell culture. A further advantage of magnetofection, especially in vivo, could 
be the localization of gene transfer to the site of magnetic field influence. 
As a model for in vivo gene delivery, it was tested whether gene vectors can be targeted to a 
selected area of a target tissue by magnetic force. Therefore, transfections of NIH 3T3 cells 
(kept in serum-containing medium) were carried out with the LacZ reporter gene in a six-well 
plate. Two wells were incubated for 15 min with biotinylated (b)PEI / DNA / biotinylated 
inactivated adenovirus (bAdv) / streptavidinylated trMAG-PEI (trMAG-PEI-Sta) complexes 
and meanwhile a permanent Neodymium-Iron-Boron magnet (NeoDelta; remanence Br, 
1080-1150 mT; purchased from IBS Magnet, Berlin, Germany) with 20 x 10 x 5 mm was 
placed underneath one of these two wells. As an additional control, the third well was 
incubated for 15 min with AVET complexes (bPEI / DNA / bAdv, without trMAGs) and no 
magnetic field was applied. A DNA dose of 6 µg DNA/well, bPEI-DNA (N/P = 8) and a 
trMAG / DNA (w/w) ratio of 1 was used. The complexes were prepared in HBS. After 
incubation with complexes, the cells were washed and fresh complete medium was added. 
After 24 hours the cells were subjected to X-gal staining for 45 min. 
 
 
 
Figure 76 Localization of Lac Z gene delivery by a magnetic field. The NIH 3T3 
cells in the right well were incubated for 15 min with bPEI / DNA / bAdv / 
trMAG-PEI-Sta complexes and a rectangular magnet was applied. As controls 
without magnet, cells in the well in middle were incubated with the same vector 
formulation and cells in the left well with AVET (bPEI / DNA bAdv) 
complexes. Cells stained in blue indicate reporter gene expression. 
Macroscopically, only in the right well blue cells were visible and gene delivery 
was confined to an area defined by the shape of the applied magnet and its 
gradient field. 
 
This experiment showed that the magnetofection method (i.e. using trMAG containing 
complexes and a magnetic field) enables the targeting of gene transfer to a selected area 
within the well. The explanation is that the magnetic gradient field induces a movement of the 
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paramagnetic vectors towards the highest density of magnetic field lines. Therefore when a 
permanent magnet is placed underneath the cell culture dish, the vectors accumulate on cells 
reflecting the shape of the applied magnet and its gradient field. 
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3.3.7 Magnetofection of other cells 
 
In all magnetofection experiments so far, either the mouse fibroblast cell line NIH 3T3 or the 
chinese hamster ovarian cell line CHO-K1 (both see e.g. in fig. 73) or the human hepatic 
carcinoma cell line HepG2 (see e.g. figure 52-55) was used. Therefore it was interesting to 
find out if magnetofection would be also successful in transfecting other types of cells like 
e.g. the human keratinocyte cell line HaCaT, primary human keratinocytes or the mouse 
radiation-induced fibrosarcoma cell line RIF-1. 
 
3.3.7.1 HaCaT cells 
 
HaCaT cells (cell line derived from human keratinocytes), kept in serum-free medium, were 
incubated for 4 hours with the magnetofectins trMAG-16/1 / DNA / PEI and trMAG-16/1 / 
DNA / GenePORTER (GP) and the corresponding standard vectors PEI-DNA and GP-DNA. 
During the time of incubation, a magnetic field was applied. The vectors were formulated 
with 0.1 µg DNA/well, a trMAG/DNA w/w ratio of 4, a N/P ratio of 8 and 5 µl GP/µg DNA. 
Complexes containing PEI were prepared in 150 mM NaCl solution and complexes 
containing GP in serum-free cell culture medium. 
After incubation with complexes, the cells were washed and fresh serum-free medium was 
added. The next day, the reporter gene expressions of magnetofected and standard transfected 
cells were determined. 
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Figure 77 Transfection of 
HaCaT cells in the 
presence of a magnetic 
field. Each transfection 
was carried out in 
triplicates. 
Only the PEI based vectors 
lead to detectable 
luciferase gene expression 
whereas the formulation 
containing magnetic beads 
(trMAG-16/1) was the 
most efficient. 
 
 
The experiment showed that the magnetofection method was successful in transfecting 
HaCaT cells but only with PEI as endosomolytic additive and not with the cationic lipid 
GenePORTER. Standard PEI-DNA complexes lead to luciferase gene expression as well but 
trMAG-16/1 / DNA / PEI vectors in the presence of a magnetic field were nearly 5 times 
more efficient. It appears that magnetofection leads to an increase in transfection 
efficiency only if already the parental vector is able to successfully transfect the target 
cells. It can be concluded that the efficiency of magnetofection is strongly dependent on the 
parental vector. 
 
3.3.7.2 Primary human keratinocytes 
 
As an example for primary cells (which are usually harder to transfect than cell lines) primary 
human foreskin keratinocytes, kept in serum-free medium, were chosen. These cells were 
incubated with trMAG-16/1 / DNA / PEI (1 µg DNA/well, trMAG/DNA w/w ratio = 2, N/P = 
8, preparation in 150 mM NaCl) complexes. Different times of incubation with vectors (10’ or 
4 hours) and variations in the time of magnetic field exposure (10’, 4 hours or no magnet) 
were tested to approach the optimum conditions. Each transfection was carried out in 
triplicates. After incubation with gene vectors, the cells were washed and fresh serum-free 
medium was added. The next day, reporter gene expression of the transfected cells was 
determined. 
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1   10’ + vectors,  
     no magnet 
 
2   4 h + vectors,  
     no magnet 
 
3   10’ + vectors,  
     4 h + magnet 
 
4   4 h + vectors,  
     4 h + magnet 
 
5   10’ + vectors,  
     10’ + magnet 
 
6   4 h + vectors,  
     10’ + magnet 
 
Figure 78 Transfection of primary human keratinocytes with trMAG-16/1 / DNA / PEI as vector. The time of 
incubation with these complexes and the time a magnetic field was applied is indicated in the graph. 
The most important result was that the magnetofection method is able to transfect these primary cells. But also 
transfections with magnetofectins without magnetic field (1 and 2) showed luciferase gene expression whereas 
longer incubation (4 h) with vectors led to a significant enhancement because the number of vector-cell contacts 
by Brownian motion and by sedimentation increased. With magnetofection method 5 (10’ + vectors, 10’ + 
magnet) and 3 (10’ + vectors, 4 h + magnet) the highest values for gene expression were achieved but there was 
no significant enhancement compared to 4 h incubation with vectors and no magnet (2). The longer exposure to 
a magnetic field in method 3 compared to method 5 did not significantly change reporter gene expression 
indicating that the magnet has no additional effect on transfection apart from magnetic sedimentation. The lower 
values with magnetofection method 6 and 4 indicate that a 4 h incubation with complexes and the additional 
influence of a magnet for 10’ or 4 h may reduce reporter gene expression due to toxicity effects. 
 
 
Magnetofection was successful in transfecting primary keratinocytes. Additional exposure 
to a magnetic field after incubation with vectors (3) did not significantly change reporter gene 
expression, indicating that the magnet has no additional effect on transfection apart from 
magnetic sedimentation. This finding was confirmed by experiments of Huth et al. (Huth et 
al., 2004). 
But longer incubation times (4 h) with magnetofectins plus application of a magnetic field (6 
and 4) lowered the luciferase gene expression probably due to toxic effects to the primary 
cells which are usually more sensitive than cell lines. On the one hand, this gene expression 
reducing effect is obvious from the graph but on the other hand the reduction of gene 
expression due to longer incubation times plus the influence of a magnet was always lower 
than 2-fold which is not very significant. 
 
Further, incubation with magnetofectins for 4 h and no magnet (2) led to a gene transfer 
efficiency which was not significantly lower than the one achieved with the most successful 
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magnetofection methods (5 and 3). An explanation could be that the high concentrations of 
gene vectors on cells, obtained by magnetic sedimentation, are toxic and therefore with 
magnet there is no significant enhancement. But with magnetofection it is possible to achieve 
the same gene expression levels with only 10 min incubation (5) whereas without magnetic 
field (2) a 4 h-incubation time with complexes is necessary. 
 
3.3.7.3 RIF-1 cells 
 
Mouse radiation-induced fibrosarcoma (RIF-1) cells (kept in serum-containing medium) were 
incubated for 30 min with the magnetofectins trMAG-16/1 / DNA and trMAG-16/1 / DNA / 
PEI (1 µg DNA/well, trMAG/DNA w/w = 4, N/P = 8) and meanwhile a magnetic field was 
applied. Further RIF-1 cells were incubated with the standard vector PEI-DNA (1 µg 
DNA/well, N/P = 8) for 2 hours. All complexes were prepared in 150 mM NaCl. 
After incubation with vectors, the cells were washed and fresh serum-containing medium was 
added. The next day, luciferase gene expression was determined. 
 
 
Figure 79 Transfection of RIF-1 cells with trMAG containing vectors in the presence of a 
magnetic field and for comparison with PEI-DNA. Each transfection was carried out in 
triplicates. 
Magnetofection with trMAG-16/1 / DNA / PEI and trMAG-16/1 / DNA was approximately 
20 and 3 times more efficient in luciferase gene transfer than the standard PEI-DNA 
transfection. 
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The magnetofection was successful in transfecting RIF-1 cells and a 30 min incubation 
time with magnetofectins and an applied magnet resulted in clearly higher reporter gene 
expression than a 2 hour incubation time with the standard PEI-DNA gene vectors. 
The addition of free PEI to trMAG-16/1 / DNA complexes enhanced the gene transfer 
efficiency of the magnetofection method roughly 7-fold. 
 
In summary, the results showed that magnetofection is useful for a variety of different cell 
lines and even for primary cells. Magnetofections with shorter incubation times can be more 
efficient in gene transfer than standard transfections with longer incubation times. But 
magnetofection leads only to an increase in transfection efficiency if already the parental 
vector is able to successfully transfect the target cells. 
Meanwhile, the applicability of magnetofection to further cells types was shown by several 
groups: e.g. in HeLa (human cervix carcinoma) and BEAS-2B (bronchial epithelial) cells 
(Huth et al., 2004), in 16HBE (human bronchial epithelial) and human or porcine primary 
airway epithelial cells and an ex vivo porcine airway epithelium organ model (Gersting et al., 
2004), in primary HUVEC (human umbilical vein endothelial) and primary porcine aortic 
endothelial cells (Krotz et al., 2003b), in HT 1080 (human fibrosarcoma) cells (Plank et al., 
2003a), in CT 26 (colon carcinoma) cells (Plank et al., 2003c), and in B16F10 (murine 
melanoma) and primary rabbit chondrocytes and nasal epithelial cells and peripheral blood 
lymphocytes (Plank et al, unpublished data). 
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3.4 Magnetofection in animal experiments 
 
From the experiments shown previously it can be concluded that magnetofection is a method 
which enables efficient and localized gene transfer in cell culture. Even primary cells were 
transfected successfully by magnetofection. Now, it was interesting if magnetofection is also 
efficient in animal models and if gene transfer can be localized in vivo as well. 
 
3.4.1 Injection into the ear veins of pigs 
 
For proof-of-principle that with magnetofection in vivo localized gene transfer is possible and 
also as a model for gene delivery to endothelial cells, trMAG-PEI / DNA / PEI complexes 
(prepared in water and subsequently the ionic strength was adjusted to 150 mM NaCl) were 
infused into the right and left ear vein of 5 pigs and a permanent Neodymium-Iron-Boron 
magnet (NeoDelta; remanence Br, 1080-1150 mT; purchased from IBS Magnet, Berlin, 
Germany) with 20 x 10 x 5 mm was was attached for 1 hour above the right veins proximal to 
the injection site. The left ear veins served as controls without magnet. An injection volume 
was 5 ml, containing a DNA dose of 500 µg, a trMAG/DNA w/w ratio of 1, and a N/P ratio of 
8. The dose was injected over a time span of 3 min. 
24 hours after injection, the ear veins and other major organs (heart, lung, liver, spleen and 
kidney) were isolated, blood samples were taken and their reporter gene expressions (in pg 
luciferase/g tissue) were determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80 Experimental set-up:  
A permanent magnet, attached to a 
plunger adjustable for height, was 
placed above the ear vein of a pig 
without causing any pressure on the 
blood vessel. Subsequently, 
paramagnetic gene vectors (brown 
suspension in the syringe) were 
injected via a cannula into the ear 
vein upstream of the magnet. 
 cannula
ear vein
magnet
vectors
magnet 
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1 injection site of the control ear (without magnet) 
2 injection site of the ear with magnet 
3 vein of the control ear (without magnet) 
4 vein underneath the magnet 
 
 
 
 
 
 
 
animal 
no. 
site 
1 
site 
2 
site 
3 
site 
4 
1 0 14.6 0 77.8
2 0 0 0.2 11.9
3 0 0 0 7.2
4 0 0.1 0 8.7
5 0 1.3 0 29.3
av 0 3.2 0.0 27
stdev 0 6.4 0.1 29.8
 
Figure 81 Luciferase gene expression in the ear veins of pigs after injection of magnetofectins with or without a  
magnet placed downstream. The graph shows that on the average without magnet (1 and 3) no significant gene 
transfer was monitored whereas with magnet, maximum values were obtained underneath the magnetic field (4). 
Single values (in pg luciferase/g tissue) of each pig are given in the table. Only the area of the ear vein which 
was under direct influence of the magnetic field (4) showed reporter gene expression in all 5 pigs. 
This animal experiment was performed in collaboration with Ulrike Schillinger, TU Munich 
(Schillinger, 2002). 
 
No reporter gene expression was observed in the control blood vessels (except in site 3 of pig 
2) and in the samples of any major organ or blood, while reproducible, though variable 
luciferase expression was found in all vein samples which were lying underneath the magnet. 
These results indicate that the magnetofection method (including magnetofectins and an 
applied magnet) enables localized gene transfer in in vivo. It is assumed that the magnetic 
field holds back the paramagnetic gene vectors and thus enables localized transfection.  
An explanation for gene expression in the injection site with magnet in three animals could be 
that in these cases the cannula tubes were pointing towards the blood vessel wall and therefore 
gene transfer was enhanced at this site. 
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3.4.2 Injection into the ear artery of rabbits 
 
As further proof-of-principle for localized gene transfer in vivo via magnetofection, trMAG-
16/1 / DNA complexes (prepared in 5% glucose) were infused into the right and left ear artery 
of 2 rabbits and a permanent Neodymium-Iron-Boron magnet (NeoDelta; remanence Br, 
1080-1150 mT; purchased from IBS Magnet, Berlin, Germany) with 20 x 10 x 5 mm was 
placed for 1 hour above the right arteries downstream to the injection site. As controls without 
magnet, the left ear arteries were used. An injection volume was 1.5 ml, containing a DNA 
dose of 200 µg and a trMAG/DNA w/w ratio of 4. The dose was injected over a time span of 
1 min. 
24 hours after injection, the ear arteries were isolated and their reporter gene expressions (in 
pg luciferase/g tissue) were determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82 Experimental set-up:  
A permanent magnet, attached to a 
plunger adjustable for height, was 
placed above the ear artery of a 
rabbit without causing any pressure 
on the blood vessel. Subsequently, 
paramagnetic gene vectors were 
injected via a cannula into the ear 
artery upstream of the magnet. 
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Figure 83 Luciferase gene expression in the ear arteries of rabbits after injection of magnetofectins with or 
without a magnet placed downstream. Two single experiments are shown, one in the upper and one in the 
lower graph.  
Upper graph: With magnet, gene expression was higher in all positions than without magnetic field. With 
magnet, maximum expression was obtained remote distal of the magnet, the second highest gene transfer 
efficiency was achieved in magnet position and distal the transfection efficiency was also comparatively 
high. An explanation for these results could be that with magnet, gene vectors were accumulated in the 
magnet position, but after removal of the magnet aggregated gene vectors were washed away and were 
trapped in arterioles (distal) and the capillary bed (remote distal). Further, with magnet, the proximal value 
was higher than without magnet, probably because the proximal position is still influenced by the magnet. 
Lower graph: The highest efficiency in gene transfer was detected in the magnet position. In this area the 
magnetic field enhanced the transfection efficiency 24.1-fold compared to without magnet. Obviously, in 
this experiment with magnet gene vectors were accumulated in the magnet position, but possibly due to 
anatomic characteristics of the artery, removal of the magnet did not lead to massive release of gene vector 
aggregates from the magnet position. Further, with magnet, gene expression was clearly higher than without 
magnet in the proximal position. In the set-up with magnet, the remote distal sample was added to the distal 
sample and therefore the expression “remote distal” is included in the value “distal”. 
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These animal experiments were performed in collaboration with Ulrike Schillinger, TU 
Munich. 
 
In both experiments, the application of a magnet (magnetofection method) led to strongly 
enhanced gene expression in magnet position. An explanation could be rapid aggregation of 
trMAGs and PEI-DNA particles after injection into the salt- and protein-containing blood and 
subsequent attraction to the site where the magnetic field lines have the highest density 
(namely in the magnet position). But also proximal, an applied magnet led to significant 
enhancements. An explanation for this phenomenon could be that even if proximal the density 
of magnetic field lines is much lower, some paramagnetic gene vectors can still be trapped. 
The maximum gene expression remote distal of the magnet and the high value distal of the 
magnet in the upper graph could be caused through vector aggregates which were washed 
away from the magnet position by the blood stream after removal of the magnet. These 
aggregates could then be trapped downstream in arterioles (distal) and the capillary bed 
(remote distal).  
 
In summary, in these two experiments with magnetofection, efficient gene transfer and a 
tendency to localized gene expression was observed even in arteries which are under higher 
pressure than veins. 
 
3.4.3 Injection into the ilea of rats 
 
For proof-of-principle that magnetofection in vivo enables localized gene transfer even in 
organs with harsh conditions for transfections, magnetofectins were injected into the ileum 
lumens of rats where degradative enzymes, degraded nutrition and bacteria are located. The 
high frequency of malignancies in the gut makes it an important target for gene therapy. 
After laparatomy of rats, the ilea were exposed and a section of 3 cm was rinsed with isotonic 
saline, clamped off and trMAG-16/1 / DNA vectors in 1 ml 5% glucose (DNA dose: 200 µg 
DNA/ml, LacZ reporter gene, trMAG/DNA w/w ratio: 2) were injected. A permanent 
Neodymium-Iron-Boron magnet (NeoDelta; remanence Br, 1080-1150 mT; purchased from 
IBS Magnet, Berlin, Germany) with 20 x 10 x 5 mm was placed under the clamped-off 
region. Five minutes after injection, both clamps were removed and the magnet was left for a 
total of 20 min. As control, the same procedure was performed but without magnet. 
Subsequently, the guts were returned into the abdominal cavity. After 48 h the treated region 
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of the gut and adjacent areas were isolated, fixed in formaldehyde/glutaraldehyde/PBS, X-gal 
stained, paraffin embedded and histological sections were stained with eosin. 
 
 a                         b 
 
Figure 84 X-gal staining performed 
48 h after trMAG-16/1 / DNA vectors 
were applied to the ilea of rats in the 
absence (a) and under the influence of 
a magnetic field for 20 min (b). 
Blue staining reveals efficient gene 
delivery only in the presence of 
magnet (b), both on the macroscopic 
level (upper panel) and on the 
microscopic level (lower panel). 
Upper panel: intestinal tubes after X-
gal stain. Inserts: cross-sections of 
tubes embedded in paraffin. Lower 
panel: Paraffin sections counter-
stained with eosin, 400x 
magnification. X-gal staining is found 
in the lamina propria. 
L, lumen; LP, lamina propria. 
This animal experiment was performed in collaboration with Julia Henke and Ulrike 
Schillinger, both TU Munich. 
 
Strong and consistent X-gal staining was found in the area of the tissue which was under 
influence of the magnetic field whereas in the absence of a magnet (untreated control tissue ) 
much weaker staining was observed. The efficient transfection with magnet was confined to 
the ileum lamina propria. 
This result indicates that magnetofection enables localized gene transfer even in organs 
with harsh conditions for transfections like e.g. the gut. 
Like in the experiment before (injection into the ear artery of rabbits), the trMAG-16/1 / DNA 
formulations were prepared in 5% glucose. But as shown previously in the binding studies, 
trMAG-16/1 particles were not able to bind DNA in salt-free solution with a trMAG/DNA 
w/w ratio of 2. But nevertheless, gene transfer via magnetofection worked. An explanation 
could be that from previous rinsing with isotonic saline, salt remained in the ileum and thus 
trMAG-16/1 particles and PEI-DNA complexes could aggregate before the magnet was 
applied. Actually, in the clamped-off region there was a similar scenario as in cell culture 
magnetofections with vectors prepared in glucose. Further, degradative enzymes (e.g. 
nucleases) in the ileum were not able to fully inactivate the paramagnetic gene vectors. 
 
From all the animal experiments it can be concluded that efficient and localized gene 
transfer in vivo is possible.
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4 DISCUSSION 
 
4.1 Background and objective of the thesis 
 
A major barrier to clinical application of nucleic acid therapy is that only a fraction of the 
applied vector dose gets in contact with the target cells. As nucleic acid delivery is a mass 
action process (Zabner et al., 1995), an increase in vector concentration at the target site 
would lead automatically to enhanced transfection efficiencies. This phenomenon can be 
shown in cell culture experiments. In vitro transfection is at least partly a diffusion-controlled 
process and acceleration of vectors towards the target cells leads to a local increase in vector 
concentration and the result is a great enhancement of nucleic acid delivery. For example by 
adding dense silica nanoparticles to nucleic acid vectors, gravitational force is used to 
sediment particles onto cells and the transfection efficiency is increased significantly (Luo 
and Saltzman, 2000). Analogously, the enhanced sedimentation of larger vector particles 
(Ogris et al., 1998), the formation of precipitates (Jordan and Wurm, 2004) and the use of 
centrifugal force (Bunnell et al., 1995) lead to an increased number of vector-cell contacts and 
contribute to enhanced nucleic acid transfer efficiencies. Additionally, convective flow of 
transfection medium towards target cells enhances the transfection efficiency (Chuck et al., 
1996).  
A further critical point in nucleic acid vector delivery is that systemic distribution can cause 
toxicity in nontarget organs. For example the overexpression of suicide genes can result in 
undesired cell death in tissues which are not the therapeutic target (van der Eb et al., 2004).  
Generally, it is difficult to achieve an effective local dose at the target site without causing 
systemic toxicity. This problem exists not only for nucleic acid vectors but also for classical 
low molecular weight drugs like e.g. cytostatics. A very promising physical method to target 
anti-cancer drugs in vivo is provided by magnetic drug targeting (see 1.6.9 and 1.8). In this 
method, the anti-cancer drugs are bound to magnetic particles and guided by an external 
magnetic field to the target tissue.  
The major objective of this thesis was to apply the principle of magnetic drug targeting for 
the delivery of nucleic acids which are high molecular weight molecules with a high number 
of negative charges. 
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4.2 Binding of nucleic acids to magnetic particles 
 
A fundamental prerequisite for combination of magnetic drug targeting with nucleic acid 
therapy is the binding of nucleic acid vectors to magnetic particles in a way that enables 
targeting plus functionality of the nucleic acid drug. In principle, possible ways of binding are 
biological binding (e.g. via streptavidin-biotin or antigen-antibody bridges), chemical-
covalent binding and physical binding (via electrostatic or van der Waals interactions). In this 
thesis we concentrated on physical binding as it is reversible which may be advantageous for 
intracellular processing of the nucleic acid vector. For this purpose Christian Bergemann from 
Chemicell (Berlin) developed superparamagnetic iron oxide nanoparticles coated with 
cationic or anionic polymers (called trMAGs). Especially the coating with PEI seemed 
promising because it is an excellent transfection reagent (Demeneix et al., 1998). 
Binding studies using magnetic sedimentation of radioactive labelled DNA revealed that 
naked plasmid DNA can be bound efficiently to positively charged magnetic particles by 
electrostatic interactions (fig. 2). But as soon as additional components like e.g. PEI or 
DOTAP-Cholesterol are present, efficient electrostatic binding of DNA (vectors) to positively 
and negatively charged magnetic particles in pure water is not possible (chapter 3.2). Efficient 
electrostatic binding of DNA to charged magnetic beads in the presence of a third component 
is only possible via salt-induced colloid aggregation (chapter 3.2), a natural process where 
charged particles (like e.g. charged magnetic beads and charged PEI-DNA or DOTAP-
Cholesterol-DNA particles) associate with each other at physiological salt concentration (150 
mM NaCl) to form supramolecular aggregates (Hiemenz, 1986). Salt-induced aggregation 
provides a simple and efficient method for the binding of nucleic acids and additional 
components to charged magnetic particles. A problem might be that injection of larger 
aggregates into blood vessels could lead to embolism or that e.g. serum proteins could cause 
dissociation of small aggregates. But as size measurements showed (fig. 3), the (appropriate) 
size of aggregates can be chosen by their incubation time in 150 mM NaCl.  
Contemporaneous to our work, Hughes et al. found three different biological strategies to bind 
retroviral vectors to magnetic particles (Hughes et al., 2001). They conjugated 
streptavidinylated magnetic particles to (i) a biotinylated antibody directed against the 
retroviral vectors (ii) biotinylated lectin which binds to retroviral vectors and (iii) biotinylated 
retroviruses. Later, also Pandori et al. used streptavidin-biotin bridges to couple their 
magnetic particles to adenoviral vectors (Pandori et al., 2002) and Mah et al. used (magnetic) 
avidin-microspheres to bind biotinylated heparan sulfate which was reversibly bound to 
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adeno-associated viruses (Mah et al., 2002). A further physical strategy was employed by 
Haim et al. who formed complexes between lentiviral vectors and negatively charged 
magnetic beads by colloidal clustering which was facilitated by positively charged ions (Haim 
et al., 2005). In general, more stable conjugations like biotin-streptavidin or antigen-antibody 
bridges are assumed to be advantageous for efficient targeting whereas reversible binding e.g. 
via physical interactions may facilitate intracellular processing of nucleic acid vectors. 
Further, molecules like streptavidin could stimulate immune responses when applied in vivo. 
But at least in vitro, all these binding methods enable magnetic targeting plus functionality of 
the nucleic acid vectors and future studies (under in vitro and in vivo conditions) will reveal 
which way of binding is the most appropriate for applications in research and therapy. In any 
event, the way of magnetic vector assembly chosen and optimized in this thesis, self assembly 
by physical interaction was sufficient to achieve magnetic nucleic acid targeting in vitro and 
in vivo. 
 
4.3 Transfections with magnetic particle/DNA associates 
 
Having established this simple way of magnetic vector assembly, the question was if nucleic 
acid transfer with magnetic particles is possible and if magnets placed underneath cell culture 
dishes could improve transfection efficiencies. 
For this purpose transfections in cell culture with various positively and negatively charged 
magnetic particles were carried out in the presence and absence of a magnetic field (3.3.1 and 
3.3.2) and the results showed that nucleic acid transfer via magnetic particle/DNA 
associates (magnetofectins) is possible and that an applied magnetic field enhances gene 
expression. Transfection with magnetofectins in the presence of a magnetic field is named 
“magnetofection”. 
Among the positively charged magnetic beads, particles coated with multilayers of PEI and 
unbound PEI in suspension show the highest transfection efficiencies (3.3.1.1). An 
appropriate magnetic particle/DNA (w/w) ratio is between 1 and 4. But not only the 
preparation in 150 mM NaCl which allows association of magnetic particles, DNA and PEI 
by salt-induced aggregation but also the preparation in 5 % glucose leads to gene transfer. The 
explanation is that despite inefficient electrostatic binding of DNA to charged magnetic beads 
in the presence of free PEI, the charged particles associate with emerged charged PEI-DNA 
particles when the vectors are added to the salt- and serum-containing cell culture medium for 
transfection. But complexes prepared in 150 mM NaCl are more efficient in gene transfer than 
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vectors prepared in 5 % glucose, presumably because they have more time to aggregate (not 
only in the salt- and serum-containing medium but also during incubation in 150 mM NaCl) 
and larger aggregates are shown to be more efficient in cell culture transfections (Ogris et al., 
1998). The enhancing effect of free PEI and preparation in 150 mM NaCl on transfection 
efficiency could be confirmed by transfections with positively charged magnetic particles 
which show gene transfer only in the presence of free PEI plus preparation in salt solution 
(3.3.1.2). 
In addition, transfections with negatively charged magnetic particles (e.g. coated with 
polyaspartic acid) plus preformed PEI-DNA complexes (N/P = 8) led to similar efficiencies in 
gene transfer as positively charged magnetic beads (3.3.2), which means that both types of 
magnetic particles are useful for magnetic field guided nucleic acid delivery 
(magnetofection). 
 
4.4 Mechanism of magnetofection 
 
Transfections in cell culture revealed that nucleic acid transfer via magnetic particle/DNA 
associates (magnetofectins) into cells is possible and that a magnetic field improves gene 
expression (3.3.1 and 3.3.2). But what is the mechanism of magnetic field-guided nucleic acid 
delivery (magnetofection)? Are the paramagnetic vectors pulled into the cell by the applied 
magnetic force? Does endocytosis play any role? Is it possible that the permanent magnet 
alone (without magnetic beads) has an enhancing effect on the reporter gene expression? 
A first interesting finding was that free PEI enhances the efficiency of magnetofectins in 
magnetofections (3.3.1.1 and 3.3.1.2). A possible explanation for this enhancement was that 
via the proton sponge effect PEI promotes the release of DNA which is captured in 
endosomes after its cellular uptake by endocytosis (Sonawane et al., 2003). But to find out if 
endosomal escape and consequently endocytosis do really play a role in magnetofection, it 
was examined if magnetofectins containing endosomolytic additives are generally more 
efficient in magnetofection than magnetofectins lacking these components. Apart from PEI, a 
chemically inactivated adenovirus, the cationic lipid Lipofectamine, the cationic lipid 
GenePORTER or the synthetic influenza virus peptide INF7 were used as endosomolytic 
additives (3.3.3.1) and all of them had an enhancing effect on gene transfer via 
magnetofection. These results indicate that in magnetofection the cellular uptake mechanism 
for nucleic acid vectors is endocytosis. But what is the fate of the magnetic particles during 
magnetofection? Are they taken up by the cell like the nucleic acids or are they left outside? 
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To answer this question, transmission electron microscopy pictures of magnetofected cells 
were taken (3.3.3.2). These images showed that the magnetic particles were concentrated 
around the cell within minutes and immediately their cellular uptake starts. The accumulation 
of magnetic particles in endosomal structures suggests endocytosis as uptake mechanism and 
not the traction of paramagnetic vectors through the cellular membrane by magnetic forces. 
These results were later confirmed by Huth et al (Huth et al., 2004). With gold-labeled DNA 
they could even show that magnetic particles and DNA are co-internalized into the cell. From 
transfections with endocytosis inhibitors and fluorescence microscopy, this group came to the 
conclusion that the uptake mechanism for magnetofectins containing free PEI is similar as for 
PEI-DNA complexes where clathrin-dependent and caveolae-mediated endocytosis are 
involved and the extent of involvement is cell line-dependent. The size of magnetofectins may 
influence the uptake mechanism as well because by using fluorescence-activated cell sorting 
and fluorescent/confocal microscopy Rejman et al. found that fluorescent latex beads smaller 
than 200 nm are taken up by the clathrin-dependent pathway, but with increasing particle size 
there is a shift to the caveolae-mediated internalization which becomes the predominant 
pathway of entry for particles of 500 nm in size (Rejman et al., 2005; Rejman et al., 2004). 
From the enhancing effect of a magnetic field in transfections with relatively short incubation 
times (10-20 min) with paramagnetic vectors (3.3.1 and 3.3.2) and from the electron 
micrographs (3.3.3.2) which showed that magnetic particles under influence of a magnet are 
concentrated around the cell within minutes, it is assumed that through magnetic 
sedimentation gene vectors get in contact with cells much faster than through diffusion or 
non-magnetic sedimentation. Now it was interesting to find out if this accelerated 
sedimentation in the magnetofection method leads to a different time course of reporter gene 
expression compared to a standard polyplex transfection. Therefore magnetofections with 
magnetofectins containing free PEI and transfections with PEI-DNA complexes were 
performed and in magnetofected cells reporter gene expression could be detected much earlier 
(already after 2 hours) than in standard PEI-transfected cells (after 8 hours). Additionally, 
magnetofection consistently leads to higher gene expression (3.3.3.3). Presumably, in 
magnetofection all steps from cellular contact with gene vectors to gene expression proceed 
similar as with standard polyfection but they proceed earlier and in a synchronized manner 
(Haim et al., 2005). The higher gene expressions in magnetofection experiments could be 
explained by higher vector concentrations on the cellular surface. 
Finally, the question arose if the enhancing effect of a magnetic field on transfections with 
paramagnetic vectors is (only) the result of accelerated sedimentation or if the neodymium-
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iron-boron (Nd-Fe-B) magnet used in all our experiments influences cell physiology in a 
manner that enhances transfection and/or reporter gene expression. It is well documented that 
low frequency electromagnetic fields (EMFs) and static magnetic fields can have biological 
effects on cells and tissues. It is assumed that their primary site of action is the plasma 
membrane (Pagliara et al., 2005; Rosen, 2003) and e.g. phagocytosis (Flipo et al., 1998; 
Mykhaylyk et al., 2005) or cellular metabolic activity (Sabo et al., 2002) can be reduced by 
magnetic fields. Further, it is known that EMFs activate genes under control of EMF-sensitive 
promoters (Goodman and Blank, 2002), that static electromagnets induce the expression of 
oncogenes (Hiraoka et al., 1992; Hirose et al., 2003) and that a permanent static neodymium 
magnet (300 mT) changes the expression of some genes in Escherichia coli (Potenza et al., 
2004). Therefore we performed transfections with various non-magnetic standard vectors and 
our permanent static Nd-Fe-B magnet (1080-1150 mT) was applied simultaneously (3.3.3.4). 
The results showed that application of the permanent static magnet (which was used in all 
experiments in this thesis) does not influence the measured reporter gene expression. Further, 
Huth et al. used magnetic particle containing vectors to examine the same question (Huth et 
al., 2004). The magnetofectins were spun down onto the cellular surface and incubated with 
and without application of a permanent static magnet. But also these experiments with 
magnetic particle containing vectors showed no detectable enhancement (or decrease) in 
reporter gene expression when a magnetic field was applied. Thus it can be concluded that the 
enhancing effect of a magnetic field is mainly the result of accelerated vector sedimentation 
and not of changes in cell physiology, enhancement of cellular uptake or activation of 
luciferase gene expression driven by the hCMV promoter.  
In summary, from our experiments and the experiments of Huth et al (Huth et al., 2004), the 
following mechanism is proposed for magnetofection: The paramagnetic nucleic acid 
vectors are concentrated efficiently by magnetic force on the cell surface within minutes 
and immediately their endocytotic uptake starts. Further steps leading to gene expression 
proceed similar as with standard polyplexes but earlier. Higher efficiency in nucleic acid 
transfer with magnetofection is probably mainly a result of more efficient sedimentation and 
therefore higher availability of nucleic acid vectors on the cellular surface for endocytosis. 
 
4.5 Critical parameters in optimizing magnetofection 
 
As it was shown that the principle of magnetofection works (3.3.1 and 3.3.2) and the 
mechanism was elucidated (3.3.3), the next challenge was to optimize the magnetofection 
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method in cell culture. From various transfection experiments it is known that the addition of 
endosomolytic substances (3.3.3.1) and the preparation of vectors in 150 mM NaCl (3.3.1) 
improve the efficiency of magnetofection. Additionally, mechanistic studies (3.3.3) revealed 
that in magnetofection cellular uptake of vectors and further steps leading to gene expression 
proceed similar as in standard transfections, therefore it can be assumed that all components 
which improve the efficiency of standard vectors (like e.g. nuclear localization signals) lead to 
an improvement of magnetofection vectors as well. 
To further optimize magnetofection, dose-response studies were carried out at different 
magnetic particle to DNA ratios, the magnetofection efficiency of positively and negatively 
charged magnetic beads was compared, different sequences of mixing the components of 
magnetofectins were examined and the incubation time of cells with paramagnetic vectors 
was varied. 
Magnetofections with increasing magnetic particle / DNA (w/w) ratios and various doses of 
DNA (3.3.4.1) revealed that for each type of vector (here magnetofectins including either the 
cationic lipid DOTAP-Cholesterol, GenePorter or Lipofectamine) the individual optimum 
magnetic particle / DNA (w/w) ratio and DNA dose has to be found. But a magnetic 
particle / DNA (w/w) ratio of 2 turned out to be very efficient in all the examined types of 
paramagnetic vectors. Within the ranges of DNA doses tested (which comprised relatively 
low doses) increasing amounts of DNA lead to increasing magnetofection efficiency in most 
cases. In general, increasing amounts of magnetic particles or (and) DNA enhance the 
availability of vectors for cells until saturation or even toxicity sets in. 
To answer the question if positively or negatively charged magnetic beads are more 
efficient in magnetofection, gene transfer experiments with magnetic particles coated with a 
monolayer of PEI (trMAG-PEI) and magnetic particles coated with starch-phosphate 
(trMAG-PO4) were performed under identical conditions (3.3.4.2). But no significant 
differences in magnetofection efficiency were detected and thus it can be concluded that in 
regard to efficiency it does not play any role if positively or negatively charged magnetic 
beads are chosen. 
To find out if the sequence of mixing the components of magnetofectins influences the 
magnetofection efficiency, complexes consisting of (i) DOTAP-Cholesterol, DNA and 
positively or negatively charged magnetic beads, (ii) PEI, DNA and negatively charged 
magnetic beads and (iii) PEI, DNA, chemically inactivated adenovirus and negatively charged 
magnetic beads, were examined (3.3.4.3). But when the magnetofectins were prepared in salt-
containing solution, no significant differences in magnetofection efficiency were obtained 
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except for preformed PEI-DNA particles which significantly reduced the efficiency of 
magnetofection. It is assumed that in 150 mM NaCl aggregates are formed which harbour all 
components added and therefore the mixing sequence is usually not crucial. The lower 
magnetofection efficiencies with preformed PEI-DNA particles are difficult to understand and 
require further examination.  
In magnetofection experiments, cells are usually incubated with vectors for 10-20 minutes. To 
find out the optimum incubation time, cells in culture were incubated with cationic lipid 
(Lipofectamine or GenePorter) containing magnetofectins for 5, 10, 20, 40 and 240 minutes in 
the presence of a magnetic field (3.3.4.4). The results revealed that with magnetofection 
already 5 minutes of incubation with vectors prepared in salt-containing solution lead to 
optimum gene transfer efficiency or to an efficiency close to the optimum. But still, optimum 
incubation time has to be found out individually for each vector type and presumbly also for 
each cell type. 
 
4.6 Comparison of magnetofection and conventional transfection methods 
with regard to their gene transfer efficiency 
 
As already observed in experiments to optimize the incubation time of cells with complexes 
for magnetofection (figure 71 and 72), five minutes incubation of cells with magnetic particle 
containing lipoplexes in the presence of a magnetic field (magnetofection) resulted in 
significantly higher transgene expression than 4 hours incubation with the same lipoplexes 
without magnetic particles (corresponding conventional or standard transfection). But is 
magnetofection (in which cells are usually exposed to paramagnetic vectors plus a magnetic 
field for 30 min or less) always more efficient than the corresponding standard transfection (in 
which cells are usually incubated with nonmagnetic vectors for 2 to 4 hours)? 
To compare the gene transfer efficiency of standard transfections and magnetofections 
comprehensively (fig. 73), two different cell types (NIH 3T3 and CHO-K1) were incubated 
for 4 hours with four different standard vectors (PEI-DNA, DNA /PEI / inactivated 
adenovirus, GenePorter-DNA and Lipofectamine-DNA) and for comparison for 10 minutes 
with the same vectors but plus magnetic particles and in the presence of a magnetic field 
(magnetofections). The results showed that with all vector types except GenePorter, the 
magnetofection method leads to significantly higher gene expression (up to 971-fold) in both 
cell lines than the corresponding standard transfection. The explanation for the enhanced gene 
transfer efficiencies with magnetofection is that magnetic sedimentation enables in a short 
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period of time (here 10 min) more vector-cell contacts than the standard transfection with 
relatively long incubation times (here 4 hours). This assumption was proven to be true by 
Gersting et al. (Gersting et al., 2004) who compared magnetofection and standard transfection 
in regard to adhesion patterns of fluorescently labeled gene transfer complexes on airway 
epithelial (16HBE) cells by fluorescence microscopy. In contrast to the 3 to 5-fold 
enhancement in figure 72, magnetofection with GenePorter complexes in figure 73 did not 
lead to a significant enhancement. This difference may be due to slight variations in 
transfection parameters such as incubation times during vector preparation, cell density and 
passage number at the time of transfection. In general, it is assumed that high concentrations 
of GenePorter-DNA vectors on cellular surfaces lead to saturation of uptake processes or even 
toxicity and therefore the higher number of vector-cell contacts achieved through magnetic 
sedimentation do not enhance gene transfer dramatically.  
In the experiments mentioned above, the nucleic acid transfer efficiencies of magnetofection 
and the corresponding standard transfection were only compared at one DNA dose each. The 
next interesting question is how these two methods compare at different DNA doses. 
Therefore dose-response profiles of magnetofection and standard transfection with 
Lipofectamine-DNA complexes in two cell lines (NIH 3T3 and CHO-K1) were established 
and compared (figure 74 and 75). Over the range of DNA doses tested (from 0.0125 to 0.1 µg 
DNA/well), with equal DNA doses magnetofection showed always significantly higher gene 
expression than the corresponding standard transfection. Additionally, magnetofections with 
lower DNA doses can be more efficient than standard lipofection with much higher doses. For 
example in CHO-K1 cells (figure 75), magnetofection with an incubation time of 10 minutes 
achieved with 0.0125, 0.025 and 0.05 µg DNA/well 6.3, 43.2 and 336.8-fold higher gene 
expression than the standard transfection with 0.1 µg DNA/well and an incubation time of 4 
hours. Obviously, even if higher DNA doses and longer incubation times significantly 
increase the the number of vector-cell contacts by Brownian motion and sedimentation in 
standard transfections, in some cases with magnetic sedimentation with low DNA doses and 
shorter incubation times still more vectors get in contact with the cells. 
In addition to the experiments presented in this thesis, a number of colleagues from our 
institute and from other groups compared the efficiency of magnetofection and standard 
transfection as well. Gersting et al. found that in airway epithelial cells (16HBE cell line and 
primary cells) magnetofection was, with an incubation time of 15 min, more or at least 
equally efficient in gene transfer than standard PEI-polyfection with a 4 h incubation time. 
Further, magnetofection improved the DNA dose-response relationship significantly (Gersting 
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et al., 2004). Improved transfection efficiencies and DNA dose-response profiles through 
magnetofection were also observed with the lipofection reagent Metafectene in NIH 3T3 cells 
(Plank et al., 2003a), with various cationic lipids and PEI in primary human umbilical vein 
endothelial cells (HUVECs) (Krotz et al., 2003b) and with the lipofection reagent DMRIE in 
CT26 cells (Plank et al., 2003c). In the latter experiment, Plank et al. further demonstrated 
that not only the overall transgene expression but also the percentage of transfected cells can 
be enhanced by magnetofection. In a further publication of Krötz et al. (Krotz et al., 2003a), it 
was shown that magnetofection with various lipid vectors and PEI does not only improve the 
transfection efficiencies and dose-response relationships with plasmid DNA but also with 
antisense-ODNs in HUVEC cells. In these experiments Krötz and coworkers also found that 
magnetofection with its shorter incubation time is less toxic and therefore a useful tool for 
physiological examinations in sensitive primary cells. But it has to be mentioned that in 
contrast to magnetofection with FUGENE plus plasmid DNA (Krotz et al., 2003b), 
magnetofection with FUGENE plus antisense-ODNs was less efficient than the standard 
FUGENE transfection. Among the many comparisons performed, this was the only case 
where magnetofection led to a decrease in transfection efficiency. Additionally to DNA, 
magnetofection also increased the efficiency of transfections of siRNA. Plank et al. (Plank et 
al., 2003a) demonstrated that efficient knock down of stable eGFP expression in HT1080 cells 
with linear PEI and synthetic siRNA was only achieved through magnetofection. This result 
also indicates the potential of magnetofection for nucleic acid transfer into cells which are 
difficult to transfect with standard methods. The experiments described so far concerned only 
nonviral nucleic acid vectors, but magnetofection also improved the transduction efficiencies 
of adenoviruses (Scherer et al., 2002a), retroviruses (Haim et al., 2005; Scherer et al., 2002a) 
and measles viruses (Kadota et al., 2005).  
All the experiments discussed in this chapter compared magnetofection with the 
corresponding standard transfection or transduction but it would also be interesting to perform 
side by side comparisons with other physical methods like e.g. centrifugation, convective flow 
towards the target cells, biolistic methods or electroporation. 
In summary, usually magnetofection is significantly more efficient than standard 
transfection or transduction, but there are rare cases in which magnetofection is only 
equally or even less efficient. The often improved nucleic acid dose-response profiles and 
reduced incubation times with vectors make magnetofection a less material and time 
consuming method which could be especially useful for automated high throughput screening 
of genes and of therapeutically useful sequences. 
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4.7 Localization of nucleic acid transfer using the magnetofection method 
 
The magnetic field-guided sedimentation of paramagnetic vectors enhances significantly the 
efficiency of nucleic acid transfer into cells in culture. But is a distinct localization of nucleic 
acid transfer to a certain target area via magnetofection possible as well? As a model, it was 
tested whether gene vectors (consisting of PEI, plasmid DNA harbouring the LacZ reporter 
gene, a chemically inactivated adenovirus and magnetic particles) can be targeted to a 
selected area within a well of a six-well plate. The results (fig. 76) showed that LacZ gene 
expression was confined to an rectangular area defined by the shape of the permanent magnet 
placed underneath the well. The same result was obtained by Martina Anton with 
adenoviruses (Scherer et al., 2002a). Using the same principle as in magnetofection, also 
Hughes et al. (Hughes et al., 2001), Pandori et al. (Pandori et al., 2002) and Mah et al. (Mah et 
al., 2002) illustrated impressively the magnetic field-guided localization of reporter gene 
delivery with retroviruses, adenoviruses and adeno-associated viruses, respectively. 
Obviously, the magnetic field gradient induces a movement of the paramagnetic vectors 
towards the highest density of magnetic field lines and therefore the vectors accumulate on 
cells reflecting the shape of the applied magnet. Therefore magnetic field-guided nucleic acid 
vector delivery offers e.g. the possibility to evaluate transfected cells compared to the 
untransfected control cells within the same well or it enables the examination of the influence 
of secreted transgene-encoded factors on neighbouring untransfected cells. 
 
4.8 Applicability of magnetofection to different cell types 
 
To establish and to examine the magnetofection method, the mouse fibroblast cell line NIH 
3T3, the chinese hamster ovarian cell line CHO-K1 (both e.g. in fig 73) and the human 
hepatic carcinoma cell line HepG2 (e.g. in fig. 52-55) were used. But is magnetofection also 
succesful in transfecting other types of cells? To answer this question, the human keratinocyte 
cell line HaCaT, primary human keratinocytes and the mouse radiation-induced fibrosarcoma 
cell line RIF-1 were transfected via magnetofection. The results (fig. 77-79) showed that 
magnetofection enables successful transfection of all three types of cells (including also the 
primary cells, which are usually harder to transfect) but in some cases vector components or 
exposure times with vectors and magnet have to be optimized to yield satisfying results. 
Meanwhile, the applicability of magnetofection to further cell types was shown in several 
publications: for example HeLa (human cervix carcinoma) and BEAS-2B (bronchial 
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epithelial) cells (Huth et al., 2004), 16HBE (human bronchial epithelial) and human or 
porcine primary airway epithelial cells and an ex vivo porcine airway epithelium organ model 
(Gersting et al., 2004), primary HUVEC (human umbilical vein endothelial) and primary 
porcine aortic endothelial cells (Krotz et al., 2003a; Krotz et al., 2003b), primary rabbit 
articular chondrocytes (Schillinger et al., 2005), HT 1080 (human fibrosarcoma) cells (Plank 
et al., 2003a), CT 26 (colon carcinoma) cells (Plank et al., 2003c), K562 (human myeloid 
leukemia) cells and primary human peripheral blood lymphocytes (Scherer et al., 2002a), 
B95a (adherent marmoset β-cervical carcinoma) and Vero (African green monkey kidney) 
and L929 (mouse fibrosarcoma) cells (Kadota et al., 2005), and RAE (primary rat aortic 
endothelial) cells (Haim et al., 2005) were accessible to magnetofection. Additionally, all 
cells which were ever tested for magnetofection (more than 90 different cell lines and more 
than 25 different primary cells) are listed on the homepage of OZ BIOSCIENCES 
(www.ozbiosciences.com) and the list is regularly updated. 
In summary, it can be concluded that magnetofection is an efficient transfection / transduction 
method for a huge number of different cells, including primary and other hard-to-transfect / 
transduce cells. 
 
4.9 Magnetofection in vivo 
 
As described in the previous chapters, magnetofection is highly efficient in nucleic acid 
delivery in cell culture and it enables localization of nucleic acid transfer within a cell culture 
dish (fig. 76). These features make magnetofection attractive for in vitro research and for ex 
vivo nucleic acid therapy. But is magnetofection also efficient in localized nucleic acid 
delivery in vivo?  
To answer this question, three proof-of-principle experiments were performed. Firstly, 
magnetofectins (consisting of magnetic particles, DNA and PEI) were injected into ear veins 
of pigs (fig.81) and a permanent magnet was placed above the blood vessel downstream of the 
injection site. Secondly, magnetofectins (magnetic particles with free PEI in suspension and 
DNA) were injected into ear arteries of rabbits (fig. 83) and a permanent magnet was attached 
on the artery downstream of the injection site. Thirdly, after laparatomy magnetofectins 
(magnetic particles with free PEI in suspension and DNA) were injected into the ileum lumen 
of rats and a permanent magnet was placed downstream of the administration site (fig. 84). 
The results of these three experiments revealed that reporter gene transfer was strongly 
enhanced in the area under influence of a magnetic field whereas without application of a 
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magnet (controls) either no or only poor transfection was achieved. Similar results were 
obtained by two other groups which work in close collaboration with us. Martina Anton and 
coworkers injected magnetic particle-adenovirus associates into the stomachs (which were 
exposed after laparatomy) of mice while a permanent magnet was positioned to the outside of 
the stomach wall. Despite the harsh conditions in the stomach (low pH and degradative 
enzymes), effective localized reporter gene delivery was obtained, while a control experiment 
without magnet hardly yielded any gene transfer (Scherer et al., 2002a). Further, Krötz et al. 
injected fluorescence-labeled antisense oligodeoxynucleotides (ODNs) into the femoral artery 
of mice and during injection a permanent magnet was applied to one testicle exposed by 
surgery. Confocal fluorescence microscopy revealed that specific uptake of ODNs was only 
observed in cremaster muscle blood vessels of testicles which were exposed to a magnetic 
field (Krotz et al., 2003a). This experiment demonstrated that magnetic-field-targeted nucleic 
acid delivery is even possible if the the magnetic field-exposed target site is not in the direct 
vicinity of the administration site.  
These proof-of-principle experiments with reporter genes or fluorescence-labeled ODNs 
demonstrate the feasibility of magnetic-field targeted and –enhanced nucleic acid delivery in 
blood vessels (endothelial cells) and in the gastrointestinal tract. Hopefully, further 
experiments will reveal that magnetofection is applicable to many more organs and tissues 
and especially to tumors. Magnetofection may be useful as an in vivo research tool for 
studying locally the function of genes or expressed proteins (which could e.g. contribute in 
endothelial cells of blood vessels to the development of atherosclerosis or hypertension) either 
through introduction of plasmid DNA or through knock down of genes by antisense ODNs or 
siRNAs. Additionally, magnetofection could have potential for clinical applications through 
targeted delivery of nucleic acids encoding therapeutic sequences. For example in a tumor 
therapy, paramagnetic vectors harbouring tumor suppressor genes (e.g. P53), cytokine genes 
(e.g. GM-CSF) or suicide genes (e.g. HSV thymidine kinase) could be injected either into 
tumor-feeding blood vessels or directly into the tumor tissue and an applied magnetic field 
could hold the vectors in the tumor. This retention could enable efficient local transfection or 
transduction and only vectors which are not retained at the the target tissue (in the ideal case 
all vectors are retained) can be spread systemically and contribute to systemic side effects, 
respectively. It remains to be shown that similarly as for magnetic drug targeting with 
classical anti-cancer drugs (Alexiou et al., 2000), magnetofection is able to enhance 
therapeutic effects and to reduce undesired side effects.  
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4.10 The place of magnetofection in the field of nucleic acid transfer and 
targeting 
 
In vitro, magnetofection enables rapid contact of nucleic acid vectors with cells and it 
increases the number of vector-cell contacts. In this way, magnetofection improves 
conventional (standard) nucleic acid transfer methods like polyfection, lipofection or 
viral transduction with regard to efficiency, nucleic acid dose-response profile and reduced 
incubation time in many cases. Through its enhanced efficiency, magnetofection is able to 
compensate for low viral titers as shown e.g. for retroviruses (Scherer et al., 2002a) and 
measles viruses (Kadota et al., 2005). It is assumed that magnetofection can be applied to 
any type of vector and different vector components can be combined in a way that results in 
an optimum vehicle for a desired application. Additionally, magnetofection is not restricted to 
one type of nucleic acid but is applicable e.g. to cDNAs, oligodeoxynucleotides and RNA 
molecules. Magnetofection can also enable nucleic acid delivery to otherwise nonpermissive 
cells (Plank et al., 2003b) like e.g. shown for adenoviral transduction of cells lacking the 
coxsackie and adenovirus receptor (CAR) (Scherer et al., 2002a) or for measles viral 
transduction of cells lacking the signaling lymphocytic activation molecule (SLAM) receptor 
(Kadota et al., 2005). Further, magnetofection is an ideal tool for the delivery of nucleic 
acids to difficult-to-transfect / transduce cells (including primary and eventually also stem 
cells) and its toxicity is low enough to enable the examination of sensitive cellular gene / 
protein functions (Krotz et al., 2003a; Krotz et al., 2003b). Considering the shorter incubation 
times (reduced from hours to minutes) and the improved nucleic acid dose-response 
relationships, magnetofection may be a method of choice for automated high throughput 
screening of genes and of therapeutically useful sequences. An interesting application of 
magnetofection could also be the ex vivo delivery of genes encoding immunomodulatory and 
graft-protecting molecules to organs determined for transplantation. The tight association of 
vectors to the target cells could improve the gene transfer efficiency and the reduced 
incubation times may be advantageous as the grafts should be implanted as fast as possible to 
avoid serious damage to the organ. Despite all these positive aspects of magnetofection, one 
has to remember that there are cases in which magnetofection is only equally or even less 
efficient than conventional transfection with the corresponding non-magnetic standard 
vector. In these cases, the increased number of vector-cell contacts may lead to saturation of 
uptake processes or toxicity and it is also conceivable that the magnetic particles disturb 
(inhibit) the function of some vector types. Up to date, no experimental side by side 
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comparison of magnetofection and other physical methods enhancing nucleic acid delivery, 
such as centrifugation, convective flow towards the target cells, biolistic methods or 
electroporation, has been carried out. But each of these methods has its merits. Centrifugation 
and convective flow is simple and not expensive, biolistic methods enable exact localization 
of delivery and electroporation is highly efficient. Magnetofection is probably less efficient 
than electroporation, but it is still a very efficient method and it does not require such an 
expensive equipment. It also does not require tedious handling steps such as in centrifugation 
or convective flow and is simpler than biolistic methods (Plank et al., 2003a). When 
compared to all the other physical methods, the major advantage of magnetofection is that 
it is able to combine simplicity, non-expensiveness, localization of delivery, enhanced 
efficiency and reduction of incubation time and of vector doses. 
In vivo, not only the nucleic acid transfer efficiency but especially the targeting of vectors is 
of great importance. Magnetofection is assumed to be a very promising targeting method. In 
the ideal scenario, paramagnetic vectors would be injected either into blood vessels or directly 
into the target tissue and they would accumulate in a magnetic gradient field. The magnetic 
field enables even extravasation and tissue penetration at the target site for cytostatics 
(Widder et al., 1978) and also for gene vectors (unpublished observations by Eissner B and 
Schillinger S, TU Munich, Germany). The localized vector accumulation would provide a 
high dose of vectors in the target tissue, an increased number of vector-cell contacts and 
consequently nucleic acid transfer would be locally strongly enhanced. In the ideal case, the 
paramagnetic vectors would not distribute systemically and toxic side effects could be 
prevented. In theory, the magnetic field can be applied to any organ or tissue and thus 
magnetic drug targeting is not limited e.g. to special types of cells harbouring special 
receptors, like it is the case for targeting via receptor-ligand interactions. In practice, proof-
of-principle experiments revealed that via magnetofection targeted and efficient nucleic 
acid transfer is possible. But unfortunately, in practice up to date it is not possible to apply a 
strong magnetic gradient field to any desired organ or tissue. Additionally, the magnetic field 
can be too weak to attract paramagnetic vectors efficiently in blood vessels with high flow 
rate or to enable extravasation or tissue penetration. Further possible limitations are e.g. 
dissociation of the nucleic acids from the magnetic particles before the target site is reached or 
reduced functionality of vectors irreversibly bound to the magnetic particles. Magnetofection 
may also not be the first choice for all in vivo applications. Only experimental side by side 
comparisons of magnetofection and other methods of nucleic acid targeting (like e.g. 
receptor-ligand interactions, local injection of non-magnetic vectors, hydroporation, 
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aerosolization, ballistic methods, occlusion of the blood outflow from the target organ, 
transcriptional targeting and even passive targeting) will reveal the value of magnetofection 
for certain applications. The ultimate delivery system might even combine the principle of 
magnetic targeting with methods of passive and active targeting. Magnetofection could 
e.g. assist the target accumulation of a delivery system whose biophysical properties alone 
favour a passive target tropism and which in addition is equipped with active targeting 
modules such as receptor ligands or nuclear localization signals (Plank et al., 2003a). One 
could even think of combinations between magnetofection and e.g. transcriptional targeting, 
local injection, hydroporation or aerosolization. 
 
4.11 Conclusions and outlook 
 
A very exciting aim of magnetofection is to use it therapeutically, like e.g. in tumor 
targeting or local neo-vessel formation. Therefore, recently a veterinary clinical study of 
immuno gene therapy of feline fibrosarcoma has been started (Schillinger et al., 2005). The 
gene coding for human GM-CSF (granulocyte macrophage colony stimulating factor) in 
magnetic formulation was administered twice in a 1 week interval prior to surgery into the 
biologically active margins of the fibrosarcoma and a permanent magnet was fixed on the 
tumor adjacent to the injection site during one hour after vector injection. The 
immunohistochemistry showed that the GM-CSF gene was expressed in the tumor and some 
tissue penetration by the vector could be observed. The preliminary clinical outcome after a 
phase II study with more than 20 patients is a significant increase in tumor-free survival of the 
cats from only 23% at the 1 year time point in the case of standard therapy (surgery only) to 
52% with pre-surgical magnetofection of the human GM-CSF gene (Schillinger et al., 2005). 
The long-term follow-up will be very interesting as it will reveal the true benefits of this 
treatment. 
Apart from direct injection into the target tissue, the injection into blood vessels which are 
rather distant to the target site is assumed to become the most important form of vector 
administration for therapeutic magnetofection. But in blood vessels, hydrodynamic forces 
like the viscous drag force (according to Stoke’s law in the blood stream) counteract the 
magnetic retention and at blood flow rates around 20 cm/s (like in the human aorta) magnetic 
drug targeting appears even impossible (Plank et al., 2005; Voltairas et al., 2002). To 
overcome the barrier of hydrodynamic forces in blood vessels, several approaches are 
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conceivable. For example the magnetic fields could be improved and the magnetic particles 
and their delivery systems could be optimized.  
Improvement of the magnetic fields:  
The force F exerted on a magnetic particle is determined by the formula 
 
 
 
where V is the volume and χ the susceptibility of the magnetic particle, µO the magnetic 
permeability in vacuum, B the magnetic induction (= magnetic flux density) and  B the field 
gradient (Babincova et al., 2001). From this expression it is clear that the movement of 
magnetic particles in a magnetic field is proportional to the magnetic induction (measured in 
Tesla [T]) and the magnetic field gradient (measured in T/m). But this relationship is only 
valid when the particles are not magnetically saturated. In the case of saturation magnetization 
(measured in A•m2/kg), an increase in particle movement is not possible through higher 
magnetic induction but only through an increase in the field gradient. In all magnetofections 
so far, permanent neodymium-iron-boron magnets (according to the supplier, IBS Magnet 
Berlin, with magnetic inductions of 1.08-1.15 T) were used. The magnetic field gradient of 
these magnets is dependent on the size and the shape of the magnet and on an eventual 
placement next to other magnets. For magnetofections in 96-well plates, cylindrical (d = 6 
mm, h = 5 mm) magnets inserted in an acrylic glass template in 96-well plate format with 
strictly alternating polarization were used. Measurements with a Tesla-meter revealed that in 
the the center of the ground of each well (approximately 2 mm distant from the surface of the 
magnet) the magnetic induction was approximately between 0.13 and 0.24 T and the magnetic 
field gradient approximately between 67 and 123 T/m. This magnetic induction leads to 
approximately 80% saturation of particles consisting of almost pure magnetite (unpublished 
data, Mykhaylyk O, TU Munich) and the field gradient is comparatively high. Although 
induction and gradient decrease rapidly with increasing distance from the surface of the 
magnet, for magnetic sedimentation in cell culture this magnetic device is relatively efficient. 
Single rectangular (dimensions 20 x 10 x 5 mm) magnets chosen for experiments in 6-well 
plates and in animal experiments are also not assumed to have higher inductions and field 
gradients than the 96-well plate magnetic device. In cell culture experiments these magnetic 
properties are sufficient, but for in vivo applications, where e.g. the viscous drag force is 
counteracting, more improved magnetic fields are desired. Improvements are possible with 
regard to magnetic induction (an induction of 0.5-0.6 T is necessary to achieve saturation 
magnetization of magnetite particles) and magnetic field gradient. The strongest magnetic 
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field ever applied in magnetic drug targeting (here with an anti-cancer drug) was used by 
Alexiou et al. (Alexiou et al., 2000). It was an electromagnet with a maximum magnetic 
induction of 1.7 T on the tip of the pole shoe and 10 mm distant to the pole shoe there was 
still an induction of 1.0 T. Additionaly, the magnet was constructed to achieve high magnetic 
field gradients. This advanced magnet exerts a strong attractive force on magnetic particles 
even in regions more distant to the pole shoe. However, all the magnetic fields described 
above are not assumed to be sufficient for capturing magnetic particles in vessels with very 
high blood flow rates. A general problem is the rapidly decreasing magnetic induction and 
field gradient with increasing distance from the pole and also that gradients can not be 
generated arbitrarily in space. Thus magnetic drug targeting with the magnets mentioned 
above is only feasible if they can be applied directly to the target site which is often only 
possible by surgery. A new approach to generate high magnetic field gradients for magnetic 
drug targeting was proposed by Babincova et al. (Babincova et al., 2001). In an experimental 
set-up, they placed a ferromagnetic wire alongside a tube (used as a model for blood vessels) 
which was positioned in a magnetic field and strong gradients were induced which were 
sufficient to locally capture magnetic (nano)particles under constant flow rate. The authors 
suggested the use of strong static homogenous magnetic fields (1.5 T or more) generated by 
magnetic resonance imaging machines plus the placement of ferromagnetic wires near the 
target site to induce locally very high field gradients. They concluded that with such a 
construction magnetic particles could be targeted with an efficiency 3-5 magnitudes higher 
than using permanent magnets. Additionally, the study of Nagel suggests that the magnetic 
particles themselves generate local field gradients that facilitate the targeting of further 
particles (Nagel, 2004). If static magnetic fields are harmful, neutral or even positive for the 
human health is still unknown, but it is documented that they can e.g. have effects on the 
cellular plasma membrane (Rosen, 2003), cellular metabolic activity (Sabo et al., 2002), trans-
membrane flux of calcium ions, apoptosis, phagocytic activity (Flipo et al., 1998), cell 
differentiation (Pagliara et al., 2005) and oncogene expression (Hirose et al., 2003). In the 
future, the success of magnetic drug targeting is largely dependent on the developments in 
magnetic field technology. Perhaps, one day there are even magnets which are able to capture 
magnetic nanoparticles in blood vessels with high flow rates, the magnetic field can be 
applied to any region of the body without the need of any surgical intervention and the 
applied magnetic fields are proofed to be totally harmless or even healthy for the human body. 
Improvement of the magnetic particle chemistry and physics:  
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In all magnetofection experiments so far, iron oxide nanoparticles were used. These particles 
are "superparamagnetic", meaning that they are strongly attracted to a magnetic field but they 
do not retain residual magnetism after the field is removed. Therefore they can not 
agglomerate (like ferromagnetic particles) after removal of the magnetic field. Further, 
Weissleder et al. found that iron oxide particles used as contrast agents in magnetic resonance 
imaging (MRI) are fully biocompatible (Weissleder et al., 1989). After intravenous 
application in rats, the particles were cleared by macrophages in liver and spleen, the iron 
oxides were degraded in lysosomes via hydrolytic enzymes, and the resulting elemental iron 
was integrated into the natural iron metabolism (e.g. incorporation into hemoglobin). 
Additionally, Weissleder and coworkers showed that in rats and beagle dogs a relatively high 
dose of 167 mg iron/kg body mass still had no toxic effects on the liver or other organs and 
they mentioned that for clinical MRI a dose of approximately 1 mg iron/kg is proposed. Thus, 
the 76.9 µg iron oxide particles/kg applied intravenously in pigs for magnetic nucleic acid 
targeting experiments (3.4.1) can be assumed to be totally safe. Despite the advanced 
magnetic properties and the biocompatibility of iron oxides, for improvement of magnetic 
nucleic acid targeting materials with even higher magnetic susceptibility (see χ in the formula 
above) would be desirable. For example, the ferromagnetic material elementary iron has a 
higher magnetic susceptibility and a higher saturation magnetization as iron oxide (magnetite) 
and composite microparticles made from elementary iron and activated carbon were already 
used for magnetic drug targeting with chemotherapeutic agents in human clinical trials 
(Johnson et al., 2002; Rudge et al., 2001). Therefore in future it might be interesting to work 
on the efficient and functional binding of nucleic acids to elementary iron particles and to test 
these associates in magnetofection. 
Further, as shown in the formula above, the magnetic force acting on a particle is not only 
proportional to the magnetic induction and the field gradient but also to the volume of the 
particle. Although the viscous drag force in the blood stream is proportional to the particle 
size as well, it is only proportional to the first power of the particle radius whereas the 
magnetic force is proportional to the third power of the radius (= volume of the particle) and 
therefore magnetic particles should be as large as possible to achieve optimum magnetic 
retentability. But for future optimization of particle sizes it must be considered that the 
particles should be as large as possible but also that they should not exceed a size which 
harbours the danger of inducing embolisms in capillaries which only have diameters of 
approximately 5 µm (Plank et al., 2003a; Plank et al., 2005). For extravasation, it has to be 
taken into account that the capillary bed is generally permeable to particles smaller than 2 nm, 
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that the fenestrations in bone marrow, liver and spleen are up to 150 nm, and that in certain 
tumors there are endothelial gaps or transcellular holes of up to 500 nm (Mykhaylyk et al., 
2005). 
Improvement of the delivery system:  
An advantageous delivery system could e.g. use a multitude of magnetic nanoparticles which 
are coupled to each other physically, so that the attractive magnetic forces which act on each 
single nanoparticle could be multiplied and also counteracting physical events like Brownian 
relaxation could be reduced in this way. Recently, colleagues in our laboratory developed 
such a system. They incorporated a multitude of paramagnetic nucleic acid vectors into the 
lipid shell of gas-filled microbubbles (Hellwig et al., 2005). These microbubbles are stable in 
the blood stream and even if they can adapt their shape to the environment they are 
constructed smaller than 5 µm in order not to obstruct blood capillaries. The magnetic 
microbubbles are e.g. injected into the blood stream, held back at the target site by magnetic 
force and by localized ultrasound release of a multitude of paramagnetic nucleic acid vectors 
is achieved. Thus using this approach two physical methods of targeting and their benefits are 
combined: magnetic drug targeting and the use of ultrasound to trigger localized nucleic acid 
delivery.  
Further possibilities to improve magnetic nucleic acid targeting in vessels with higher blood 
flow rates are e.g. the local reduction of the flow rate and localized application of 
magnetofectins through catheters. 
With all the efforts in magnetic field physics, in magnetic particle physics and chemistry, in 
pharmaceutical formulations and in medical application, hopefully once magnetofection will 
become an efficient clinical standard therapy for many diseases.  
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5 SUMMARY 
 
Among the physical methods of drug localization, especially magnetic drug targeting 
promises great potential. In this method, an anti-cancer drug is bound to magnetic particles 
and an external magnetic field can guide the administered magnetic particle-drug complex to 
the desired site.  
The objective of this thesis was to apply the principle of magnetic drug targeting to the 
delivery of nucleic acids in cell culture and in vivo.  
To establish the method of magnetic nucleic acid targeting (magnetofection), the 
characteristics (sizes and organization) of different superparamagnetic iron oxide 
nanoparticles coated with cationic or anionic polymers (termed “trMAGs”, synthesized by 
Chemicell GmbH Berlin), the binding of DNA to the magnetic beads, transfections with the 
different types of magnetic particles, the mechanism of magnetofection, optimization of 
magnetofection, the gene transfer efficiency of magnetofections compared to standard 
(conventional) transfections, magnetic field-guided localization of gene transfer, 
magnetofection of a variety of cells and the applicability of magnetofection in vivo, were 
examined.  
In binding studies, it turned out that efficient binding of charged DNA vectors to charged 
magnetic particles could be achieved by salt-induced colloid aggregation. Incubation of cells 
with magnetic particle/DNA associates (magnetofectins) resulted in gene transfer and 
application of a magnetic field significantly increased gene expression. Additionally, 
polyethylenimine (PEI) had an enhancing effect on magnetofection efficiency. Mechanistic 
studies revealed that the paramagnetic vectors are concentrated efficiently by magnetic force 
on the cell surface within minutes and the predominant uptake mechanism is endocytosis. 
Comparison of magnetofections and the corresponding standard transfections (same vectors 
but without magnetic particles and no applied magnetic field) showed that with 
magnetofection the gene transfer efficiency was usually significantly enhanced (up to 971-
fold), the nucleic acid dose-response profile could be improved and the incubation times (of 
cells with vectors) could be reduced from hours to minutes. Finally, in animal experiments 
(injection into ear veins of pigs, into ear arteries of rabbits and into ilea of rats) it was 
demonstrated that magnetofection enables targeted and efficient gene transfer in vivo. 
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